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ABSTRACT 
 Proteins are macromolecules involved in a diverse array of functions. Mutations or 
abnormal levels of proteins are indicated in several diseases. Despite showing early 
promise, the translation of protein therapeutics into the clinics has been challenging. The 
stability of these macromolecules, their delivery, and penetration inside the cells have been 
the main hurdles limiting their true potential. In the dissertation, various strategies to 
overcome such protein delivery challenges are discussed. 
 Insulin is a lifesaving peptide for millions of diabetics around the world. Despite 
significant progress in insulin therapies, the quality of life in diabetics is constrained by the 
burden of multiple daily injections, invasive nature of therapy and inability to control the 
blood glucose tightly. To address these concerns, we constructed a photoactivatable insulin 
depot (PAD). In the approach, an insoluble depot of modified insulin was created by 
linking insulin covalently to photolabile caging moieties. Transcutaneous irradiation 
breaks the bond to release insulin from the depot into the systemic circulation. Chapter 3 
describes the first successful testing on our PAD technology in diabetic animal models. In 
Chapters 2 and 4, I describe second-generation materials incorporating more efficient 
photolabile groups utilizing visible light wavelengths and PAD material with greater 
iv 
insulin loading. These changes improved the overall performance by several folds when 
tested in-vivo. 
 Chapter 5 discusses the strategies addressed to deliver siRNA inside cells for 
effective light-activated RNA interference (LARI). LARI can be used for studying biology 
and cellular processes.  
Once administered, proteins are prone to degradation by ubiquitous proteases, 
limiting their circulation time and therapeutic effect significantly. Chapter 6 discusses 
prodrug strategies to temporarily modify proteins to shield them against proteases. We 
envisioned cross-linking amino acid residues on the surface via small crosslinkers. The 
tight bridges would hinder proteases from binding to proteins and unwinding the helices 
preventing their proteolysis. We also attempted integration of this approach to achieve 
intracellular protein delivery which is another obstacle in protein delivery. Here, the cross-
linking was performed via disulfide linkages. The disulfide groups would be reduced once 
inside the cells, yielding native proteins.   
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CHAPTER 1 
INTRODUCTION: PHOTOACTIVATABLE INSULIN DEPOT 
Insulin and glucose metabolism 
Insulin is a peptide hormone secreted by beta cells of Islets of the pancreas. It plays 
a pivotal role in the regulation of carbohydrates, fats, and amino acids metabolism as shown 
in Figure 1. Primarily, it lowers the blood glucose levels by promoting its absorption into 
liver, fat and muscle cells. It also regulates glucose levels by inhibiting glucose release 
from the liver.1  
When blood glucose levels are elevated after carbohydrate-rich meals, insulin 
restores it to the normal range through several mechanisms by acting on muscle cells, fat 
cells, and the liver. Insulin promotes the uptake of glucose in muscle cells and fat cells via 
insulin dependent GLUT-4 transporters. Upon binding of insulin to the cell surface 
receptor, glucose enters the cell via GLUT-4 transporters by facilitated diffusion. Once 
inside, glucose gets phosphorylated to glucose-6-phosphate and gets trapped inside. Insulin 
is then stored in the form of glycogen in the muscle tissues. This way insulin promotes 
glycogen synthesis. It also aids in decreasing protein breakdown. In fat cells, insulin 
promotes lipogenesis while inhibiting lipolysis. In the liver, insulin inhibits the release of 
glucose. There, insulin promotes glycogen synthesis while preventing gluconeogenesis. In 
the whole body, muscle cells are accountable for 60-70% of insulin-mediated glucose 
uptake, fat cells 10% and the liver 30%.2,3 In contrast, the glucose uptake in the brain tissue 
is not dependent on insulin.4  
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Figure 1: Regulation of glucose metabolism by insulin. Reprinted by permission from 
Springer Nature.5 
 
Insulin structure, its biosynthesis, and secretion 
Insulin is a small peptide with a molecular weight of 5808 Da. It is composed of 51 
amino acids (AA), chain A is made up of 21 AA, and chain B consists of 30 AA as shown 
in Figure 2. Three disulfide bridges are present among cysteine residues. Insulin structure 
is highly conserved across many different species in nature. Several AA residues on both 
chain A and B are involved in the binding of insulin to its receptor.6 Although insulin is a 
51 AA peptide, the peptide that is translated from the insulin gene is 110 AA long, known 
as preproinsulin. Preproinsulin is converted to proinsulin by the action of an enzyme which 
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cleaves a signal peptide. Proinsulin further undergoes folding, and disulfide linkages are 
formed by the action of different enzymes.7 Proinsulin has an additional C chain along with 
chain A and B. This C-peptide is cleaved by another protease to give mature insulin protein. 
Glucose is an important molecule which acts as a stimulus for the transcription and 
translation of insulin.8  
 
Figure 2: Structure of human insulin. The top segment (on the right) is chain A (21 amino 
acids), and the bottom chain is chain B with (30 amino acids). The cysteines (in red) are 
bridged by disulfide linkages. Other insulin analogs with their AA substitutions are also 
shown. Reprinted by permission from Springer Nature.9 
 
Because insulin must be quickly released by the body in response to elevated blood 
sugar levels, β cells in the pancreas keep insulin stored in the form of insoluble crystalline 
insulin hexamers. Insulin hexamers are stable due to complexation with zinc cations 
through histidine residues. The concentration of insulin in the hexamers is approximately 
40 mM.10 Insulin is secreted from the β cells mainly in response to increased glucose levels 
but certain amino acids, free fatty acids can also act as triggers (Figure 3). The hormones 
such as leptin, glucagon-like-peptide-1 (GLP-1) play a role in the regulation of insulin 
secretion as well. From the β cells, insulin secretion is regulated by glucose concentrations 
and ATP/ADP balance. The ATP/ADP ratio inside the cells is closely linked with KATP 
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channels, which regulate the flux of potassium in the cell. At low glucose concentrations, 
the KATP channels allow free outflow of K+ ions. This outflow of K+ ions allows the cell to 
maintain a negative resting potential. However, at high glucose concentrations, more 
glucose gets metabolized through glycolysis which leads to higher production of ATP. 
More ATP synthesis leads to higher ATP/ADP ratio. Because KATP channels are linked 
with this ATP/ADP ratio, it stops the outflow of K+ ions. When the channels are stopped, 
the membrane potential depolarizes, which causes the Ca2+ channel to open and release 
insulin from the vesicles.10 
 
Figure 3: The mechanism of insulin secretion by the β cell of the pancreas in response to 
glucose. When glucose is at an elevated concentration (right figure), ATP/ADP ratio in 
the cell is increased which leads to membrane depolarization and release of insulin from 
the vesicles in the cells.11 
 
Insulin is secreted from the β cells in an oscillating manner. There are two types of 
oscillatory secretory patterns; one is ultradian oscillations which occur over a period of 1-
2 hours, and another is through rapid oscillations which occur over a short period of 10-15 
minutes.12 Millions of β cells in the pancreas synchronize insulin secretions so that they 
are in the same phase of the oscillation. These oscillatory secretions are more efficient in 
5 
the regulation of blood glucose than administration of multiple discrete injections of insulin 
throughout the day. This pattern of pulsatile insulin release is something which could be 
considered while designing insulin delivery systems. Most of the current insulin delivery 
systems follow different pharmacokinetic profiles than that of endogenous insulin.13  
Diabetes mellitus 
Diabetes mellitus (DM) is a group of disorders characterized by elevated blood 
glucose levels for prolonged periods of times. Figure 4 and Figure 5 describe the 
differences in DM 1 and 2 respectively. DM is caused due to either deficiency of insulin in 
the body or the resistance to the produced insulin. High glucose concentration in the blood 
is damaging to many organs and results in a variety of serious complications. Acute 
complications include diabetic ketoacidosis, coma or death. Long-term complications 
include diabetic retinopathy, nephropathy, cardiovascular complications, and foot ulcers.14 
A fasting plasma glucose value of 6.1 mM (110 mg dL-1) and above is considered abnormal 
and in the diabetic range.15,16  
Type 1 DM is characterized by an insufficient amount of insulin production in the 
body. The processes which destroy β cells of the pancreatic islets are responsible for type 
1 DM. The underlying causes of type 1 DM are not yet fully understood, but the 
autoimmune system destroys β cells.17 Lack of insulin results in high blood glucose and 
complications mentioned above. About 5-10% of the diabetic population has type 1 DM. 
In the U.S. alone, approximately 3 million people are affected by the type 1 DM.18 Because 
insulin is no longer produced in the body of patients, the patient must rely on treatments 
such as insulin therapies, β cell replacement therapies, and follow special diets, etc.    
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Figure 4: Type 1 diabetes. 
 
 
Figure 5: Type 2 diabetes. 
 
Type 2 DM is characterized by insulin resistance, high blood glucose levels and 
lack of insulin. Both genetic and lifestyle factors can predispose a person towards type 2 
DM. Approximately 90% of the total diabetic population suffer from type 2 DM. 
Complications of type 2 DM include similar disorders – cardiovascular complications, 
diabetic retinopathy, kidney problems and so forth. The onset of type 2 diabetes can be 
delayed through regular exercise, physical activity, and proper nutrition.19  
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Insulin analogs 
Type 1 diabetes is managed by taking insulin externally as the body fails to secrete 
an adequate amount of insulin. As insulin is a protein, it undergoes rapid degradation when 
taken orally. Insulin is degraded by a harsh environment presented by the stomach as well 
as the presence of ubiquitous proteases present in the gut. Hence it is most commonly 
injected via the subcutaneous route. A landmark study published in 1993 named Diabetes 
Control and Complications Trial (DCCT) demonstrated that patients undergoing intensive 
insulin therapy or using continuous glucose monitoring (CGM) to tightly control blood 
glucose levels have a significantly lower risk of developing retinopathy, nephropathy, and 
albuminuria than in patients who rely on traditional insulin therapy.20      
Along with the invention of recombinant DNA technology, various insulin analogs 
have been prepared. Insulin analogs are designed to have altered physical and 
pharmacokinetic properties. Figure 6 describes the pharmacokinetic profiles of various 
insulin analogs. For example, fast-acting insulin analogs (e.g., Lispro, Aspart) enter 
bloodstream just within 15-20 minutes after administration. They typically function by 
preventing insulin aggregation and allowing it to be predominantly in a monomeric form. 
Aggregated insulin in the form of hexamers is inactive while the monomers are active 
therapeutically. Mutations in these analogs prevent the hexamers formation and thus 
directly deliver a larger amount of monomeric insulin quickly in the bloodstream.21 In 
addition, long-acting insulin (e.g., Lantus, Degludec) have been developed whose effect 
could last for more than 24 hours. These formulations typically work by slowing the 
diffusion of insulin into the body from the site of injection either due to increased protein 
binding or changes in its isoelectric point. The common mechanism of long-acting insulin 
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formulations is via complexing insulin with zinc so that it forms insulin hexamers. The 
hexamers are inactive and dissociate slowly from the depot site to form monomeric insulin 
molecules. Thus, insulin absorption is delayed, and its effect is prolonged.21 Similarly, 
there are intermediate-acting insulin formulations (e.g. NPH insulin). In the clinical 
settings, different insulins are mixed in optimal proportions and prescribed to patients as 
per their needs.22 
  
Figure 6: Pharmacokinetic profiles of various insulin analogs. Reproduced with 
permission from, Copyright Massachusetts Medical Society.23  
 
Methods to deliver insulin 
Figure 7 shows several different routes and approaches to deliver insulin in the 
body into the systemic circulation. Most of these routes are being investigated for insulin 
delivery, but the subcutaneous (SC) route is the most practical way for administration and 
hence it is being used clinically. 
Insulin syringes, insulin pumps, and insulin pens are common devices being used 
currently for the delivery. Insulin syringe design has undergone several changes over the 
years. Nowadays, the syringes are smaller, relative pain-free with micro-fine needles, and 
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easy to use, etc., yet there are still barriers to overcome. For example, the accuracy of the 
dosage, the frequency of injection is typically 2-3 times a day, and a proper injection 
technique is required to be learned by the patient, etc. 
 
Figure 7: Methods to deliver insulin through different routes.24 
 
Insulin pumps are convenient alternatives to insulin syringes. In insulin pumps, a 
cannula is inserted into the body SC through which insulin can be infused. Tubing is 
connected to the other end of the cannula which goes inside a reservoir of insulin. The 
amount of insulin required can be precisely infused using insulin pumps. The main 
advantage of the insulin pump over insulin injections is that the requirement of multiple 
daily injections is averted.25 Several other benefits include precise infusion of the dose (as 
minimum as a fraction of a unit of insulin), a bolus dose can be planned ahead based on 
the intake of carbohydrates, supply a continuous and variable amount of insulin, overall 
increase in the quality of life and it allows flexible lifestyles.26,27 Unfortunately, insulin 
pumps have their own limitations – sometimes there is an allergic reaction to the tape or a 
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scar tissue forms near the site of injection. Much insulin is wasted since pumps require a 
larger reservoir particularly at the time of changing it. In the case of cannula malfunction 
or other problems near the site of injection, insulin leakage can occur.28 We are developing 
an alternative delivery system which retains the advantages of insulin pumps while 
eliminating the challenges. 
The photoactivatable depot (PAD) approach 
To overcome the limitations of syringes and insulin pumps, we have conceived of an 
idea to deliver insulin in a minimally invasive manner called a photoactivatable insulin 
depot (PAD). The schematic is in Figure 8. The concept is to make a shallow depot of 
photolabile insulin in the dermal layer. Here photolabile insulin refers to the insulin that is 
covalently modified with a photocleavable linker. Upon exposure of light, the 
photocleavable moiety detaches from insulin and triggers the release of insulin from the 
site of the depot. Once injected, this depot can be irradiated from the top transcutaneously 
using an LED. After irradiation on the skin, insulin will be released from the site into the 
systemic circulation. In the absence of light, no insulin will be released. Since the nature 
of light penetration through the skin is non-invasive, this approach is minimally invasive 
as opposed to insulin syringes which require multiple daily injections or a permanently 
inserted cannula in the case of insulin pumps. In addition, insulin dose can be precisely 
controlled by controlling the exact number of photons hitting the depot minute-by-minute. 
The number of photons could be regulated either by changing the light intensity or the 
duration of exposure. Ultimately the PAD approach can be coupled with continuous 
glucose monitoring (CGM) to make it into a part of the artificial pancreas. This would 
ensure continuous and variable supply of insulin which could be controlled minute-by-
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minute and could maintain tighter control over fluctuating blood glucose. 
 
Figure 8: Photoactivatable depot and its components. 
 
The PAD approach provides these benefits over currently available approaches – 
i. The depot can hold days’ worth of insulin in a single injection; this will reduce the 
need for the number of daily injections dramatically.  
ii. The insulin release is proportional to the amount of light. Hence insulin release can 
be controlled easily by manipulating light intensity or duration of exposure. 
iii. As the blood glucose levels fluctuate frequently, the amount of insulin should vary 
accordingly. These fluctuations in blood glucose can be minimized by multiple 
irradiations of the depot based on the knowledge of blood sugar. Insulin syringes 
have limitations in achieving tight control of blood glucose. 
The first-generation material consisted of three parts; an insoluble polymer, a 
photolabile linker, and insulin.29 The role of an insoluble polymer is to hold the depot 
material at the site of injection. Photolabile insulin would otherwise diffuse from the depot 
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site upon injection. To prevent it from migrating away from the site, it is immobilized on 
bulky material like an insoluble polymer. Ideally, this polymer would be a biodegradable 
material which will be degraded once all insulin is used up. The biodegradable polymer 
could be made up of a non-toxic and biocompatible material such as hyaluronic acid, poly-
amino acid polymers or any other natural polymers. The photolabile group could be any 
chemical group which can be conjugated covalently to insulin and should release insulin 
by breaking the covalent linkage upon absorption of light of certain wavelengths. Several 
such photolabile groups have been reported in the literature.30 
The depot could be injected into an arm or any other convenient site. An LED could be 
fit into a small belt or pouch which could be wrapped around the depot site. The depot 
could be injected intradermally rather than subcutaneously. Because an intradermal depot 
would be shallower than subcutaneous, more photons would be hitting the depot from the 
top. We suspect that an intradermal depot would help prevent diffusion of PAD material 
from the injection site due to its thickness. All of these factors would ensure maximum 
PAD efficiency. 
 
  
13 
Synthesis of first-generation PAD material 
For the synthesis of first-generation material, mainly two approaches were pursued 
as shown in Figure 9. Divergent synthesis, in which, the chemistry was performed on an 
insoluble polymer to conjugate a photolabile group in the first step. Then in the final step 
insulin was conjugated to the photolabile group. In contrast, in the convergent synthesis 
approach, insulin was conjugated (caged) with the photolabile group first. Then this caged 
insulin was immobilized onto the polymeric material. Both routes were explored in our lab. 
Each approach had its own challenges and advantages. 
The rationale for pursuing the divergent approach was as follows – 
i. Insulin is required only in the final synthetic step. This reduces the total quantity of 
insulin required during synthesis as it is being utilized only in the last step.  
ii. The chances of denaturation of insulin are reduced.  
iii. Since there are no tedious purification steps involved in the solid phase synthesis, 
the synthesis takes lesser time to finish.  
iv. This approach could be utilized directly for other protein molecules as well without 
further optimization. 
On the other hand, convergent synthesis has its own merits - 
i. Here caged insulin is easy to synthesize. The lab has expertise in conjugating 
photolabile groups with nucleic acids, the same chemistry was extended towards 
proteins and peptides. Caged insulin can be studied and characterized to determine 
photocleavage kinetics, the exact site of caging on insulin and the total number of 
modification.  
ii. Furthermore, distinct caged insulin species can be readily purified using HPLC, 
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characterized and used in subsequent reactions as required.  
iii. Because the material can be purified at each step, reactions are cleaner and can be 
analyzed at each step. The main disadvantage is that much insulin gets wasted 
during each step and purification. It also increases its chances of undergoing 
denaturation like any other protein and may render it inactive by the final step. The 
material and chemical groups selected here will be discussed first followed by each 
of the approaches in details. 
 
Figure 9: Synthetic approaches attempted for first-generation materials. 
 
To start this synthesis, we decided to use solid phase synthesis (SPS) resin as an 
insoluble polymer. The solid phase resin offers the following advantages, and hence it was 
chosen: i) The SPS chemistry has been well refined over the years to give high yielding 
reactions. ii) These resins have higher surface/volume ratio; loading density is much greater 
and hence more insulin can be immobilized on the resin. iii) Many kinds of chemical 
reactions have been shown to work on a solid phase.31 Traditionally polystyrene has been 
the material of choice for synthesis. However, polystyrene is neither tolerable when 
15 
injected into the body, nor it is biodegradable. Hence other alternative such as chitosan, 
sepharose, cellulose, etc. were considered but synthesis turned out to be challenging with 
them. Hence, for the synthesis of PAD material, polyethylene glycol (PEG) based resin 
had been used. PEG rink amide resin is sold under brand name ChemMatrix® (PCAS 
BioMatrix Inc, Catalog number 7-600-1310) shown in Figure 10. 
                                          
Figure 10: Structure of polyethylene glycol. ChemMatrix resin is made up of cross-linked 
PEG. 
 
The Friedman laboratory has used O-nitrobenzyl group (Figure 11) extensively in 
the past for the application of light-activated RNA interference.32–35 1-(4,5-dimethoxy-2-
nitrophenyl)ethyl (DMNPE) was based on the work reported by C. Holmes.36 An ortho-
nitro group is responsible for DMNPE’s photocleaving properties. It has been coupled to 
insulin using an ester linkage which undergoes cleavage upon irradiation. Ester linkage can 
be formed using diazo which reacts with a carboxylic acid of insulin. Insulin has a total of 
six carboxylic acid groups – two terminal and four from glutamic acid side chains.  
Both the approaches, synthetic routes and the work performed in the lab previously 
is described below.        
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Figure 11: Structure of the bifunctional photolabile group. Diazo is used for conjugation 
with insulin, and the carboxylic acid side was employed for immobilizing it on the solid 
phase. 
 
Divergent approach 
In the divergent approach as shown in Figure 12, the synthesis was initiated by 
modifying ChemMatrix resin with a spacer linker such as 6-aminohexanoic acid. The 
spacer was added to increase the distance between insulin and the resin surface and to 
prevent overcrowding and steric issues. The second step was to conjugate (4-Acetyl-2-
methoxy-5-nitrophenoxy)acetic acid (commonly referred to as nitro keto acid (NKA) in 
the lab) onto it. The aim was to convert ketone from NKA into the reactive diazo via 
hydrazone route. The synthesis up to the hydrazine step was successfully carried out 
previously on both polystyrene and ChemMatrix resin (unpublished data). The next step 
was to oxidize hydrazine to diazo using an oxidizing agent like MnO2. The oxidation, when 
carried out in the solution phase, takes approximately 45 minutes and MnO2 can be 
removed easily by filtration. However, when attempted on the solid phase, the reaction 
failed, and the separation was tedious as tiny MnO2 particles remained bound to the resin 
tightly and couldn’t be washed off. Hence the synthesis scheme was slightly modified using 
tosyl hydrazone in which MnO2 is not required. Here, the ketone can be converted first into 
a tosyl hydrazone. This hydrazone can be converted into diazo using trimethylamine 
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(TEA).37 In this case, both tosyl hydrazone and TEA can be washed off easily from the 
resin, unlike MnO2.    
This reaction between insulin and diazo formed through tosyl hydrazone route 
worked successfully only once and wasn’t reproducible. The exact mass of the insulin 
conjugate was observed in the mass spectrometer (MS) upon completion of all reactions 
and post-TFA cleavage but it couldn’t be reproduced afterward. Because of the following 
issues, this wasn’t pursued further – 
i. The final reaction of conjugation with insulin was not reproducible, and the yield 
was minimal.  
ii. The insulin conjugate was not very stable, and some amount of free insulin was 
also observed along with the mass of the conjugate.  
iii. The conversion of the ketone to hydrazone in the third step was very slow, and it 
took almost a week for reaction completion. As an alternative to TEA, peroxyacetic 
acid was also used as a reagent for conversion of hydrazone to diazo. Peroxyacetic 
acid was successful in diazo transformation in the solution phase but failed when 
attempted on the solid phase. 
At this point, because the diazo approach was not yielding any promising results, it 
was decided to use other functionality to cage insulin. Instead of carboxylic acid groups, 
amines can also be utilized for this purpose as shown in Figure 13. The amino group can 
be conjugated to an alcohol functionality through a carbamate ester linkage using 1,1'-
carbonyldiimidazole (CDI). The primary amine of B29 lysine of insulin is suggested to be 
reactive and we thought that this amine could be targeted.38 The ketone from NKA can be 
converted into primary alcohol by a reducing agent like NaBH4. This reaction was a very 
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high yielding reaction and was completed with 3-4 hours. However, in the final step, the 
carbamate ester could not be formed with insulin on the solid phase. When a small molecule 
containing a primary amine was used as a substitute for insulin, the reaction was successful 
with higher yields. Significant efforts were put by varying reactions conditions – solvents, 
pH, concentrations, temperatures, timings, but no reaction was observed with insulin. It 
was suggested that maybe the amines on insulin are less accessible or less reactive. In 
summary, the first approach failed for immobilizing insulin on the resin. Perhaps it would 
be useful to review literature related to the conjugation of insulin using amines. It might 
provide helpful insights into why this route did not work and possible solutions.    
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Figure 12: Immobilization of insulin on the resin through the diazo route. 
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Figure 13: Insulin immobilization through the imidazole carbamate route. It is a 
modification of the synthetic route shown in Figure 12. 
 
Convergent approach 
In the convergent approach (Figure 14), insulin was first caged using DMNPE diazo 
in the solution phase. This formed conjugate was then immobilized on the resin. This work 
has been successfully confirmed in the lab.29 To immobilize caged insulin on the resin, 
click chemistry was used. The click reaction utilized was first reported by the Bertozzi lab 
and readily takes place between an azide and an alkyne; it could be carried out with or 
without requiring any catalysts.39 Insulin was caged using the photolabile group bearing an 
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azide functionality. This azide can be conjugated to the resin bearing alkyne functionality 
through a triazole linkage. First copper was used for the catalysis, but Cu-assisted click 
chemistry was unsuccessful. Hence copper-free click chemistry was used with a strained 
alkyne, dibenzo cyclooctyne (DBCO) in this case.40 The synthesis scheme is outlined in 
Figure 14. Briefly, NKA was first conjugated to a bifunctional PEG-based linker having 
an azide group (which will be used for the click chemistry). Then, ketone was converted to 
diazo via hydrazone route. Once the diazo was formed, it was reacted with insulin to give 
conjugated insulin, named, DMNPE insulin mono-azide (DIMA). DBCO acid was coupled 
to resin first and then allowed to react with DIMA via click reaction to yield resin bound 
insulin. The immobilized insulin was characterized by two methods – one by performing 
TFA cleavage of the entire construct and analyzing it by MS, and secondly by performing 
photolysis of the resin bound conjugate to show the release of native insulin. Both 
treatments yielded correct masses when analyzed by mass spectrometry. For the irradiation 
experiment, the light of 365 nm wavelength was used. In one experiment, this material was 
subjected to alternating periods of light and darkness – as there was no leaching of insulin 
observed from the material which suggested that the release was solely due to the 
photocleavage. When the material was irradiated with alternating periods of illumination 
and darkness, no insulin was released in the dark; the release was seen only in the lit-state. 
The dark/light alternate release pattern is very crucial and relevant to the real-life 
application because insulin should only be released from the depot when the body needs it 
in response to rising glucose levels. It should not be released during the dark period, i.e., 
when it is not being irradiated. In Chapter 3, we will discuss attempts to test the i-PAD 
hypothesis in an animal model. 
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Figure 14: The convergent approach of insulin immobilization.  
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CHAPTER 2 
SYNTHESIS OF INSULIN MACROPOLYMER 
What were the limitations of first-generation PAD material? 
 The first-generation material here refers to the material described earlier and is 
published from this lab.29 It involves immobilizing caged insulin on an insoluble polymer. 
The insoluble polymer chosen in the first-generation material was a PEG-based resin 
(ChemMatrix®). It was preferred because it has a very high loading density of 
approximately 0.5 mmol/g, high surface/volume ratio, biocompatibility, and PEG material 
is FDA approved.41 It served as a basis for demonstrating the proof of concept that insulin 
can be tethered onto the resin surface and cleaved specifically using 365 nm light in a 
controlled manner. However, there were many potential problems with this material – 
i. PEG is not biodegradable. Because insulin depot will require repetitive 
administration, PEG will keep on accumulating at the injection site or in the body 
elsewhere unless it undergoes biodegradation. Also, because of the larger size of 
ChemMatrix resin (< 200 µm), elimination from the body would be difficult. PEG 
is biocompatible and doesn’t show toxicity at low doses, but it has a potential for 
toxicity at higher doses.42 Accumulation after a few doses would give rise to 
toxicity as there is no obvious pathway for the clearance of PEG beads. 
ii. Insulin density in the final conjugate is very low (<10% w/w). Because the majority 
of the volume is occupied by the resin, it limits the amount of insulin that can be 
given in a single injection.  
iii. Because of the larger particle size of the resin, it cannot be injected using a 
conventional 31G needle which is used in insulin syringes. For this, a larger needle 
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size of 22-23G would be required, which might be painful. It might be challenging 
to inject depot in thin dermis layer precisely. Because of all these limitations, we 
started looking for ways how we could prepare PAD material without the need for 
the solid phase polymer. The insulin macropolymer approach described in Figure 
15 was pursued to address these limitations. 
The insulin macropolymer approach 
 
Figure 15: The insulin macropolymer approach. 
 
The insulin macropolymer approach is described above in Figure 15. The idea here 
was to form a photocleavable polymer made up of insulin where insulin itself acts as a 
monomer in the polymerization process, hence the name macropolymer. DMNPE insulin 
mono-azide (DIMA), DMNPE insulin di-azide (DIDA) and a tris-DBCO (TD) linker 
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containing three strained alkynes were synthesized to achieve this. Mixing them in 1:1:1 
proportion, we expected to see random polymerization with higher molecular constructs. 
We hoped that these constructs would form a precipitate in aqueous solutions because of 
the higher MW, hydrophobicity and due to aggregation. From this suspension, we expected 
insulin to be released in a controlled fashion upon light stimulation. The advantages of this 
approach over first-generation material were the following – 
i. It gets rid of the requirement of the resin in the PAD approach. Also, it would 
eliminate all the problems associated with the usage of the resin and PEG material.  
ii. Because the particle size could be controlled while preparing, it would be easily 
injectable as opposed to bulky ChemMatrix resin.  
iii. Because insulin is a monomer in the polymerization process, it will occupy the 
majority of the mass in the final macropolymer (~ 85% w/w). It would significantly 
increase insulin density, hence total insulin loading and dose. This strategy would 
allow injecting more insulin moles per injection. 
iv. As a result, the lifetime of the depot would increase significantly.  
 The principal mechanism of polymerization is via click chemistry. We utilized 
copper-free click chemistry in our synthesis approach. The click chemistry has been used 
for making polymers for biomedical applications using small molecules, peptides, proteins, 
hydrogels, etc.43 The polymerization attempts using click chemistry have been reviewed 
extensively in the literature.44–48  
Synthesis of insulin macropolymer components 
In this section, the synthesis of DIMA, DIDA, and tris-DBCO moieties is described. 
DIMA and DIDA were synthesized as reported earlier in the lab. To cage insulin, DMNPE 
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diazo azide (DDA) was synthesized first, and its reaction with insulin was optimized to 
give DIMA and DIDA. Figure 16 outlines the synthetic steps for DDA. 
 
Figure 16: Synthesis of DDA. 
 
         Briefly, we started with acetovanillone (Sigma-Aldrich, catalog # A10809). We first 
alkylated acetovanillone using t-butyl bromoacetate (Sigma-Aldrich, catalog # 124230). 
The purpose of this step was to introduce a carboxylic acid functionality to turn DMNPE 
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into a bifunctional caging group. In the second step, nitration was performed to introduce 
a nitro group which is essential for the photocleavage activity of DMNPE. In the same step, 
the t-butyl ester hydrolyzed to give a free carboxylic acid. In the third step, an azide moiety 
was added so that it could be utilized in the click reaction. The conjugation was performed 
via an amide linkage. In the fourth step, the ketone is converted to hydrazone using 
hydrazine monohydrate. In the final step, hydrazone was converted to the reactive diazo 
using an oxidizing agent, MnO2. 
tert-Butyl (4-acetyl-2-methoxyphenoxy)acetate  
Acetovanillone (5.25 g, 31.6 mmol), t-butyl bromoacetate (5.1 mL, 34.5 mmol) and 
K2CO3 (7.2 g, 52 mmol) were mixed in a round bottom flask (RBF) and stirred at room 
temperature for 48 hours in 35 mL DMF. After 48 hours, water was added to dissolve the 
salts and, partitioned between ethyl acetate (EtOAc) and saturated NaCl. The organic layer 
was washed once again with saturated NaCl, dried over MgSO4, filtered and dried. Yield 
= 8.1 g (92%); analytical method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 
29 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
gradient 0% B to 100 % B over 29 min, C18 Hypersil column (5 μm, 250 × 4.6 mm, 
Agilent), retention time: 18.8 min (Figure 17); ESI-MS (m/z): [MH]+ C15H20O5 calculated 
for 281.1; found, 281.2 (Figure 18). 
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Figure 17: HPLC chromatogram of purified tert-butyl (4-acetyl-2-
methoxyphenoxy)acetate. 
 
 
Figure 18: MS of tert-butyl (4-acetyl-2-methoxyphenoxy)acetate [MH]+=281.2, the ester 
gets fragmented during ionization, the fragmented product is seen at [MH]+=225.3.   
 
(4-Acetyl-2-methoxy-5-nitrophenoxy)acetic Acid (nitro keto acid (NKA)) 
One gram (3.57 mmol) of ketoester was dissolved in 4.7 mL of acetic anhydride. 
This mixture was cooled in the fridge before using. Simultaneously, in a 25 mL cold RBF, 
three mL of 70% nitric acid and two mL acetic anhydride were mixed and kept in ice for 
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cooling. The chilled solution of keto-ester in acetic anhydride was added to the mixture 
dropwise. It was kept in an ice bath for the first two hours and then was stirred at room 
temperature for the next four hours. The precipitate was seen. After a total of 6 hours of 
reaction, the mixture was transferred to a beaker containing a small amount of ice and kept 
at 4 °C overnight. Next day, the precipitate was collected by filtration and washed twice 
with cold water and dried. Yield (0.61 g, 63.5%); 1H NMR (400 MHz, DMSO-d6); ppm 
2.53 (s, 3 H) 3.95 (s, 3 H) 4.91 (s, 2 H) 7.26 (s, 1 H) 7.60 (s, 1 H) 13.3 (s, 1 H, br) (Figure 
19); ESI-MS (m/z): [MH]+ calculated for C11H11NO7, 270.1; found, 270.1 (Figure 20). 
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Figure 19: Proton NMR of (4-acetyl-2-methoxy-5-nitrophenoxy)acetic Acid. 
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Figure 20: MS of (4-acetyl-2-methoxy-5-nitrophenoxy)acetic acid. The product is seen at 
[MH]+=270.1 
 
2-(4-Acetyl-2-methoxy-5-nitro-phenoxy)-N-(2-{2-[2-(2-azido-ethoxy)-ethoxy]- 
ethoxy}-ethyl)-acetamide 
NKA (200.8 mg, 748 µmol), 11-azido-3,6,9-trioxaundecan-1-amine (Sigma-
Aldrich, catalog # 17758, 150.8 µL, 760 µmol), hydroxybenzotrizole hydrate (Peptide 
International, catalog # KBT-1021-PI, 226.4 mg, 1.48 mmol) were dissolved in 2.7 mL 
anhydrous DMF. To this solution, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (ThermoFisher Scientific, 245.6 mg, 1.28 mmol) was added. The reaction 
was run overnight. The crude reaction mixture was partitioned between EtOAc and water. 
The organic layer was then washed first with saturated NaHCO3, followed by another wash 
with 1N HCl. Finally, it was washed with a saturated NaCl solution.  Then EtOAc layer 
was dried over MgSO4, filtered and dried using rotavap to obtain a viscous yellow solid. 
Yield (0.309 g, 89.4%); analytical method – reversed-phase HPLC (flow rate 1 mL min−1, 
runtime 29 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA 
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in ACN), gradient 0% B to 100 % B over 29 min, C18 Hypersil column (5 μm, 250 × 4.6 
mm, Agilent), retention time: 17.9 min (Figure 21); ESI (m/z): [MH]+ calc. C19H27N5O9 
for, 470.2; found, 470.2 (Figure 22). 
 
Figure 21: HPLC chromatogram of keto azide. 
 
 
Figure 22: MS of 2-(4-acetyl-2-methoxy-5-nitro-phenoxy)-N-(2-{2-[2-(2-azido-ethoxy)-
ethoxy]-ethoxy}-ethyl)-acetamide. The product is seen at [MH]+=470.2.           
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N-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-
methoxy-5-nitro-phenoxy]-acetamide 
 (120 mg, 255.7 µmol) of 2-(4-Acetyl-2-methoxy-5-nitro-phenoxy)-N-(2-{2-[2-(2-
azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-acetamide was dissolved in the 9.6 mL mixture of 
acetonitrile: ethanol (1:1). To this, glacial acetic acid (162.4 µL, 1.42 mmol) and hydrazine 
monohydrate (Sigma-Aldrich, 162.4 µL, 3.35 mmol) were added. The reaction was 
performed in a closed sealed vial at 90 °C for 5 hours. After 5 hours, the reaction mixture 
was evaporated using rotavap. The crude mixture was dissolved in 5% methanol (MeOH) 
in dichloromethane (DCM) and purified using flash chromatography.  
 
Figure 23: LCMS of N-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-
hydrazono-ethyl)-2-methoxy-5-nitro-phenoxy]-acetamide. The product is seen at 
[MH]+=484.1 at the retention time of 8.29 minutes. 
 
Yield (63.3 mg, 51.2%); TLC (EtOAc/MeOH, 75:25 v/v): Rf = 0.37 and 0.48; analytical 
method – reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 25 min with 5 min 
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post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 30 % B 
isocratic over 25 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time:  
8.29 min; ESI−MS (m/z): [MH]+ calculated for C19H29N7O8, 484.2; found, 484.1 (Figure 
23). 
The diazo group is unstable, highly reactive and easily gets hydrolyzed in the 
presence of water. Hence, it was always prepared immediately before the caging reaction. 
Depending on the scale of reaction and how many DMNPE per insulin were required, the 
ratio of insulin: diazo was varied accordingly. Higher the diazo equivalents, more 
modifications on insulin were seen. The exact yield of hydrazone to the diazo reaction is 
not yet measured in our lab; the diazo is unstable and it is challenging to measure the yield 
correctly. It is assumed that this yield is approximately 80% and 1.2 equivalents of 
hydrazone to insulin were taken instead of 1 equivalent. For the macropolymer approach, 
we needed only DIMA and DIDA species but no other higher modifications. Hence a series 
of reactions with varying insulin: diazo ratios were set up and analyzed. The condition 
which yielded optimum results was selected for this project. The reactions and results are 
described below. 
N-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-diazo-ethyl)-2-methoxy-5-
nitro-phenoxy]-acetamide  
5 equivalents of diazo for caging insulin 
269 µL (100 mM solution in anhydrous DMSO, 26.9 µmol) of N-(2-{2-[2-(2-
Azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-methoxy-5-nitro-
phenoxy]-acetamide was mixed with 26.8 mg MnO2 and vortexed for 45 min in the dark. 
The red-black mixture was centrifuged, and the supernatant was filtered through Celite 545 
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using glass-wool/glass-pipette. The pipette was washed with anhydrous DMSO thrice to 
get a final volume of 870 µL. The successful diazo conversion was indicated by red color 
formation. In another tube, 25 mg (4.3 µmol, Sigma-Aldrich, catalog # SAFC-91077C) of 
insulin was dissolved in 1 mL of anhydrous DMSO. The filtered diazo solution was added 
to insulin. The volume was made up to 2.15 mL by adding DMSO to make the final 
concentration of insulin 2 mM. The reaction was performed in the dark for 24 hours. After 
24 hours, DMSO was evaporated using freeze-drying. The dried residue was dissolved in 
0.01N HCl. This solution was analyzed using HPLC. The fractions were collected from 
HPLC and infused into MS to determine how many DMNPE groups were conjugated per 
insulin molecule. Analytical method – reversed-phase HPLC (flow rate 1 mL min−1, 
runtime 29 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA 
in ACN), gradient 0% B to 100 % B over 29 min, C18 Hypersil column (5 μm, 250 × 4.6 
mm, Agilent). The results are shown in Figure 24. 
2x diazo + insulin caging 
107 µL (100 mM solution in anhydrous DMSO, 10.75 µmol) of N-(2-{2-[2-(2-
Azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-methoxy-5-nitro-
phenoxy]-acetamide was mixed with 11 mg MnO2 and allowed to vortex for 45 min in 
dark. The diazo was filtered using a celite-glass wool filter. Insulin (25 mg, 4.3 µmol) was 
dissolved in 1 mL anhydrous DMSO. The diazo with a total volume of 0.78 mL after 
filtration was mixed with insulin solution and diluted to make a volume of 2.15 mL and 
insulin concentration was 2 mM. The mixture after 24 hours of the reaction was processed 
as mentioned above and filtered through 5 kDa MWCO filters. The numbers of 
modifications were determined by running it on HPLC, collecting HPLC fractions and 
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infusing individual fractions in MS. The HPLC method was slightly modified to run on a 
semi-prep column to purify in larger quantity. Purification method – reversed-phase HPLC 
(flow rate 2 mL min−1, runtime 45 min with 5 min post-run), solvent A (0.1% TFA in H2O), 
solvent B (0.1% TFA in ACN), gradient 0% B to 75 % B over 45 min, C18 Hypersil column 
(5 μm, 250 × 10 mm, Phenomenex). The data are shown in Figure 25. 
Two equivalents of diazo yielded optimum results – this ratio produced only DIMA 
and DIDA and no higher modifications on insulin. Since we wanted only these two species 
for macropolymer, this ratio was used in subsequent syntheses to cage insulin at 0.1-0.2-
gram scale to obtain larger quantities of DIMA and DIDA. The concentration of insulin 
was kept the same at 2 mM whether it was performed on a smaller or larger scale. The 
DIMA and DIDA were purified by multiple HPLC runs, and the fractions were combined. 
Final stock solutions were prepared in DMSO.  
DIMA and DIDA characterization 
DIMA Analytical method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 
30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
gradient 0% B to 100 % B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm), 
retention time: 18-19 min (Figure 26); ESI-MS (m/z): [M]+ calculated for, 6262.0; found, 
6259.0 (Figure 27); Extinction coefficient (at 280 nm) = 8400 M-1cm-1.  
DIDA Analytical method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 
30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
gradient 0% B to 100 % B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm), 
retention time: 18-20 min (Figure 28); ESI-MS (m/z): [M]+ calculated for, 6714.0; found, 
6712.0 (Figure 29); Extinction coefficient (at 280 nm) = 11700 M-1cm-1. 
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Figure 24: HPLC of crude mixture 5:1 (diazo: insulin) reaction and MS infusion of 
collected individual fractions. 
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Figure 25: HPLC of crude mixture 2:1 (diazo: insulin) reaction and MS infusion of 
collected individual fractions. 
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DIMA HPLC and MS 
 
 
Figure 26: HPLC chromatogram of purified DIMA. 
 
 
Figure 27: MS of purified DIMA. The product is seen at [M]+=6259.0, calc. 6262.0. 
 
 
 
 
 
39 
DIDA HPLC and MS 
 
Figure 28: HPLC chromatogram of purified DIDA. 
     
                   
 
Figure 29: MS of DIDA. The product is seen at [M]+=6712.0, calc. 6714.0. 
 
Synthesis of tris-DBCO linker 
To synthesize the tris-DBCO (TD) linker (Figure 30), (tren) Tris (2-
aminoethyl)amine (Acros Organics, catalog # AC314791000, 10 µmol, 1.46 µL), DBCO 
acid (Click Chemistry Tools, catalog # A101-100, 45 µmol, 15 mg), hydroxybenzotrizole 
hydrate (90 µmol, 13.8 mg) were dissolved in 0.3 mL anhydrous DMF. After that 1-ethyl-
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3-(3-dimethylaminopropyl) carbodiimide hydrochloride (76.5 µmol, 14. 7 mg) was added 
to the mixture with additional 0.5 mL anhydrous DMF and vortexed overnight. It was 
called TD linker 1 (TDL1). It was purified using HPLC.  
 
Figure 30: Synthesis of 1-{2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-
10-yn-2-yl}-6-(2-{bis[2-(6-{2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-
hexaen-10-yn-2-yl}-6-oxohexanoylamino)ethyl]amino}ethylamino)-1,6-hexanedione. 
 
HPLC purification method – reversed-phase HPLC (flow rate 2 mL/min, runtime 40 
minutes), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 
100% B over 30 minutes, isocratic 100% B for 10 minutes, C18 Hypersil column (5 μm, 
250 × 10 mm, Phenomenex), retention time: 29.83 min (Figure 31); ESI−MS (m/z): [MH]+ 
calculated for C63H54N6O6, 1092.5; found, 1092.5 (Figure 32). The purified material was 
41 
also analyzed using the same method mentioned here on HPLC. 
 
Figure 31: HPLC chromatogram TDL1. 
 
 
Figure 32: MS infusion of TDL1. The product is seen at [MH]+=1092.5. 
 
TD linker 2 synthesis 
We had difficulty in purifying TDL1 via liquid-liquid extraction or via flash 
chromatography, hence it was purified using a semi-prep column on HPLC. We thought, 
if we synthesize more non-polar TD linker, it would be easier to purify it using aqueous-
organic phase separation, as it would partition in organic phase predominantly. We then 
replaced tren with cyclohexanetricarboxylic acid. Hence, TDL2 (Figure 33) was 
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synthesized. 
 
Figure 33: TDL2 synthesis scheme 
 
1,3,5-cyclohexanetricarboxylic acid (CTA) (Sigma Aldrich, 344346-1G, 6.94 mg, 
32.1 μmol), DBCO amine (Click Chemistry Tools, 40.6 mg, 146.9 μmol) and HOBt 
hydrate (22 mg, 143.6 μmol) were dissolved in 0.3 mL of anhydrous DMF. Once the 
solution became clear, EDC (29 mg, 151.2 μmol) was added, vortexed and allowed to react 
for 18 hours. As we modified TDL1 by introducing a cyclohexane moiety, we were 
expecting to purify it by aqueous-organic phase extraction due to its hydrophobicity. 
However, we couldn’t isolate it using that method. Also, when attempted via HPLC 
purification, the presence of TFA in HPLC solvents is not recommended since even trace 
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amounts of TFA (or any acid) is found to degrade DBCO ring. First, the presence of product 
was confirmed by purifying a fraction on reversed phase HPLC and infusing it into MS. 
Once the correct fraction was identified, it was purified on a larger scale using a semi-prep 
column. The collected fractions were dried using a rotavap. HPLC purification method – 
reversed-phase HPLC (flow rate 2 mL/min, runtime 40 minutes), solvent A (H2O), solvent 
B (ACN, gradient 0% B to 100% B over 30 minutes, isocratic 100% B for 10 minutes, 5-
minute post run with 100% A, C18 column (5 μm, 250 × 10 mm, Phenomenex). Yield 14.1 
mg (44.4%); UV/vis (methanol): 312 nm (34500 M−1 cm−1); analytical run method – 
reversed-phase HPLC−MS (flow rate 0.4 mL/min, runtime 35 minutes), solvent A (0.1% 
FA in H2O), solvent B (0.1% FA in ACN), gradient 0% B to 50% B over 15 minutes, 
gradient 50% B to 100% B over 30 minutes, isocratic 100% B for 3 minutes, 100% B to 
0% B over 2 minute, C18 Hypersil column (5 μm, 100 × 4.6 mm, Varian), retention time: 
22.31 min; ESI−MS (m/z): [MH]+ calculated for C63H54N6O6, 991.4; found, 991.5 (Figure 
34); reversed phase HPLC (flow rate 1 mL/min, runtime 35 minutes), solvent A (0.1% TFA 
in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100% B over 30 minutes, 
isocratic 100% B for 5 minutes, C18 Hypersil column (5 μm, 100 × 4.6 mm, Varian), 
retention time: 27.48 min (Figure 35); 1H NMR (400 MHz, DMSO-d6) d ppm 1.04 - 1.18 
(m, 1H) 1.23 (s, 2H) 1.42 (d, J=11.71 Hz, 1H) 1.76 - 1.93 (m, 2H) 2.38 (tt, J=14.93, 7.13 
Hz, 1H) 2.83 - 3.00 (m, 1H) 3.01 - 3.17 (m, 1H) 3.62 (d, J=14.06 Hz, 1H) 5.03 (d, J=14.06 
Hz, 1H) 7.15 - 7.82 (m, 10H); 13C NMR (100 MHz, DMSO-d6):174.3, 170.6, 151.8, 148.8, 
132.8, 129.9, 129.3, 128.6, 128.4, 128.1, 127.2, 125.6, 122.8, 121.9, 114.8, 108.5, 55.2, 
42.9, 35.4, 34.6, 31.7, 29.4, 29.1 (Figure 36). 
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Figure 34: LCMS of TDL2. The product is seen at [MH]+=991.5 at the retention time of 
22.31 minutes. 
 
 
Figure 35: HPLC chromatogram of TDL2. 
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Figure 36: Proton (top) and 13C (bottom) NMR of TDL2. 
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Instability of DBCO ring in the presence of strong acids 
It has been our persistent observation that DBCO ring is highly unstable in the 
presence of strong acids, it degrades within minutes to hours. Although we observe this, 
the pathway or mechanism of how it happens is not clear. We hypothesize that the amide 
bond here may not be a canonical amide, it may not have the planar geometry as seen in 
regular amide bonds due to its position in the DBCO ring. Hence, it might be susceptible 
to acid hydrolysis. Regular amides have very long half-lives in the presence of acids but 
this one might be an exception. When we attempted to purify TD linkers using liquid-liquid 
extraction, despite being very non-polar, it always partitioned into 1N HCl layer instead of 
EtOAc. If our hypothesis is correct, in the presence of acids, the nitrogen in the amide gets 
protonated as it is not a typical amide. At this point, the amide undergoes hydrolysis which 
is the reason for ring degradation. Hence the HPLC purification method was used without 
adding TFA to HPLC solvents. In the presence of TFA, the purified material degraded very 
quickly. However, when TFA was eliminated in HPLC solvents, the product was stable 
and could be stored in -20 °C freezer for years without any issues of degradation. The 
proposed hydrolysis and the hydrolyzed products are shown in Figure 37. 
 
Figure 37: Hypothesis about the instability of DBCO ring in the presence of acids. The 
amide here may not be a regular planar amide bond; hence it might be susceptible to 
attack by strong acids to cause hydrolysis. 
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DMNPE insulin trimer synthesis and photolysis     
Insulin macropolymer synthesis is a complex reaction with many possible products; 
hence, we decided to start with the synthesis of simpler molecules like insulin trimer as 
shown in Figure 38. The trimer is a molecule in which we conjugate three molecules of 
DIMA on all three alkynes of TD linker, hence the name trimer. The DIMA and TDL2 
were synthesized and purified as described above. The stock solutions were prepared in 
DMSO, and the concentrations were measured using the UV-vis spectroscopy. 
 
Figure 38: Synthesis of DMNPE insulin trimer. 
 
Synthesis of DMNPE insulin trimer 
DIMA (61 µL, 462 nmol) was mixed with TDL 2 (16.1 µL, 140 nmol). The stock 
solutions of these were prepared in DMSO. The reaction was run for 48 hours at 37 °C in 
the dark protected from light. The trimer was used directly without further purification. In 
the analysis via MS and gel, a small amount of dimer was observed in MS analysis. 
ESI−MS (m/z): [M]+ for dimer calculated, 13513.0; found, 13512.0, [M]+ for trimer 
calculated, 19774.0; found, 19771.0 (Figure 39).  
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Figure 39: MS infusion of the trimer reaction mixture. The insulin trimer [M]+ is seen at 
19771.0 (calc. [M]+ = 19774.0) and insulin dimer [M]+ is seen at 13512.0 (calc. [M]+ = 
13513.0). 
 
DMNPE insulin trimer photolysis in DMSO 
In addition to the MS analysis of trimer, it was also analyzed by SDS-PAGE. The 
trimer sample prepared above was run on a gel (Criterion TGX Any kDa precast gel from 
Bio-rad) using Criterion vertical midi-format electrophoresis cell (Bio-rad) at 150V. The 
samples in DMSO were withdrawn and mixed in 1:1 with Laemmli loading buffer. This 
mixture was loaded in a gel. Upon running on a gel, two bands were observed. These 
correspond to dimer and trimer. In parallel, the crude reaction mixture in DMSO was 
photolyzed using a Blak-Ray lamp (Model XX-15L, 30 watts) source. For this photolysis, 
3.85 µL of the reaction mixture was diluted to 35 µL in DMSO and aliquoted into a 96 
well-plate (BD Falcon). The mixture was irradiated from the top using the UV-vis lamp at 
a 10 cm distance. 5 µL samples were withdrawn at 0, 1, 2, 4, 6, 8  minutes time points and 
diluted with 5 µL of Laemmli loading buffer. This 10 µL mixture was run on SDS-PAGE 
(Figure 40).  
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Figure 40: Characterization of DMNPE insulin trimer using SDS-PAGE. Lane 1-
molecular weight ladder, lane 2-insulin std., lane 3-insulin mixed with TDL2 in 3:1 ratio, 
lane 4-DMNPE insulin trimer crude mixture at t=0, lane 5-mixture at t=1 min, lane 6-
mixture at t=2 min, lane 7-mixture at t=4 min, lane 8-mixture at t=6 min, lane 9-mixture 
at t=8 min after photolysis in DMSO using the lamp. 
 
In lane #3 of the gel, insulin was mixed with TDL2 in 3:1 ratio. Only one band is 
visible in that lane corresponding to insulin. However, when DIMA was mixed with TDL2 
in the same proportion, we saw two new bands. The highest band corresponds to the trimer 
and another to the dimer. The mixture was then photolyzed from the top using the blak-ray 
lamp at a 10-cm distance. As the sample was being irradiated, the top band gradually 
disappeared, and the bottom band became darker. It suggested that trimer was being 
photocleaved by light to give native insulin molecules. The bottom band is consistent with 
the position of insulin band. The final time point at t=8 min was also infused in MS to 
detect insulin. It only showed a single mass of insulin: ESI (m/z); [M]+ calculated, 5808.0; 
found, 5807.0 (Figure 41). 
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The 3 bands on the trimer gel were quantified using Photoshop®. The bottom band 
is a superposition of two bands which correspond native insulin and insulin monomer 
(resulting from the photolysis of insulin dimer). 
 
Figure 41: MS infusion of the final time point from the photolysis of DMNPE insulin 
trimer. The product is seen at [M]+=5807.0, calc. for 5808.0. 
 
Kinetics of insulin trimer photolysis in DMSO 
Because native insulin and insulin monomer cannot be quantitated individually, 
they are being considered as one species in deriving equations of the kinetics of this. In 
Figure 42, A refers to insulin trimer, B refers to insulin dimer, and C refers to both insulin 
+ insulin monomer. The sequential photolysis of A→ B→ C can be fit using the equations 
below.49 The concentration of each species was determined by normalizing total insulin 
concentration to 0.66 mM. The concentration here of A, B and C refers not to the 
concentration of each species but the concentration of insulin present in each species. The 
curve fitting was performed using Kaleidagraph® software.     
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Figure 42: Photocleavage of insulin trimer. When insulin trimer is irradiated, it gets 
converted into dimer and one molecule of insulin. When dimer undergoes photolysis, it 
gets converted to monomer and one molecule of insulin. However, insulin monomer and 
insulin have the same mobility on the gel; they are considered as one species. 
 
𝐴 = 𝐴0. 𝑒−𝑘1.𝑡 
𝐵 = 𝐵0. 𝑒−𝑘2.𝑡 + (
𝐴0. 𝑘1
𝑘2 − 𝑘1
)(𝑒−𝑘1.𝑡 − 𝑒−𝑘2.𝑡) 
𝐶 = 𝐶0 + 𝐴0(2 − 𝑒−𝑘1.𝑡) + 𝐵0(1 − 𝑒−𝑘2.𝑡) +
𝐴0
𝑘2 − 𝑘1
(𝑘1. 𝑒−𝑘2.𝑡 − 𝑘2. 𝑒−𝑘1𝑡) 
Where A0, B0, and C0 are concentrations of A, B, and C at t=0 respectively. This was 
determined by quantitation of gel bands and knowledge of insulin concentration in the 
mixture.  
A0 is 81.7% of total (.00066 M) = .00053922 M 
B0 is 14.5% of total = .0000957 M 
C0 is 3.77% of total = .000024882 M 
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M0 is the time in minutes, and M1 and M2 are rate constants for the degradation of A and 
B respectively. Each set of data (A, B and C) was fit to the appropriate equation given 
above, and resulted in the following fit values for k1 and k2 (fit errors in parenthesis): 
A  k1= .47 min-1 (.035) 
B  k1= .39 min-1 (.028), k2= .35 min-1 (.015) 
C  k1= .21 min-1 (.015), k2= .016 min-1 (.0076) 
These results (shown in Figure 43) demonstrated that trimer material was 
synthesized and undergoing photolysis as it is expected from this kind of substance. It 
sequentially underwent photocleavage reactions from trimer to dimer to monomer and 
finally to native insulin. The sequential reactions (A→ B→ C) follow the first order 
kinetics. The kinetic constants are very close. The transitions can be detected using SDS-
PAGE as shown above. The native insulin released at the end was also analyzed by MS 
and showed an exact mass corresponding to insulin. 
 
Figure 43: Curve fitting of sequential photocleavage of trimer→dimer→monomer/ 
insulin. 
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The above experiment was performed in DMSO in which the trimer is soluble. 
However, in the real-world, DMSO will be replaced by bodily fluids which are aqueous. It 
is critical that trimer material remains insoluble in such aqueous solutions if we want to 
retain it at the site after injection. Otherwise, after injection, the material would diffuse 
away from the site. To test this hypothesis, the trimer material which was originally 
synthesized in DMSO was dried using a freeze dryer. PBS was added to the dried residue, 
the trimer material precipitated out, and the solution became turbid. PBS was used because 
of its composition, osmolarity is closer to plasma. The way the material behaves in PBS 
might give us an idea of how it would behave in a patient. The photocleavage of this trimer 
material was tested using a 365 nm LED designed by Dr. Friedman.  
 
Photocleavage of DMNPE insulin trimer in PBS 
The trimer crude mixture (containing 66 nmol of DIMA) was added to two HPLC 
glass inserts (one for the experimental and one for the control). HPLC glass vial insert (flat 
bottom glass vial inserts 250 μL, diameter 3.4 mm (inner), 4.5 mm (outer), height 30.5 mm 
(Agilent, 5183-2090) was used. The original reaction mixture in DMSO was added to these 
vials and freeze-dried overnight to get rid of all DMSO. Then 100 µL PBS was added to 
it, and the pellet which was at the bottom was scratched out using a needle to suspend the 
trimer material uniformly in PBS. For t=0, the sample in the insert was vortexed, 
centrifuged and half of it was withdrawn and replaced with fresh PBS. This procedure was 
repeated at the time of collection for each time point. The experimental samples were 
irradiated from the bottom by keeping the glass insert right on top of the LED, refer to 
Figure 44. The control samples were kept in the dark, not exposed to light.  
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Figure 44: Setup for photolysis of samples. The samples were photolyzed in a glass insert 
and kept right on top of 365 nm LED as shown on the right. 
 
HPLC was not used for analysis because analyte was released was not concentrated 
enough. Also, there was a concern whether other trimer components might get solubilized 
and elute at the same retention time as insulin. This would make the analysis challenging. 
The supernatant was analyzed using MS. Because we were anticipating a much lower 
quantity of insulin in the material, we pooled all the supernatant solutions for MS analysis. 
This pooled solution was spin-filtered using 5000 Da MWCO filter to remove salts from 
PBS. The salts prevent ionization of insulin in MS. After spin filtration, the sample was 
dissolved in 0.01 N HCl and infused in MS. The molecular ion [M]+ of insulin was 
calculated, 5808.0; found, 5809.0 (Figure 45). The samples were also analyzed by SDS-
PAGE to confirm the presence of insulin in the supernatant. Because of the small quantity 
of insulin, it could not be detected using Coomassie blue staining. Hence, we used silver 
staining (Thermo Fisher Scientific), which is much more sensitive and has a lower limit of 
detection than Coomassie blue staining. For gel data, refer to Figure 46. The samples were 
finally analyzed using ELISA to measure the concentration of released insulin present in 
the supernatant at each time point. 
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Figure 45: MS of insulin released from DMNPE insulin trimer (pooled samples). The 
product mass is seen at [M]+=5809.0, calc. for 5808.0. 
 
In the gel, all the time points from t=5 min showed a band which corresponds to 
insulin. In the later time points, other higher bands start appearing. It is probably because 
the portion of the material is slowly leaching into PBS. The heat generated from the LED 
might be accelerating this leaching process by heating the solvent and raising the overall 
temperature. The samples were all pooled together, and after spin filtration, showed a mass 
of insulin upon MS infusion. This gives additional confirmation that insulin is being 
released. We also performed ELISA on the samples. It was observed that insulin was being 
released steadily in the test (irradiated) sample but not in the control (unirradiated) sample. 
As the irradiation went on, the cumulative amount of insulin released also increased (Figure 
47). The final yield of insulin release was 15.9% of the total. From these experiments, we 
demonstrated that trimer was synthesized, and it was behaving as expected; after that, the 
macropolymer was synthesized and characterized. 
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Figure 46: Characterization of photolysis of DMNPE insulin trimer in PBS using SDS-
PAGE (silver staining). Lane 1-molecular weight ladder, lane 2-insulin std., lane 3-
insulin trimer mixture in DMSO, lane 4-DMNPE insulin trimer crude mixture at t=0, lane 
5-mixture at t=5 min, lane 6-mixture at t=15 min, lane 7-mixture at t=25 min, lane 8-
mixture at t=35 min, lane 9-mixture at t=45, lane 10-mixture at t=55 min after photolysis 
in DMSO using the point source. 
 
    
Figure 47: DMNPE insulin trimer was photolyzed in PBS as a suspension using 365 nm 
point source LED. Insulin release was measured using ELISA. 
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DMNPE insulin macropolymer synthesis and characterization 
The approach to synthesize macropolymer from the components described above 
will be discussed here. DIMA, DIDA, and TDL2 if mixed in 1:1:1 proportion is expected 
to give multimers and insulin polymers of different lengths as shown in Figure 48. 
 
Figure 48: Synthesis of insulin macropolymer by mixing DIMA, DIDA and tris DBCO 
linker in 1:1:1 ratio. 
 
Optimization of macropolymer synthesis 
Attempt # 1 – Effect of changing ratio of DIMA: DIDA: TDL2 
  This was the very first attempt for the polymerization reaction. Theoretically, 
having DIMA: DIDA: TDL2 in 1:1:1 ratio is expected to yield higher MW polymeric 
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species. However, we anticipated that it would also result in a heterogeneous mixture of 
products and not a single product. Hence first we wanted to see what the effect is of 
changing the ratio of DIMA + DIDA to TD linker. The solutions of DIMA (15.7 mM), 
DIDA (3.9 mM) and TDL2 (7.76 mM) were prepared in DMSO and characterized by 
HPLC and MS to make sure they are pure. The overall insulin azide (both DIMA and 
DIDA) were used in 3.5 equivalents to TDL2. Both DIMA and DIDA were mixed in the 
desired proportion first and then added to TDL2 (Table 1).  
Results 
 The very first reaction used a 100:0 ratio, it is the same ratio used in the synthesis 
of insulin trimer. In other reactions, a few higher MW bands were observed – specifically, 
3-4 newer bands were observed on top of existing trimer band; however, the bottom three 
bands remained dark. We expected that the higher bands would be darker and lower MW 
bands would disappear as the reaction progressed. Here, although we varied the proportion 
of DIMA: DIDA from 0 to 100%, the pattern of bands looked very similar across all 
reactions (Figure 49) – this was rather unexpected. It suggested that the polymerization 
reaction was stopping at a certain threshold under all conditions. One possible reason is 
that there is overcrowding of insulin molecules and due to the steric hindrance, the reaction 
sites are inaccessible to each other. The stearic hindrance could be a reason for limited 
polymerization. The inherent tendency of insulin molecules to polymerize with each other 
non-covalently and form dimer, hexamers, and aggregates might make this issue even more 
challenging to resolve.50 Another possibility is that during the reaction, the DBCO ring 
might be undergoing degradation as mentioned earlier, preventing the progress of the 
reaction. 
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Table 1: A set of reactions with different ratios of DIMA and DIDA to TDL2. 
 
  Total insulin azide (3.5eq.) 
Proportion of DIMA: DIDA 
 TDL2 (nmol) DIMA  
(%) 
DIDA 
(%) 
Reaction 1 1 100 0 
Reaction 2 2 80 20 
Reaction 3 3 60 40 
Reaction 4 3 50 50 
Reaction 5 3 40 60 
Reaction 6 3 20 80 
Reaction 7 3 0 100 
 
 
Figure 49: Characterization of the extent of polymerization of DMNPE insulin polymer 
using SDS-PAGE. Lane 1-molecular weight ladder, lane 2-insulin std., lane 3 to lane 9 – 
reaction 1 to 7 in order. 
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Attempt # 2- The effect of changing overall equivalents of insulin azides to TD linker 
keeping the ratio of DIMA: DIDA to 1:1 constant 
 In the previous experiment, we tested different ratios of DIMA: DIDA to TDL2. 
1:1 ratio makes more sense theoretically, and also it was showing relatively better results. 
Here we thought of changing the overall equivalents of insulin azides to TD linker keeping 
the ratio (1:1) constant. The following conditions were used. The solutions of DIMA (15.7 
mM), DIDA (3.9 mM) and TDL2 (7.76 mM) were prepared in DMSO. In each reaction, 
2.5 nmol of TDL2 was used (Table 2). The effect of concentration on the reaction yields 
was tested by performing the reaction at a higher and lower concentration. The effect of 
other solvent systems was also investigated. We used PBS as well as water as solvents as 
the formed complexes might have different conformations in these solvents. The 
hypothesis was that using different solvents, the overcrowding could be prevented to 
improve the reaction efficiency. 
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Table 2: A set of reactions of TDL2 with DIMA: DIDA in 1:1 proportion varying 
equivalents, solvents, and concentrations, etc. 
 Solvent 
TDL2 
(nmol) 
Ins 
azide eq. 
DIMA 
(nmol) 
DIDA 
(nmol) 
Vol. 
(µL) 
1 DMSO 2.5 3.5 4.375 4.375 2.3 
2 DMSO 2.5 3 3.75 3.75 2.0 
3 DMSO 2.5 3 3.75 3.75 10.2 
4 50%DMSO/water 2.5 3 3.75 3.75 4.1 
5 20%DMSO/water 2.5 3 3.75 3.75 10.3 
6 50%DMSO/PBS 2.5 3 3.75 3.75 4.1 
7 DMSO 2.5 2.2 2.75 2.75 1.6 
8 20% DMSO/water 2.5 2.2 2.75 2.75 8.2 
 
Results 
The results are as shown in Figure 50. The pattern of polymer formation was similar to the 
pattern observed in attempt #1. There were no additional or newer bands formed after 
changing the equivalents of insulin azides to TDL2.  
The higher the concentration of insulin in the solution, the higher is its tendency to 
form multimers and aggregates.51 This aggregation might sterically hinder sites from 
undergoing polymerization reactions. Because of this, we thought of reducing insulin 
concentration in the reaction, but it did not affect the extent of the polymerization reaction. 
Solvents other than DMSO for example water, PBS were also used hoping to observe if 
there is any change in the pattern of bands  
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Figure 50: Characterization of the extent of polymerization of DMNPE insulin polymer 
using SDS-PAGE. Lane 1-molecular weight ladder, lane 2 to lane 9 – reaction # 1 to 8 in 
order. 
 
Attempt # 3 
In this attempt, the equivalents of insulin azide to TDL2 were varied over a wide 
range to see whether it helps in the improvements in synthesizing higher MW 
macropolymers (Table 3). 
Results 
 As the equivalents of insulin azides increased to 3, gradually there was an 
improvement over the polymerization reaction, showing better reaction progression in a 
reaction where 3 eq. was used, as shown in Figure 51. This, however, didn’t show any 
improvement over previous attempts.  
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Table 3: A set of reactions by varying the equivalents of insulin azides to TDL2. 
 
  TDL2 (nmol) Equivalents 
DIMA 
(nmol) 
DIDA 
(nmol) 
Total vol. 
(µL) 
1 3 1 1.5 1.5 1.2 
2 2.5 1.3 1.625 1.625 1.2 
3 2.5 1.7 2.125 2.125 1.4 
4 2.5 2 2.5 2.5 1.7 
5 2.5 2.3 2.875 2.875 1.8 
6 2.5 2.7 3.375 3.375 2.1 
7 2.5 3 3.75 3.75 2.3 
 
 
 
Figure 51: Characterization of the extent of polymerization of DMNPE insulin polymer 
using SDS-PAGE. Lane 2 – MW ladder, lane 3 to lane 9 – reaction # 1 to 7 in order. 
 
At this point, different reaction conditions were manipulated, but there were no 
significant changes in the extent of the polymerization. Other things to promote the 
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polymerization reaction were tried as described below. None of it seemed to yield 
improved results though. 
i. Along with PBS, water, 0.01N HCl, 20% acetic acid were used as solvents.  
ii. Also, the reactions were also performed in the presence of chaotropic reagents like 
6M urea, 1% Triton- 100x, 5 mM SDS to potentially break down non-covalent 
aggregates of insulin.  
iii. The reactions were performed with or without sonication.  
iv. The sequence of addition of DIMA or DIDA to TDL2 was also altered. Instead of 
mixing DIMA and DIDA together first and then adding to TDL2, either DIMA or 
DIDA were mixed with TDL2 first individually and allowed to react overnight, 
then remaining insulin azide was added. 
  After seeing no significant changes, we decided to change the arms length so that 
making these changes might improve the extent of the polymerization reaction. 
Synthesis of a longer TD linker 
Step 1 – Coupling of PEG boc linker to cyclohexane tricarboxylic acid followed by 
TFA cleavage 
1,3,5-cyclohexanetricarboxylic acid (CTA) (Sigma-Aldrich, 344346-1G, 2.56 mg, 
11.86 μmoles), O-(2-Aminoethyl)-O′-[2-(Boc-amino)ethyl]hexaethylene glycol (Sigma-
Aldrich, 25 mg, 53.35 µmol), EDC (11.6 mg, 60.5 µmol) and HOBt hydrate (10.9 mg, 71.2 
µmol) were mixed in 50 µL anhydrous DMF for 24 overnight (Figure 52). Here, we 
inserted a PEG-based arm between DBCO alkyne and central CTA molecule. This 
increased the length of each arm of TDL and we anticipated that the flexibility of TDL3 
would overcome stearic restrictions potentially forming higher MW macropolymers.  
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Figure 52: Synthesis of long arm TDL3. 
 
The intermediate was attempted to be purified using flash chromatography. This 
purification was challenging because the product does not have any chromophore or 
ionizable group, the fractions from the flash column were difficult to analyze using TLC. 
On HPLC as well, the product had to be monitored at 205 nm where the baseline is often 
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noisy. Because the purification by flash chromatography was challenging, finally, it was 
purified using reversed phase semi-prep column. HPLC purification method – reversed-
phase HPLC (flow rate 2 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% 
TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to100 % B over 30 min, C18 
Hypersil column (5 μm, 250 × 10 mm, Phenomenex), retention time: 33 min (Figure 54). 
The product purified was subjected to TFA cleavage in 10% DCM in TFA (0.5 mL) for 2 
hours. Then TFA was evaporated, and the sample was dried. 1.8 mg of material was 
recovered. ESI-MS (m/z): [M]+ calculated for, 1266.8; found, 1267.6 (Figure 53); 
analytical method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 
min post-run),  solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% 
B to 100 % B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm, Phenomenex), 
retention time: 16-17 min (Figure 54). 
 
 
Figure 53: MS of purified TDL3 intermediate after TFA cleavage. The product is seen at 
[MH]+=1267.6. 
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Figure 54: Upper chromatogram - Crude reaction mixture of the reaction, 33’ peak was 
the product. After purification and TFA cleavage, it was analyzed by HPLC and is eluting 
at 17’(bottom). The peak between 6-9’ in the bottom chromatogram is a solvent peak. 
 
Step 2 – Coupling of DBCO acid to the intermediate to synthesize TD linker # 3 
 Once the TFA cleavage was performed, and the product was dried, and it was 
coupled to DBCO acid using HATU, DIEA conjugation chemistry. The intermediate (1.8 
mg, 1.42 µmol), DBCO acid (3 mg, 9 µmol), HATU (Chem-Impex, 3.4 mg, 9 µmol) and 
DIEA (3.13 µL, 18 µmol) were mixed in 50 µL DMF. Then it was purified using normal 
phase HPLC (flow rate 2 mL min−1, runtime 35 min with 5 min post-run), solvent A (H2O 
(no TFA)), solvent B (ACN (no TFA)), gradient 100% B to 16.4 % B over 30 min, isocratic 
at 16.4% B for next 5 min, Silica Hypersil column (5 μm, 250 × 10 mm, Phenomenex), 
retention time ≈ 28 min (Figure 55); ESI-MS (m/z): [M]+ calculated for, 2213.6; found, 
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2213.0 (Figure 56). Not all the crude mixture was purified, only a couple of rounds of 
HPLC were performed. About 20 nmol of TDL 3 were purified based on quantification 
using UV-vis spectrophotometry. 
 
Figure 55: HPLC chromatogram of purified TDL3. 
 
 
Figure 56: MS of purified TDL3. The product is seen at [M]+=2213.0, calc. for 2213.6. 
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Polymerization attempt with long arm TDL3 
The polymerization reactions were set up under similar conditions as performed 
earlier. The aim was to see if extending the length of arms of TD linker would affect the 
polymerization pattern and the extent of the polymerization reaction. For comparison, both 
TDL2 along with TDL3 was incorporated. The trimer reactions were also run in parallel. 
The stock solutions of each reagent were prepared in DMSO and analyzed by MS, HPLC 
and UV-vis spectroscopy. DIMA (25 mM), DIDA (5 mM), TDL2 (7.76 mM) and TDL3 
(1.09 mM) (Table 4). The polymer reactions were diluted to 69.7 µL in 0.01 N HCl, and 
all reactions were performed overnight and analyzed using SDS-PAGE. The purpose of 
performing dilution using 0.01 N HCl was that diluting reduces the overall concentration 
of insulin and possibly helps to avoid aggregation. Extreme pH conditions may aid in this 
process too.  
 
Table 4: A set of reactions of DMNPE insulin trimer and polymer using TDL2 and 3. 
 
 Reaction TDL2 
(nmol) 
TDL3 
(nmol) 
Equivalents DIMA 
(nmol) 
DIDA 
(nmol) 
Total 
vol. 
(µL) 
Trimer – TDL2 1  3 3  1.2 
Trimer – TDL3  1 3 3   
Polymer – 
TDL2 
2  3 3 3 69.7 
Polymer – 
TDL3 
 2 3 3 3 69.7 
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Results 
 
Figure 57: Characterization of the extent of polymerization of DMNPE insulin polymer 
using TDL2 and 3. Lane 1 – MW ladder, lane 2 – insulin std., lane 3 – insulin std. + 
TDL2, lane 4 – DIMA, lane 5 – DIDA, lane 6 – insulin trimer with TDL2, lane 7 – 
insulin trimer with TDL3, lane 8 – insulin polymer with TDL2, lane 9 – insulin polymer 
with TDL3. 
 
In Figure 57, Lane 6 and 8 show insulin trimer and polymer respectively as 
demonstrated earlier using TDL2. Lane 7 shows insulin trimer using TDL3. Interestingly, 
it shows a very similar pattern as expected but the distance among bands is slightly larger, 
this makes sense as the MW of this linker is also larger compared to TDL2. However, the 
results were not so encouraging for polymerization reaction where the extent of 
polymerization is lesser than earlier polymer. Extending the length of TD arms had an 
unfavorable effect on the polymerization reaction. In fact, it predominantly stopped at the 
dimer stage. The quenching at the dimer stage was probably because of cross-linking 
occurring due to DIDA as explained in Figure 58. When one DIDA is conjugated on the 
TD linker, due to the increase in effective molarity, another end also reacts readily on an 
open alkyne of TD linker, effectively cross-linking intramolecularly and blocking a 
potential site of reaction as shown in Figure 58. 
71 
 
Figure 58: Cross-linking of TD linker caused by both azides of DIDA clicking on the 
same molecule of TD linker. A possible reason why polymerization stops at dimer step as 
shown here. 
 
TD linker #4 – A short arm linker 
Because we failed to see any effect after lengthening the arms of TD linker, for 
TDL3, in this approach, the length was reduced. We wanted to explore whether length 
might restrain the issue of intramolecular cross-linking by DIDA as shorter arms cannot 
undergo intramolecular cross-linking. The small linker chosen was 3-azido-1-propanamine 
(Sigma-Aldrich, 762016-100MG). Instead of incorporating it into TD linker; it was decided 
to incorporate it in DIMA and DIDA species. Using this linker, a new synthesis of insulin 
azide was designed. Newly synthesized DIMA and DIDA species were reacted with TDL2 
to see how it works. The species were synthesized as shown in Figure 59 below and using 
newly synthesized DDA, insulin was caged.      
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Figure 59: Synthesis of short length DDA by using 3-Azido-1-propanamine. 
 
2-(4-Acetyl-2-methoxy-5-nitrophenoxy)-1-(3-azidopropylamino)-1-ethanone 
 NKA (100 mg, 371 µmol), 3-Azido-1-propanamine (39.1 µL, 380 µmol), HOBt 
hydrate (113.2 mg, 739.4 µmol) were dissolved in 1.3 mL DMF. Then EDC (123 mg, 640 
µmol) was added and allowed to react overnight. The product was purified by partitioning 
the crude reaction mixture in water and EtOAc. The organic layer was first washed with 
1N HCl, followed by saturated NaHCO3, and finally with saturated NaCl. Then EtOAc 
layer was dried over MgSO4 and filtered off. Yield = 121 mg (92.5%); ESI-MS (m/z): 
[MH]+ calculated for C14H17N5O6, 352.1; found, 352.4 (Figure 60); analytical method – 
reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-run), solvent 
A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 % B over 30 
min, C18 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 14.5-15 min 
(Figure 61). 
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Figure 60: MS infusion of 2-(4-acetyl-2-methoxy-5-nitrophenoxy)-1-(3-
azidopropylamino)-1-ethanone. The product mass is seen at [MH]+=352.4. 
 
 
Figure 61: HPLC chromatogram of 2-(4-acetyl-2-methoxy-5-nitrophenoxy)-1-(3-
azidopropylamino)-1-ethanone. 
 
1-(3-Azidopropylamino)-2-{2-methoxy-4-[1-(methylimino)ethyl]-5-nitrophenoxy}-1-
ethanone 
(35.2 mg, 100 µmol) of 2-(4-Acetyl-2-methoxy-5-nitrophenoxy)-1-(3-
azidopropylamino)-1-ethanone was dissolved in the 2.8 mL mixture of acetonitrile: ethanol 
(1:1). To this, glacial acetic acid (32.2 µL, 0.563 mmol) and hydrazine monohydrate 
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(Sigma-Aldrich, 64.6 µL, 1.33 mmol) were added. The reaction was performed in a closed 
sealed vial at 90 °C for 5 hours. After 5 hours, the reaction mixture was evaporated using 
rotavap. The crude mixture was dissolved in 5% methanol (MeOH) in dichloromethane 
(DCM) and purified using flash chromatography. Yield (17 mg, 46%); TLC 
(EtOAc/MeOH, 75:25 v/v): Rf = 0.33 and 0.46; LCMS method – reversed-phase HPLC-
MS (flow rate 0.4 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% FA in 
H2O), solvent B (0.1% FA in ACN), gradient 0% B to 50 % B over 5 min, gradient 50% B 
to 100 % B until 27, gradient 100% B to 0% B for next 2 min and isocratic 100% A for 
next 1 min; C18 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 15.04 
min; ESI−MS (m/z): [MH]+ calculated for, 366.1; found, 366.1 (Figure 62). 
 
Figure 62: LCMS run of 1-(3-azidopropylamino)-2-{2-methoxy-4-[1-
(methylimino)ethyl]-5-nitrophenoxy}-1-ethanone showing a single peak at                     
15' with a mass of 366.1. 
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Caging of insulin by shorter DDA 
     167 µL (70.0 mM solution in anhydrous DMSO, 11.7 µmol) of 1-(3-
azidopropylamino)-2-{2-methoxy-4-[1-(methylimino)ethyl]-5-nitrophenoxy}-1-ethanone 
was mixed with 15 mg MnO2 and allowed to vortex for 45 min in the dark. The red-black 
mixture was centrifuged, and the supernatant was filtered through Celite 545 using glass-
wool/glass-pipette. The pipette was washed with anhydrous DMSO thrice to get final diazo 
solution of 800 µL. The successful diazo conversion was indicated by red color formation. 
In another tube, 25 mg (4.3 µmol, SAFC-91077C) of insulin was dissolved in 1 mL of 
anhydrous DMSO. The formed diazo solution was added to insulin. The volume was made 
up to 2.15 mL to make the concentration of insulin 2 mM by adding DMSO. The reaction 
was run for 24 hours in the dark. After 24 hours, DMSO was removed via freeze-drying. 
The dried residue was dissolved in 0.01N HCl and filtered through 5 kDa MWCO filters 
(Vivaspin®) and washed twice with 0.01N HCl. The fractions were collected from HPLC 
and DIMA, DIDA stock solutions in DMSO were prepared. Analytical method – reversed-
phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-run),  solvent A (0.1% 
TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 % B over 30 min, C18 
Hypersil column (5 μm, 250 × 4.6 -mm, Agilent), retention time: DIMA-16-17 min, DIDA-
17-18 min (Figure 63); ESI-MS (m/z) [M]+ calculated for DIMA, 6144.0; found, 6143.0 
(Figure 64); [M]+ calculated for DIDA, 6478.0; found, 6476.0 (Figure 65). 
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Figure 63: HPLC chromatograms of DIMA (top) and DIDA (bottom) with the short 
linker. 
 
 
Figure 64: MS infusion of DIMA (top). The purified DIMA mass is seen at [M]+=6143.0 
(calc. 6144.0). 
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Figure 65: MS infusion of DIDA (bottom). The purified DIDA (bottom) is seen at [M]+ 
=6476.0 (calc. 6478.0). 
 
Macropolymerization attempt with short insulin azide linker and TDL2 
 The polymer reaction of this new insulin azide linker with TDL2 was tested and 
analyzed to see if there is any improvement over long-armed linker. Both trimer and 
polymer reactions were set up. For trimer reaction, DIMA (0.38 µL, 3 nmol) and TDL2 
(1.52 µL, 9 nmol) were mixed and incubated at 37 °C overnight and analyzed by SDS-
PAGE. Similarly, DIMA (0.68 µL, 4 nmol), DIDA (1.3 µL, 4 nmol) were mixed, and TDL2 
(0.51 µL, 4 nmol) was added. The reaction was incubated overnight at 37 °C.  
Results 
 The results are shown in Figure 66 were very similar to what was observed with 
old insulin azide linker. There was no improvement in the extent of polymerization. 
Because all the other attempts to improve the polymerization have yielded no 
improvements over the very first attempts with original TD linker and insulin azides, it was 
decided to use the original reagents and perform polymerization reaction. Like the 
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photolysis of trimer, the photolysis of insulin macropolymer was conducted and analyzed.  
 
Figure 66: Characterization of the extent of polymerization of DMNPE insulin polymer 
using TDL2. Lane 1 – MW ladder, lane 2 – insulin std., lane 3 – insulin trimer, lane 4 – 
insulin polymer. 
 
DMNPE insulin polymer photolysis in DMSO 
Although we tried different tris-DBCO cross-linkers, they all seemed to give 
similar results – no linker was better than another. Since we had plenty of TDL2 
synthesized, we decided to use it for macropolymerization and its subsequent 
characterization. DIMA (19.15 µL, 145 nmol), DIDA (16.86 µL, 145 nmol) were mixed, 
and to this mixture TDL2 (16.11 μL, 140 nmol) was added. All stock solutions were 
prepared in DMSO. The reaction was incubated for 48 hours at 37 °C. It was later analyzed 
by SDS-PAGE and photolysis. 
The polymer sample prepared above was run on a gel (Criterion TGX Any Kd 
precast gel from Bio-rad) using Criterion vertical midi-format electrophoresis cell (Bio-
rad) at 150V. Upon running on a gel, a few new bands were observed as before. The 
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samples in DMSO were withdrawn and mixed in 1:1 with sample loading buffer. This 
mixture was loaded into the gels. In parallel, the crude reaction mixture which is in DMSO 
was photolyzed using a Blak-Ray lamp (Model XX-15L, 30 watts) source. For photolysis, 
6.26 µL of the reaction mixture was diluted to 45 µL in DMSO and aliquoted into a 96 well 
plate (BD Falcon). The mixture was irradiated from the top using the UV-vis lamp from 
10 cm distance. 5 µL samples were withdrawn at 0, 1, 2, 4, 6, 8, 10, 20 min time points and 
run on SDS-PAGE. The final time point was also analyzed by MS infusion.  
We saw 4-6 new higher bands (Figure 67). The upper band corresponded to higher 
MW species ranging from dimer to hexamers. The mixture was then photolyzed from the 
top using the blak-ray lamp at a 10-cm distance. As the sample was being irradiated, the 
higher bands are gradually disappeared and the bottom band which corresponded to insulin 
became darker. The pattern suggested that trimer was being photocleaved by light to give 
native insulin molecules. The bottom band was consistent with the mobility of insulin std. 
The final time point at t=20 min was also infused in MS to detect any mass of insulin. It 
only showed a single mass of insulin, [M]+ calculated, 5808.0; found, 5807.0 (Figure 68). 
80 
 
Figure 67: Characterization of DMNPE insulin polymer using SDS-PAGE. Lane 1-
molecular weight ladder, lane 2-insulin std., lane 3-DIMA+DIDA mixed with TDL2 in 
1:1:1 ratio at t=0 min, lane 4 – t=1 min, lane 5 – t=2 min, lane 6 – t=4 min, lane 7 – t=6 
min, lane 8 – t=8 min, lane 9 – t=10 min and lane 10 – t=20 min of photolysis. 
 
 
Figure 68: MS infusion of final time point from the photolysis of DMNPE insulin 
polymer. The [M]+ of insulin at 5807.0 (calc. for 5808.0). 
 
The above experiment was performed in DMSO where polymer species were 
soluble. However, in the real-world, DMSO will be replaced by bodily fluids. It is essential 
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that polymer material is insoluble in such aqueous solutions if we want to retain it at the 
site after injection. Otherwise, after injection, the material would diffuse away from the 
location and the depot no longer will exist. To test this hypothesis, the polymer material 
which was originally synthesized in DMSO was dried using a freeze dryer. PBS was added 
to the dried residue, the material precipitated out, and the solution became turbid. PBS was 
used because of its composition, osmolarity is closer to plasma, and the ways the material 
behaves here might give us some idea of how it would behave in a patient. The 
photocleavage of this material was tested using a 365 nm LED designed by Dr. Friedman 
in the same manner the trimer material was analyzed.  
Photocleavage of DMNPE insulin polymer in PBS 
The polymer crude mixture was added to two HPLC glass inserts (one for 
experimental and one for the control). HPLC glass vial insert (flat bottom glass vial inserts 
100 μL, diameter 3.4 mm (inner), 4.5 mm (outer), height 30.5 mm (Agilent, 5183-2090) 
was used. The original reaction mixture which was in DMSO was added to these vials and 
freeze-dried overnight to get rid of all DMSO. Then 100 µL PBS was added to it, and the 
pellet which was at the bottom was scratched out using a needle to suspend the trimer 
material uniformly in PBS properly. For t=0, the sample in the insert was vortexed, 
centrifuged and half of it was withdrawn and replaced with fresh PBS. This procedure was 
repeated at the time of collection of each time point. The experimental samples were 
irradiated from the bottom by keeping the glass insert right on top of the LED. For the 
control samples, the volume was withdrawn at the time points after vortexing followed by 
centrifugation. The control samples were kept in the dark, not exposed to light.  
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HPLC was not used because the quantity that was released was too low to be 
detected by HPLC. Also, there was a concern whether other polymer components might 
get solubilized and elute at the same retention time as insulin, this would make the analysis 
challenging and complicated. The samples were analyzed by SDS-PAGE to confirm the 
presence of insulin in the supernatant. Because of small insulin quantity, it could not be 
detected using Coomassie blue staining. Hence, we used silver staining which is more 
sensitive (Thermo Fisher Scientific) as shown in Figure 69. The supernatant was also 
analyzed using MS. Because we were anticipating a much lower quantity of insulin in the 
material, we pooled all the supernatant solutions for MS analysis. This pooled solution was 
spin-filtered using 5000 Da MWCO filter to get rid of salt from PBS. The salt prevents 
ionization of insulin in MS. After spin filtration, the sample was dissolved in 0.01 N HCl 
and infused into the MS. [M] calculated 5808.0; found, 5808.0 (Figure 70). The release of 
insulin is seen in the experimental points (Figure 71) which were irradiated but not from 
the control samples which were kept in the dark. There was a brief lag period before insulin 
started appearing in the supernatant. The delay might be because, in the initial phases of 
photolysis, the macropolymer is just breaking apart into smaller MW constructs but not 
much insulin is being released. However, as the irradiation went on, newly formed smaller 
MW constructs underwent photolysis to give insulin. Hence it is not seen in the initial 
phases. The samples were also analyzed by ELISA to measure the concentration of insulin 
present in the supernatant.  
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Figure 69:  Characterization of photolysis of DMNPE insulin polymer in PBS using SDS-
PAGE (silver staining). Lane 1-molecular weight ladder, lane 2-insulin std., lane 3-
insulin trimer mixture in DMSO, lane 4-DMNPE insulin trimer crude mixture at t=0, lane 
5-mixture at t=5 min, lane 6-mixture at t=15 min, lane 7-mixture at t=25 min, lane 8-
mixture at t=35 min, lane 9-mixture at t=45, lane 10-mixture at t=55 min after photolysis 
is DMSO using the point source. 
 
 
 
Figure 70: MS infusion of DMNPE insulin polymer samples photolyzed in PBS. The 
samples were pooled, combined and infused in MS. The mass [M]+ is seen at 5808.0. 
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Figure 71: Insulin release as measured using ELISA from DMNPE insulin macropolymer 
photolysis in PBS using the LED point source. 
 
Macropolymer synthesis using insulin lispro  
Insulin lispro is a fast-acting insulin analog. In lispro, lysine and proline residues 
on B chain are reversed by using recombinant DNA technology. This change prevents the 
dimer and hexamer formation in insulin lispro. Thus, lispro stays predominantly in the 
monomer form and hence it has faster absorption kinetics into the systemic circulation.52 
This is shown in Figure 72 comparing its absorption with human regular insulin. It has a 
rapid onset of action.  
Insulin monomers have an inherent tendency to undergo self-association to form 
higher order aggregates such as dimers, tetramers, hexamers, and polymers of hexamers.53 
In the pancreas, proinsulin hexamer aggregates are soluble but once converted to insulin 
hexamers, the hexamers precipitate out as microcrystals. Zn2+ ions or other divalent cations 
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are known to stabilize the hexamers by complexing with histidine residues. It is known that 
hexamer formation stores, protects, and stabilizes insulin in the pancreas.54 When insulin 
is required, it is secreted from the beta cells in response to rising blood sugar levels. In the 
bloodstream, the hexamers dissociate into monomers due to a reduced concentration of 
zinc in the blood compared to beta cells and slightly higher pH which favors the 
dissociation. The monomer is active form and binds to the receptors to promote the uptake 
of glucose. The rate of dissociation has a crucial effect on the rate of absorption of insulin 
and the pharmacokinetic properties. The faster the hexamers dissociate to form monomers, 
the faster is its absorption and quicker therapeutic effect. The fast-acting insulin analogs 
are designed such that there will be minimum aggregation and hexamer formation. While 
the delayed acting insulin analogs are prepared by complexing insulin hexamers with zinc 
to increase circulation time and prolong the response.55  
One of the hypotheses why the polymerization reaction of insulin is being quenched 
at certain stage might be because of overcrowding and steric hindrance. The inherent 
tendency of insulin to multimerize and self-aggregate might be making the reaction even 
more challenging. The overcrowding might render the reaction sites inaccessible hindering 
the progress of reactions. To prevent this issue, we thought of using insulin lispro as it has 
a reduced tendency to aggregate and form multimers. It might potentially allow the 
reactions to move forward and we can synthesize higher MW insulin macropolymers. To 
test this hypothesis, similar reactions were performed and repeated except regular insulin 
was replaced with insulin lispro analog (Sigma Aldrich, catalog # Y0000348). 
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Figure 72: Absorption profile of insulin lispro vs regular human insulin.56  
 
Caging of insulin lispro 
Aliquot (112 µL, 86.1 mM solution in anhydrous DMSO, 9.67 µmol) of N-(2-{2-
[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-methoxy-5-nitro-
phenoxy]-acetamide was mixed with 23.35 mg MnO2 and vortexed for 45 min in the dark. 
The red-black mixture was centrifuged, and the supernatant was filtered through Celite 545 
using glass-wool/glass-pipette. The pipette was washed with anhydrous DMSO thrice to 
get a final diazo solution of 576 µL. Successful diazo conversion is indicated by red color 
formation. In another tube, 21.4 mg (3.68 µmol, Sigma-Aldrich, catalog # Y0000348) of 
insulin was dissolved in 0.8 mL anhydrous DMSO. The formed diazo solution was added 
to insulin. The volume was made up to 1.84 mL using DMSO to make the final 
concentration of insulin 2 mM. The reaction was performed for 24 hours in the dark. After 
24 hours, DMSO was evaporated using freeze-drying. The dried residue was dissolved in 
0.01N HCl and filtered through 5 kDa MWCO filters (Vivaspin) and washed twice with 
0.01N HCl. Caged insulin species were purified using the semi-prep column on HPLC. 
Purification method – reversed-phase HPLC (flow rate 2 mL min−1, runtime 45 min with 
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5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 
0% B to 75 % B over 45 min, C18 Hypersil column (5 μm, 250 × 10 mm, Phenomenex). 
DMNPE insulin lispro mono-azide (DILMA) 
ESI-MS (m/z): [M]+ calculated for, 6267.0; found, 6264.0 (Figure 73); Analytical 
method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-
run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 
% B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm), retention time: 16-17 min 
(Figure 74). 
 
Figure 73: MS of purified DILMA. The product is seen at [M]+=6264.0; calc. 6267.0. 
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Figure 74: HPLC chromatogram of DILMA. 
 
DMNPE insulin lispro di-azide (DILDA) 
ESI-MS (m/z): [M]+ calculated for, 6719.0; found, 6717.0 (Figure 75); Analytical 
method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-
run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 
% B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm), retention time: 17-19 min 
(Figure 76). 
 
Figure 75: MS of purified DILDA. The product is seen at [M]+=6717.0, calc; for 6719.0. 
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Figure 76: HPLC chromatogram of purified DILDA. 
  
 The stock solutions were prepared in DMSO of DILMA, DILDA and TDL 2. The 
concentrations were as follows; DILMA (11.95 mM), DILDA (7.42 mM) and TDL2 (8.69 
mM). For the preparation of trimer, TDL2 (6 nmol, 0.69 µL) and DILMA (19.8 nmol, 1.65 
µL) were mixed and incubated at 37 °C overnight. For the synthesis of the polymer, 
DILMA (5.175 nmol, 0.43 µL) and DILDA (5.175 nmol, 0.69 µL) were premixed and then 
combined with TDL2 (5 nmol, 0.575 µL) and incubated at 37 °C overnight. The mixtures 
were then analyzed by running on a gel. A part of the mixture was also photolyzed using 
365 nm lamp to confirm that formed material is undergoing photolysis to release the native 
insulin.  
The results of polymerization as shown in Figure 77 using insulin lispro were not 
different from what we have observed with regular human insulin. There were 3-4 
prominent new bands observed but not more than. It suggested that even with non-
aggregating insulin, the reactions are being quenched. Perhaps aggregation is not the issue 
but rather something else which is causing the quenching. It will be worth investigating the 
effect of concentration, pH, solvent, and using a different length of TD linker with insulin 
lispro. 
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Figure 77: Characterization of the extent of polymerization of DMNPE insulin lispro 
trimer and polymer using SDS-PAGE. Lane 1-molecular weight ladder, lane 2-insulin 
std., lane 3 – Insulin lispro trimer, lane 4 – insulin lispro trimer photolyzed for 10 min, 
lane 5 – insulin lispro polymer, lane 6 – insulin lispro polymer photolyzed for 10 min.  
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Chapter 3 
IN-VIVO TESTING OF FIRST-GENERATION PAD MATERIAL 
Rationale and hypothesis 
 The synthesis of first-generation material was reported earlier in the lab and 
described in Chapter 1. The study demonstrated that insulin could be covalently conjugated 
to an insoluble polymer via a photocleavable linker. Irradiating this material with the light 
at 365 nm wavelength releases insulin in a predictable manner, i.e., the amount of insulin 
released can be controlled by controlling the duration and intensity of irradiation. Insulin 
release was observed only in the presence of light. In the absence of light, no insulin release 
was observed. This release pattern suggested that insulin release is happening solely due 
to photolytic processes and not due to leaching. This study demonstrated a proof of concept 
of light triggered insulin release in-vitro. However, there were several questions needed to 
be answered to show successful demonstration in-vivo in an animal model. We asked the 
following questions before initiating the studies –  
i. First question – whether insulin is still bioactive after release as it is exposed to 
organic solvents and extreme pH during and after reactions? Insulin was exposed 
to 100% DMSO during the caging reaction by DDA. DMSO was used because 
insulin has a very high solubility in DMSO. Water is not an ideal solvent for the 
diazotization reaction as diazo is unstable and gets hydrolyzed quickly. Hence, the 
caging reaction has poor yields in water. Also, during the spin-filtration step, insulin 
azide mixture is typically dissolved in 0.01 N HCl as insulin has higher solubility 
at low pH. Despite harsh conditions, in the end, photoreleased insulin shows a 
correct mass in MS and the same retention time on HPLC as native insulin. 
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However, based on this evidence, we cannot conclude if it is still bioactive. The 
bioactivity here refers to the efficacy of insulin to bring down blood glucose (BG) 
in an animal. Bioactivity is yet required to be tested experimentally. 
ii. Second question – how fast is the diffusion of insulin from the intradermal depot 
site once it is photoreleased – is it fast enough to be useful in a clinical sense? 
Insulin is typically administered via subcutaneous injection clinically. The reason 
is that insulin is released in a sustained manner from subcutaneous tissue. This 
tissue layer has a lower blood flow rate and hence slower, but steadier absorption 
of insulin occurs from the site. However, the depot here is supposed to be injected 
intradermally so that the depot material will be held at the injection site. If it is 
injected subcutaneously, it might move and diffuse away from the location which 
is undesirable, and the PAD approach would not work. Also, light penetration 
would be very limited to deeper subcutaneous tissue than a shallower intradermal 
layer. Intradermal administration as intended in our case is not practiced clinically. 
As a result, there is very little literature about the kinetics of insulin absorption from 
the intradermal layer. We do not know how fast or slow the absorption will be from 
this layer and it must be determined experimentally. If there is very slow diffusion 
from this site, insulin that is released due to photolysis will take longer to go into 
the systemic circulation, and the response would be delayed. 
iii. Third question – what is the extent of light penetration into the skin? In our 
approach, 365 nm light is being utilized to trigger insulin release from the depot 
material. The question is whether this 365 nm light has enough penetrating power 
to penetrate the dermal layer. There are not many studies investigating the depth of 
93 
penetration of light in the skin. Moreover, it is critical whether the quantity of 
insulin that is released would be physiologically relevant to cause a significant 
change in the blood glucose levels. 
Development of a cell culture-based assay for insulin bioactivity confirmation 
The assay was performed to confirm the bioactivity of insulin. The steps are 
outlined in Figure 78. It is an in-vitro assay using adipocytes as these cells express high 
levels of GLUT transporters which facilitate glucose uptake. Insulin promotes the uptake 
of glucose into the adipocytes even at lower concentrations. The glucose is radiolabeled. 
The uptake effect thus can be measured using scintillation counting to determine the extent 
of insulin-stimulated glucose uptake upon addition of insulin in the cell culture. The 
response can be compared when the cells are treated with native insulin vs photoreleased 
insulin. The assay would confirm if the released insulin has retained its bioactivity. The 
protocol was taken from the literature and is described below.57–63 
 
Figure 78: The assay for testing bioactivity of insulin using adipocytes. 
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Glucose uptake assay 
 Glucose gets metabolized into the cells upon uptake, hence 2-deoxy-D-glucose (2-
DODG) is used instead which gets trapped inside the cells once internalized and doesn’t 
undergo metabolism. Radiolabeled 2-deoxy-D-glucose was purchased from Moravek 
Biochemicals with 25 Ci/ mmol with a concentration of 1 mCi/ mL. Non-radioactive (cold) 
2-DODG was also used (Sigma-Aldrich D3179). 
 Adipocytes ATCC CL-173 (3T3-L1) were obtained from ATCC. To culture and 
differentiate adipocytes, three different culture media were recommended. They were 
prepared as reported using the following reagents. Pre-adipocytes are required to undergo 
differentiation before being utilized for this assay. To grow pre-adipocytes, 90% DMEM 
(ATCC-30-2002) with 10 % fetal calf serum (FCS) (SH3040101) was prepared and used. 
Adipocytes differentiation media was used containing 90% DMEM with 10% FCS, 1 µM 
dexamethasone Sigma-Aldrich, D4902), 0.5 mM methylisobutylxanthine (IBMX, Sigma-
Aldrich, I5879) and 1 µg/ mL bovine insulin (Sigma-Aldrich I0516) to induce 
differentiation. Once adipocytes were differentiated, adipocyte maintenance media was 
prepared to passage and maintain them. It was prepared by adding 1 µg/mL bovine insulin, 
90% DMEM and 10% FCS. The cells were plated at the density of 2000 cells/well in a 96 
well-plate in preadipocytes expansion medium. Typically, the cells were grown until they 
are 70% confluent and passaged unless we needed to perform differentiation. Cells must 
reach 100% confluency and allowed to stay confluent for the next 48 hours before inducing 
differentiation. Then, the preadipocyte expansion medium was replaced with adipocytes 
differentiation medium and incubated for the next 48 hours. After 48 hours, this medium 
was replaced with adipocytes expansion medium, and the assay was performed after about 
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12 days after inducing differentiation. The preadipocytes expansion medium was changed 
every 2-3 days while adipocytes expansion medium was changed every 2 days. The cell 
images were taken after performing calcein treatment so that it can be visualized using 
green fluorescence (Figure 79).  
 
Figure 79: The pictures of pre-adipocytes before differentiation treated with calcein (left) 
and differentiated adipocytes with visible lipid globules (right). 
 
Protocol for the glucose uptake assay -  
i. The night before the assay, adipocyte expansion medium was replaced with DMEM 
containing 0.1 % bovine serum albumin (BSA) without any serum.  
ii. On the day of the assay, the cells were washed with glucose-free, serum-free 
DMEM, 0.1 % BSA and incubated in it for 2 hours.  
iii. The well plate was brought to the lab from the incubator after 2 hours of incubation. 
iv. The cells were washed twice with Krebs-Ringer phosphate (KRPH) buffer (140 
mM NaCl, 4.7 mM KCl, 1 mM CaCl2, 5 mM KH2PO4, 1 mM MgSO4, 20 mM 
HEPES and 0.1 BSA, pH 7.4). 
v. KRPH buffer containing insulin was incubated with cells for 30 min to stimulate 
glucose uptake. Then the cells were washed twice with KRPH buffer. 
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vi. 0.2 μCi/well of [3H]-2-deoxy-D-glucose (2-DOG) in KRPH buffer supplemented 
with 100 μM 2-deoxy-D-glucose was added and incubated for 20-30 min at 37 ºC. 
The supernatant was removed and discarded.  
vii. The wells were rinsed carefully four times with ice-cold PBS to stop the uptake 
process. The cell lysis was performed by treating them with 1N NaOH for 60 min 
with shaking and transferred the whole-cell lysate in a scintillation vial containing 
6 mL scintillation fluid. The readings were taken after 3 hours. 
Experiment # 1 
In this experiment, cells were treated with various amounts of radiolabeled glucose 
to determine their optimum concentration. In the first two sets, 0.2 µCi and 0.1 µCi of 
radiolabeled 2-DODG was used respectively and the total concentration was maintained 
by supplementing with 100 µM with cold 2-DODG. While in the third case, only 
radiolabeled glucose was used, hence the concentration was much lower (Table 5). The 
cells were treated with varying concentrations of insulin to see if there is insulin-dependent 
glucose uptake. 
Table 5: Sets of samples with varying amounts of 2-DODG and radioactivity and insulin. 
 
 0.2 µCi of 2-DODG 0.1 µCi of 2-
DODG 
0.2µCi of 2-
DODG only 
Insulin 
concentration 
(nM) 
0 4 8 32 0 16 0 16 
Replicates 9 4 3 5 5 5 2 2 
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Results 
 There was no trend observed in response to a varying amount of radiolabeled 2-
DODG or different insulin concentrations (Figure 80). The 2-DODG uptake seemed 
unaffected by changing concentrations of insulin. Although in set 1, there was a very minor 
effect, it wasn’t significant between insulin versus non-insulin samples. 
 
Figure 80: 2-DODG uptake measured in adipocytes in three sets with different 
concentrations of 2-DODG and different amounts of radioactivity. 
 
Experiment # 2 
 In experiment # 1, we did not observe any specific trend in 2-DODG uptake after 
increasing insulin concentrations. In this experiment # 2, insulin concentration range was 
increased to 100 nM from 32 nM hoping to see whether higher insulin concentrations 
promote higher glucose uptake by the cells. We didn't see any difference between 0.1 
µCi/well and 0.2 µCi/well, hence, we decided to keep 2-DODG radioactivity at 0.2 
µCi/well (Table 6). 
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Table 6: 2 sets of samples with a varying concentration of native insulin and 
photoreleased insulin at 100 nM. 
 
 Insulin std. Photoreleased insulin 
Insulin concentration 
(nM) 
0 17 100 100 
Number of replicates 8 8 4 3 
 
Uptake at 100 nM concentration was higher than at zero concentration as shown in 
Figure 81. However, the observed standard deviations were too high rendering the data 
difficult to interpret. 
 
Figure 81: 2-DODG uptake measured in adipocytes with varying concentrations of native 
insulin and photoreleased insulin. 
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Experiment # 3 
 In this attempt, the following changes were made in the protocol. During many 
washing steps, the number of cells left behind may vary and non-uniform lysis of cells 
might have resulted in larger standard errors. Hence, the samples were also analyzed by 
BCA protein assay kit (Thermo Fisher Scientific) to minimize sample to sample variation 
in uptake. Final radioactivity values were normalized to protein content to get results in 
counts/µg/mL. Other lysed samples were added to the scintillation cocktail and counts were 
measured after 24 and 48 hours. This time, 2% Triton X-100 was added to lyse solution 
along with NaOH to help cell lysis effectively. Here there were only two concentrations of 
insulin 0, 100 nM used.  
 
Figure 82: 2-DODG uptake as measured in adipocytes in with 0, 100 nM insulin 
concentration normalizing it to BCA protein assay. 
 
Results 
The data is shown in Figure 82, there was 1.37 times higher 2-DODG uptake in 100 
nM insulin samples versus control samples where there was no insulin. However, 
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normalizing the counts to the amount of protein present did not help amplify the uptake 
percentage. 1.37 is not statistically significant given with % std. dev. was approximately 
40% in both samples. The results were suboptimal when compared to results reported in 
the literature. At this point, we discontinued this cell culture assay because it could not be 
established and planned to test the bioactivity in the animal models instead. 
Testing for insulin bioactivity in-vivo 
 We attempted to confirm insulin bioactivity using adipocytes-based in-vitro assay, 
but we could not establish the assay properly. Hence, to move the project forward, we 
decided to use in-vivo models. For these studies, male Sprague-Dawley (Harlan 
Laboratories) rats were chosen. These animal models are used for performing studies 
related to diabetes or insulin delivery. The protocol was approved by the University of 
Missouri-Kansas City Institutional Animal Care Use Committee protocol #1401.  
First, we generated diabetic models by inducing diabetes chemically. Diabetogenic 
chemicals such as alloxan or streptozotocin which affect β cells functionality or structural 
integrity are used.64 Both the structures are shown in Figure 83. Both work by different 
pathways but selectively destroy β-cells. These chemicals selectively enter β-cells via 
GLUT 2 transporter due to their structural similarities with glucose. When insulin-
producing cells are destroyed, insulin is no longer produced, and the condition mimics type 
1 diabetes mellitus. Alloxan generates reactive oxygen species (ROS) intracellularly in the 
presence of intracellular thiols and produces dialuric acid. Oxidation of dialuric acid 
generates superoxide radicals, hydroxyl radicals, and hydrogen peroxide. These species 
cause β-cell death and diabetes. Streptozotocin has a different mechanism of action than 
that of alloxan. When it gets internalized by cells, it breaks down into glucose + 
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methylnitrosourea. Methylnitrosourea is an alkylating agent, and once inside the β-cells 
alkylates DNA and causes cell death.65   
For our experiments, streptozotocin was chosen for inducing diabetes. It was 
injected intraperitoneally to rats at 65 mg/kg dose. To measure glucose, blood was collected 
from the tail vein, and a drop of blood was collected on a glucose strip and One Touch® 
glucose meter. Blood glucose was monitored every day to confirm that the rats were 
diabetic after administration of streptozotocin. Rats were defined as diabetic if blood 
glucose was above 250 mg/dL for three consecutive days.  
 
Figure 83: Structure of streptozotocin and alloxan, chemicals used for inducing diabetes 
in animal models. 
 
Preparation of photoreleased insulin 
First-generation material with insulin was synthesized to evaluate the bioactivity of 
photoreleased insulin. It was then subjected to the photolysis as shown in Figure 84. Insulin 
that was released upon light excitation was collected in a tube. To determine its bioactivity, 
it was injected in the rat via an intradermal route. If insulin has retained its bioactivity, it 
would exert a physiological effect, and we expected to see a drop in the blood glucose 
(BG). Simultaneously, insulin concentration in the blood was measured using ELISA as 
per the instructions provided with the kit. This activity was compared to commercially 
purchased insulin which was administered in the same manner at the same dose. 
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 To prepare first-generation material, caged insulin (DIMA) was immobilized on the 
resin. Briefly, freshly prepared DDA (approx. 43 µmol) in DMSO (1.16 mL) was added to 
a solution of human recombinant insulin (0.20 g, 34.4 µmol) in DMSO (16.04 mL). The 
mixture was gently shaken for 24 h, protected from light. The mixture was freeze-dried 
and reconstituted in 0.01 N HCl. The sample was then filtered and washed twice with 0.01 
N HCl using spin filters 5 kDa MWCO filters). The spin filtration was performed to remove 
small molecules while retaining the > 5000 MW insulin conjugates.  
 
Figure 84: Synthesis of first-generation PAD material. Irradiating the construct yields 
insulin. 
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Figure 85: HPLC (top) and MS infusion (bottom) of insulin azide mixture after spin 
filtration. 
 
The concentrate was then reconstituted in 0.01 N HCl and freeze-dried to remove 
the solvent. Insulin, insulin mono-azide and insulin di-azide were analyzed using reversed-
phase HPLC. Reversed-phase HPLC (flow rate 1 mL/min, runtime 30 min), solvent A 
(0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100% B over 30 
minutes, post-run 0% B for 5 minutes, C18 Hypersil column (5 µm, 250 × 4.6 mm, Varian), 
retention time (min), relative yields (%); insulin (15.9 min, 62.9%) insulin monoazide 
(17.2-18.4 min, 33.1%); insulin di-azide (18.7-19.7 min, 3.9%) (Figure 85). The crude 
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insulin-azide mixture was analyzed using direct infusion ESI-MS in 0.01 N HCl. Individual 
species i.e. insulin, insulin mono-azide, and insulin diazide were purified using the HPLC 
and analyzed using direct infusion in ESI-MS for MS characterization.  For direct infusion 
ESI−MS (m/z): [M]+ calculated for insulin, 5808.0; found, 5811.0; [M]+ calculated for 
insulin mono-azide, 6262.2; found, 6265.0; [M]+ calculated for insulin di-azide, 6716.4; 
found, 6719.0; Extinction coefficient calculated (ε280 nm): insulin (5130 M−1 cm−1), mono-
azide (8400 M−1 cm−1), di-azide (11700 M−1 cm−1).   
 Insulin azide was immobilized on the resin (10 µm Tentagel M-RAM (M30123, 
Rapp Polymere) via click reaction. The copper-free click reaction was selected because 
copper assisted click reaction did not work. The copper-free reaction was efficiently carried 
out using an azide and a strained alkyne like dibenzocyclooctyne (DBCO) in this case. It 
does not require any other catalyst, biorthogonal in nature and hence compatible with 
biomolecules.66–69   
For conjugating DBCO on the resin, 10 µm Tentalgel R-RAM resin (85 mg, 17 
μmols of amino groups) was washed thrice with DMF (600 μL). A solution of DBCO acid 
(6 mg, 18 μmols, 250 mM), HATU (6.84 mg, 18 μmols, 250 mM) and N, N-
diisopropylethylamine (6.25 μL, 36 μmols, 500 mM) in DMF (72 μL) was shaken for 15 
min. This activated solution was then added to the washed resin and was gently stirred for 
20 h. This resin was washed several times with DMF, methanol after the reaction. Then it 
was dried under vacuum. A small amount was treated with 95% TFA (500 μL) for 90 
minutes. The purple-colored cleaved DBCO amide was recovered by removing TFA under 
vacuum and then reconstituted in methanol. This product was analyzed by reversed-phase 
HPLC-MS (flow rate 0.4 mL/min, runtime 30 minutes), solvent A (0.1% FA in H2O), 
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solvent B (0.1% FA in ACN), gradient 0% B to 50% B over 5 minutes, gradient 50% B to 
100% B for from 5 to 27 minutes, Isocratic 100% B over next 2 minutes, gradient 100% B 
to 0% B for 1 minutes, C18 Hypersil column (5 μm, 250 × 4.6 mm, Varian), retention time: 
17.8 min; ESI−MS (m/z): [MH]+ calculated for C19H27N5O9, 333.1; found, 333.1 (Figure 
86). 
 
Figure 86: HPLC-MS of TFA cleavage of DBCO acid coupled to the resin. The product 
mass is seen at [MH]+=333.1 eluting at 17.8 minutes. 
 
 Once insulin azide and DBCO modified resin were synthesized, they were mixed 
to immobilize caged insulin onto the resin. 25 mg DBCO conjugated resin was washed 
three times with 500 µL DMF and five times with 500 µL MilliQ water. In another tube, 
11.2 mg of insulin azide mixture was dissolved in 200 µL of 0.01 N HCl, and the pH was 
brought to 7.5 using 1 N NaOH until it became a clear solution. Insulin azide solution was 
106 
then mixed with the DBCO conjugated resin and stirred at 550 rpm at 37 °C for 48 hours. 
After the reaction, it was washed multiple times with PBS to wash off any unbound insulin. 
The supernatant analysis (before and after the reaction) was performed using reversed-
phase HPLC. The disappearance of insulin azide relative to insulin from the supernatant 
was measured to calculate the amount immobilized on the resin. Both the chromatograms 
are shown in Figure 87. The integration area of insulin and insulin azide at 280 nm on 
HPLC chromatogram was normalized with its extinction coefficient to quantify the amount 
disappeared. This reaction was performed in multiple replicates on this scale. Insulin 
immobilization was also confirmed by performing TFA cleavage of a small amount of 
resin. ESI−MS (m/z): [MH]+ calculated for, 6594.0; found, 6597.0 (Figure 88). 
 
Figure 87: Supernatant analysis of insulin azide mixture from click reaction. The top 
chromatogram is insulin azide at t=0, and the bottom chromatogram is at at=48 hours. 
Insulin azide mixture peaks disappear, but insulin is not consumed. 
 
Insulin conjugated resin (20 mg, 356 nmol insulin) was washed several times with 
PBS. The final wash was run on HPLC to confirm that there is no unbound insulin leaching 
from the resin. The resin was suspended in 110 μL of PBS in a flat-bottom glass tube. A 
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200 mW Nichia® 365 nm LED was used to irradiate the sample for 20 min. The suspension 
was vortexed briefly, and the supernatant was collected. 2 µL of it was diluted to 20 µL 
and injected in HPLC to confirm insulin release (Figure 89 and Figure 90). 10 µL of this 
supernatant was desalted using 5  kDa MWCO spin filter and reconstituted in 0.01 N HCl 
for direct infusion for ESI-MS characterization (Figure 91). 
 
Figure 88: Insulin construct immobilized onto the resin was cleaved using TFA and 
infused in MS. The mass of the product is seen at [M]+=6597.0 (calc. for 6594.0) 
 
 
Figure 89: HPLC chromatogram of insulin standard. 
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Figure 90: Photoreleased insulin from the resin. 
 
 
Figure 91: Photoreleased insulin from the resin upon light irradiation infused into MS. 
The mass of insulin is seen at [M]+ 5808.0. 
  
 To prepare samples of testing the bioactivity of insulin, the concentration of 
photoreleased insulin in the supernatant (PBS) was 150 µM (determined using UV-vis 
spectroscopy). Initially, we planned to filter this solution using a 5 µm sterile syringe filter. 
However, it was observed that insulin was binding to the filter surface hence there was a 
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significant loss of insulin after syringe filtration.  
Male Sprague-Dawley rats were used for the studies. Diabetes was induced by 
injecting 65 mg/kg of streptozotocin intraperitoneally. 14.2 nmol/kg of insulin dose was 
selected for these studies. The rats were first anesthetized using isoflurane in a chamber. 
Insulin was injected intradermally on the back using a 31G needle. BG levels and insulin 
concentration were measured over a period of 2 hours. Blood samples were collected in 
Microvette 100 μL Li-HEP tubes (Sarstedt) from the tail-vein using a glass capillary. After 
collecting all time points from an experiment, the samples were centrifuged at 5000 rpm 
for 2 minutes. The supernatant was removed and stored at -20 °C until the ELISA analysis 
was performed. The ultrasensitive human insulin ELISA kit (Alpco, Salem, NH) was used 
following the manufacturer’s instructions. The experiment was carried out in triplicate 
(n=3) and the results are shown in Figure 92. 
 
Figure 92: BG and insulin values after photoreleased insulin was injected into the rats. 
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 The response after injecting photoreleased insulin suggested that insulin is still 
bioactive. Insulin was detected using ELISA; this suggested that it still has retained its 
native 3D conformation because the antibodies which are very specific were recognizing 
it. Simultaneously it also reduced the BG level significantly, and BG dropped very low by 
the end of the experiments. These results confirmed that insulin has still retained its 
bioactivity. We performed a similar experiment using native insulin obtained commercially 
and injected it in the same manner. It yielded a similar response. Typically, as reported 
elsewhere, 2-3 IU/kg dose of human insulin causes approximately 70% reduction in 
glucose levels in Sprague-Dawley rats when injected subcutaneously post 2-hour period.70–
72 We injected 2.36 IU/kg (14.2 nmol/kg) of dose here and observed similar result even 
when injected intradermally. This study was critical and answered two of our questions; 1) 
Insulin has still retained its bioactivity after photorelease. 2) Insulin can be absorbed from 
the dermal layer after intradermal injection.   
Testing light triggered insulin release in-vivo 
Experimental setup 
 Here we investigated our central hypothesis whether light can be used to trigger the 
release of insulin from a transcutaneous depot. Dr. Friedman designed a light source to 
irradiate on an injected sample from the top of the skin. It is shown in Figure 93 and Figure 
94. The light source has three components. The first element is an on/off switch for LED. 
The actual light source has two additional parts; a top disc with 365 nm LED with four 
magnets and a bottom disc with a hole in the center with four magnets. A shallow depot 
was injected intradermally. Such intradermal injection appeared as a bleb on the skin. The 
bottom disc was placed on this, centering the hole on the bleb using superglue. Then top 
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disc aligns itself directly on the bottom plate with the help of magnets. Such design allowed 
the LED light to fall directly onto the injected depot. This assembly also makes sure that 
the LED is affixed securely over the depot site.  
 
Figure 93: Design of the compact light source.  
 
 
Figure 94: How light source was placed over the intradermal PAD (bottom) in a rat. 
 
The light source was constructed using Nichia NCSU033B LED with a 365 nm 
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peak irradiation. The LED was driven by a 6.5 V power supply using a current limiting 
power resistor. The light source holds the LED ~0.32 cm from the skin surface, and the 
absolute irradiance at the skin was estimated to be 0.71 W/cm2. The absolute irradiance of 
the light source was determined using a calibrated USB2000 spectrophotometer (Ocean 
Optics) and a CC-3-UV-S cosine corrector via an optic fiber. The Spectrasuite® software 
was used to analyze absolute irradiance in the range of 350-400 nm that brackets the LED 
output. 
The time points were kept like that of photoreleased insulin bioactivity studies. 
Except, here instead of photoreleased insulin, first-generation PAD material was injected 
and then irradiated using the compact light source. The aim was to see if insulin can be 
detected in blood and if it causes any changes in BG levels after irradiation.  Original 
ChemMatrix® resin described earlier could have been used here because it is completely 
made up of biocompatible PEG and has very high loading density. However, the resin size 
was too large to be injected through a 23G needle. At this point, we started looking for 
smaller sized biocompatible resins, we requested a smaller sized resin from PCAS for these 
studies however they provided us with a limited quantity sample which was not a catalog 
item. The PAD material could be synthesized using smaller sized resin, but because it was 
not a catalog item, we decided not to use it. So, we started searching for different smaller 
sized resins, there were three main criteria - i) the resin should be smaller in size so that it 
can be injected easily in a pain-free manner, ii) it should have a high loading capacity, iii) 
it is made up of biocompatible or preferably biodegradable material. We found a company 
which sold similar products and tested these items, 5 µm polystyrene resin (HM1523, 
loading density 0.62 mmol/g) and 10 µm Tentagel M-RAM (M30123, loading density 0.2-
113 
0.22 mmol/g). In Tentagel®, polystyrene core is grafted with PEG polymers. The 
immobilization of insulin was performed in the same exact manner as performed on 
ChemMatrix resin.  
 17.7 mg (11 µmol) of 5 µm polystyrene resin and 55 mg (11 µmol) of 10 µm 
Tentagel resin were washed in 0.5 mL DMF thrice. Then it was treated three times with 
0.5 mL of 20% piperidine in DMF to remove Fmoc. A common DBCO acid activating 
mixture was prepared by mixing 7.5 mg DBCO acid (22.5 µmol), 10 mg HATU (26.3 
µmol) and 7.6 µL DIEA (44 µmol) in 146 µL DMF. The activating reaction was performed 
for 15 minutes at room temperature (RT). Then the volume was split into two equal parts 
and added to each 5 µm and 10 µm resin. The reactions were run for 18 hours, and then the 
resin was washed 5 times with 0.5 mL DMF, methanol and dried thoroughly. A small 
portion of it was treated with 0.3 mL of 95 % TFA in water for 1 hour and ran LCMS to 
confirm DBCO acid coupling. LCMS analysis – reversed-phase HPLC-MS (flow rate 0.4 
mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% FA in H2O), solvent B 
(0.1% FA in ACN), gradient 0% B to 50 % B over 5 min, gradient 50% B to 100 % B until 
27, gradient 100% B to 0% B for next 2 min and isocratic 100% B for next 1 min; C18 
Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 18.2 min; ESI−MS (m/z): 
[MH]+ calculated for, 333.1; found, 333.2 (Figure 95). 
The click reactions of caged insulin azide with each of these resins were carried out 
in DMSO as well as in water to see which solvent gives the best yield. Thus, four reactions 
were set up. First, 2 mg (1.2 µmol) of 5 µm resin were treated with 2.5 mg insulin azide 
mixture in 16 µL DMSO in reaction # 1. Then, 6 mg (1.2 µmol) of 10 µm resin was treated 
with 2.5 mg insulin azide mixture in 16 µL DMSO in reaction # 2. For reaction # 3 and # 
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4, 2 mg of 5 µm resin and 6 mg of 10 µm resin were treated with 2.5 mg insulin azide in 
0.1 mL water respectively. Insulin azide is not soluble in neutral water, it was first dissolved 
in 0.01 N HCl, and the pH was brought to 7.4 to make it neutral. The disappearance of 
insulin azide from the supernatant was measured to determine the extent of click reaction. 
The reactions were run for 48 hours with shaking. After 48 hours, it was washed with PBS 
multiple times.   
 
Figure 95: LCMS of cleaved DBCO amide. The product is seen at [MH]+=333.2 eluting 
at 18.25 min. 
 
Based on the results from the chromatograms (not shown here), it was observed 
that the yield was very poor with 5 µm resin in both solvents. In the case of 10 µm resin, 
the yield was better in water than in DMSO (Figure 96). Both the resins clumped together 
in DMSO but not in water. Hence, it was decided to use 10 µm resin for future studies and 
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water as a solvent for click reactions. Initially, DMSO was intended to be used but 
significant clumping of resin was observed in DMSO, hence water was used. 
 
Figure 96: HPLC chromatograms of insulin azide mixture before (blue) and after (red) 
the click reaction. 
   
In-vitro photolysis experiments 
 The in-vitro photolysis experiments were already performed using ChemMatrix® 
resin in the lab showing the ability of light to trigger and control insulin release. However, 
because we switched from ChemMatrix to Tentagel, we performed it again to confirm that 
the system is behaving as expected. For obtaining photoreleased insulin (described earlier 
in this chapter), this 10 µm resin was used. The procedure is already outlined earlier. 
Insulin, 140 nmol conjugated on the resin was washed with PBS multiple times. 
For the photolysis studies, it was suspended in 100 μL PBS. The photolysis was performed 
in Agilent glass vial inserts (catalog # 5183-2090). The irradiation was carried out by 
placing the glass vial insert directly above 365 nm Nichia LED as shown in Figure 97. The 
irradiation was performed twice (for two minutes each) from t=0 to t=2 min and t=65 to 
t=67 min. The sample was vortexed for 5 min and centrifuged before collecting samples 
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for each time point. A 25 μL volume was removed and replaced with the same volume of 
fresh PBS. The amount of insulin released was quantitated using HPLC using an insulin 
standard curve. The solution of the final time point was desalted with 5 kDa MWCO 
centrifugal spin filter and infused into MS to get molecular weight. The control sample was 
treated identically except the light was blocked by an aluminum foil from reaching the 
sample. Reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-
run),  solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 
% B over 30 min; C18 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 16 
min (Figure 98); ESI−MS (m/z): [M]+ calculated for, 5808.0; found, 5809.0 (Figure 99). 
 
Figure 97: For in-vitro photolysis, the resin material was suspended into a glass vial 
which then was mounted on top of a 365 nm LED. 
 
 
Figure 98: HPLC chromatogram of photoreleased insulin. 
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Figure 99: Characterization of photoreleased insulin from Tentagel resin. MS infusion 
showing insulin at [M]+=5809.0. 
  
 
Figure 100: In-vitro release study from insulin conjugated Tentagel resin. The irradiation 
was performed for 2 min at t=0 and t=65 min each (as represented by 2 vertical blue 
lines). 
 
The release pattern for the Tentagel resin was much different from ChemMatrix 
resin used earlier.29 Even though the irradiation was performed only for 2 min at t=0 and 
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t=65, we observed that insulin was still coming off from the resin after that. It is maybe 
because insulin which was released due to light remained bound to the resin non-covalently 
and slowly leached out from the resin attaining a plateau after about an hour (Figure 100). 
This binding issue was not observed with ChemMatrix resin, all the insulin which was 
released immediately came off in the supernatant. In this study, just with 4 minutes of 
irradiation, approximately 18% of insulin was released. 
In-vivo experiments 
For performing the in-vivo studies, this scale of synthesis was insufficient. This 
material once made had storage issues, and the frequency of animal studies was low (1-2 
replicates/ week) – we couldn’t finish all replicates in one or two days. Due to these 
challenges, it was decided to perform the final step i.e. click reaction just one day before 
the scheduled animal studies to use the material immediately after it was synthesized. The 
DBCO conjugated 10 µm resin, as well as insulin azide, were stored in -20 °C for a longer 
period, and they were mixed to immobilize caged insulin on resin just before the studies. 
The amount of insulin-immobilized was calculated, and the studies were performed.  
Rats were first anesthetized with isoflurane using a precision vaporizer. The upper 
backs of rats were shaved before injection of the PAD materials. Injections of ~80 µL of 
PAD material were made using a 0.5 cc syringe attached to a 27-G needle. Due to the 
limitations of the volume that can be injected into the dermal layer of skin at one time, two 
injections (of 40 µL each) of PAD materials were made side by side. The compact LED 
light source was anchored to the skin over the injection sites using superglue. The body 
temperature and hydration were maintained throughout the experiment. For the 
experiment, the depot was injected first and allowed to stay there for 20 minutes before 
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irradiation. It was to observe if there is any unwanted leaching from the site before 
irradiation. This time point was annotated as t = -20 minutes. Twenty min post-injection, 
the depot was irradiated for 2 minutes. The irradiation was between t=0 to t=2 minutes. 
There was a reason for limiting the irradiation duration to two minutes. The heat generated 
from the light source appeared to cause skin damage, and scab formation was observed 
after 5 minutes of irradiation. 2 minutes of irradiation did not show such toxicity. Hence it 
was selected rather than irradiating for a longer duration. 
The results were encouraging as shown in Figure 101 for insulin release. For the 
first 20 min before irradiation, we did not see any change in insulin levels suggesting there 
was no leaching from the depot. As soon as we irradiated for 2 minutes, insulin levels 
jumped quickly from baseline levels and peaked at 45 min then slowly dropped down. This 
release profile was comparable to what we saw with injected photoreleased insulin (Figure 
92). In the control samples, where the light was blocked using an aluminum foil, there was 
no change in insulin as expected. In irradiated animals higher insulin levels were measured 
and resultantly, BG levels dropped, and the physiological effect of the released insulin was 
seen (Figure 102). The released insulin caused BG drop which lasted for the first 60 min 
and then it started going up suggesting that the effect of insulin was over by the end of the 
hour.  
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Figure 101: Results of irradiation of PAD material in animals in triplicates. The 
irradiation was performed between t=0 to t=2 min. The plot shows insulin concentration 
in the blood. 
 
 
Figure 102: Results of irradiation of PAD material in animals in triplicates. The 
irradiation was performed between t=0 to t=2 min. The plot shows BG levels. 
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This experiment answered three questions that -  
i. Light has sufficient penetrating power in the skin to hit the PAD material and 
release insulin,  
ii. Once insulin is released from the site, it quickly gets into the systemic circulation 
as it was detected in the bloodstream just within 5 min and peaked at around 25 min 
after the irradiation, 
iii. The amount of insulin that was released due to 2 min irradiation was enough to 
reduce BG. Although the effect was not very significant and lasted only for 60 
minutes, it could be increased by increasing the duration of irradiation. 
 The next question we wanted to ask was whether additional pulses of light in 
discrete intervals irradiation would release more amount of insulin from the depot. How 
would this affect the BG levels? To test this, as performed earlier, we injected PAD 
material holding 140 nmol of insulin on the resin. There was a brief interval of 20 minutes 
between the time of injection and the time of irradiation. The first irradiation was 
performed between t=0 to t=2. The next irradiation was performed approximately after an 
hour later between t=65 to t=67 minutes. We expected that we should see a spike in insulin 
concentration after each irradiation. For the control samples, the LED was switched on, but 
the light was blocked using an aluminum foil. 
Looking at the results (Figure 103 and Figure 104), as expected, we saw an increase 
in insulin concentrations after both irradiations. Due to additional insulin being released 
due to additional pulses of light, there was a robust drop in BG. By the end of 2 hours, it 
was still going down, and it was statistically significant. The duration of study for this 
experiment was very short. However, it verified the concept that insulin release could be 
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triggered using light in a live animal using PAD. 
In these experiments, the hypothesis that insulin could be delivered in a live animal 
using light and PAD was demonstrated for the first time.73 Though it also helped reduce 
BG in rats, it is still in the very early stages of development. There are still concerns that 
need attention –  
i. The risk of toxicity due to light – in this case, we used 365 nm wavelength. 
However, longer repetitive exposure will be harmful to the skin. The risks need to 
be assessed, and if it is harmful, strategies to overcome these issues should be 
sought.  
ii. Assessing the potential of an immune reaction to the injected material. The body’s 
immune system can attack material because it may find it foreign in nature. 
iii. What is the lifetime of the depot? How long would it last and predictably release 
insulin after an injection? How would we know how much insulin is left in the 
depot and when is the time to re-inject? 
iv. In the long term, we need to automate insulin delivery system and link it to a 
glucose monitoring system. In doing so, the fluctuation in the BG levels would 
trigger the LED which would result in insulin being released, and hence lowering 
of BG.  
v. Designing material in such a way that would introduce a minimum number of 
foreign elements in the body. Such a system would result in a reduction of the 
body’s reaction to the material, reduced synthetic steps, and toxicity, etc. 
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Figure 103: Results of irradiation of PAD material twice in animals in triplicates. The 
irradiation was performed between t=0 to t=2 min and t=65 to t=67 minutes. BG levels 
are shown here. 
 
 
Figure 104: Results of irradiation of PAD material twice in animals in triplicates. The 
irradiation was performed between t=0 to t=2 min and t=65 to t=67 minutes. Insulin 
measured is shown in the figure. 
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Chapter 4 
SYNTHESIS AND TESTING OF ADVANCED SECOND-GENERATION 
MATERIAL 
Visible light-activated photolabile group 
In the lab, DMNPE has been used as the photolabile group for various projects as 
described in earlier chapters. DMNPE was used because of its higher quantum yields, clean 
photorelease reactions and due to our experience working with it.30 The quantum yield is 
defined as the number of moles of substrate released from the caged compound divided by 
the number of photons absorbed at an irradiated wavelength by the caged compound. A 
photolabile group having higher quantum yield is desirable, especially for biological and 
in-vivo medical applications. Another critical criterion to evaluate the efficiency of a 
photolabile group is the product of multiplication of quantum yield and its molar extinction 
coefficient (ε). Although DMNPE group works well and we are continuously using it for a 
variety of projects, it is not ideal for insulin project. To deliver insulin continuously, 
multiple irradiations would be needed throughout the day for a lifetime and 365 nm 
wavelength is categorized as near UV radiation which has the potential for toxicity. The 
energy contained in the radiations generate singlet oxygen species which do oxidative 
damage to fibroblasts cells when studied.74–76 The link between UV exposure and cancer 
is well established.77–79 Furthermore, DMNPE after photolysis generates a nitroso 
group,80,81 N-nitroso compounds are known to be carcinogenic.82,83 Because of the risk of 
both chemical and phototoxicity and potential for carcinogenicity, DMNPE usage in the 
long term will not be feasible. To avoid these issue, longer wavelengths in the visible light 
range or infrared range would be a much safer option. Longer wavelength radiation has 
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less, or no potential of toxicity compared to that of 365 nm light. Hence, we started looking 
for different photolabile groups which could be photocleaved using visible light. 
 Coumarin is a suitable alternative DMNPE and provides following advantages over 
DMNPE that – 
1. Coumarin could be activated by visible light wavelengths, two-photon excitation 
or infrared irradiations.84–90  
2. Longer wavelengths have a deeper penetration into the skin which provides 
advantages over shorter wavelengths as more photons would be able to hit PAD 
material in the dermal layer.91  
Considering these advantages provided by coumarin, we pursued designing coumarin-
based photolabile group which could be used for PAD material synthesis. The structures 
of coumarin and DMNPE are shown in Figure 105. 
 
Figure 105: Structure of DMNPE ketone (left) and DEACM aldehyde (right). 
 
 In the figure above, DMNPE ketone is shown which was used in all earlier 
studies, for insulin macropolymer synthesis and first-generation in-vivo studies. 7-
Diethylaminocoumarin-4-yl (DEACM) is commercially available, which has been used as 
a photocleavable group in the past.92–94 It can be modified further to introduce an aldehyde 
and subsequently a hydrazone functionality similar to DMNPE hydrazone. We decided to 
continue using alkyne-azide based click chemistry here for conjugation but introducing 
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azide functionality was a bit challenging for a variety of reasons. Below all the synthetic 
routes that were pursued and problems encountered are reported and described.  
 Synthesis of coumarin caged insulin 
 Multiple synthetic routes were explored to synthesize coumarin ring containing a 
handle for caging insulin and another handle for performing click reaction. The 
unsuccessful routes are described in the beginning. Route # 4 was the easiest and hence 
used for caging insulin.  
Route 1: Synthesis using 7-amino-4-methyl coumarin 
 The initial steps were adapted from Hagen, et al., where dialkylation of 7-amino-4-
methyl coumarin (7-AMC) was performed.86 The synthesis scheme is shown in Figure 106. 
The alkylation was followed by oxidation by selenium dioxide to introduce aldehyde 
functionality. After this, Hagen, et al., further converted it to hydrazone, hydrazone was 
later converted to diazo to cage carboxylic acid. However, we decided to cage the amino 
group on insulin rather than carboxylic acid this time. It was decided because - i) We 
wanted to explore if amino groups on proteins can be caged and whether it can be utilized 
for such applications. Insulin has six carboxylic acid groups. Earlier after caging insulin to 
synthesize DIMA we used to get a mixture of isomers. We postulated that since insulin has 
only three amino groups and only one of it is a B29 lysine which might react preferentially 
yielding only single isomer.38 ii) It might have implications in insulin hexamer formation 
and its onset of action. Hence after oxidation by selenium dioxide oxidation, we reduced 
aldehyde using NaBH4 to give alcohol functionality. Two t-butyl esters were then cleaved 
using trifluoroacetic acid (TFA) to yield free carboxylic acids. Here multiple functionalities 
like azide could be coupled to alter the properties of caged insulin. 
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Figure 106: Synthesis Scheme 1 for coumarin azido alcohol (CAA) 
  
 Originally, we planned on conjugating mono-alkylation on 7th position amine but 
in that case, the SeO2 oxidation step was problematic and resulted in many side products. 
However, when we alkylated twice forming a 3º amine, the yield improved significantly. 
Hence it was performed in this manner.  
 
tert-Butyl [(tert-butoxycarbonylmethyl)(4-methyl-7-coumarinyl)amino]acetate  
 AMC (5.26 g, 30 mmol, Chem-Impex), t-butyl bromoacetate (30 mL, 200 
mmol, Fisher Sci.), DIEA (20.5 mL, 117.7 mmol, Fisher Sci.) and sodium iodide (4.5 g, 
30 mmol) were mixed in 90 mL acetonitrile. The reaction was refluxed for five days. The 
crude reaction mixture was cooled to room temp., filtered and dried using rotary 
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evaporator. This reaction yielded a 30:70 ratio of monoalkylated to the dialkylated product. 
The reaction never went to completion to give the only dialkylated product. The product 
was purified by using flash chromatography using DCM: EtOAc (4:1) as the solvent 
system. Yield (1.55 g, 12.8%); analytical HPLC – reversed-phase HPLC-MS (flow rate 0.4 
mL min−1, runtime 15 min with 5 min post-run), solvent A (0.1% FA in H2O), solvent B 
(0.1% FA in ACN), gradient 60 % B isocratic over 15 min, C18 Hypersil column (5 μm, 
150 × 3.2 mm, Agilent), retention time: 11.15 min; ESI-MS (m/z) [MH]+ calculated for 
C22H29NO6, 404.2; found, 404.2 (Figure 107). 
 
Figure 107: LCMS of tert-butyl [(tert-butoxycarbonylmethyl)(4-methyl-7-
coumarinyl)amino]acetate. The peaks of 292.1 and 348.2 were due to the subsequent 
fragmentations of the ester bond and cleavage of the t-butyl group while flying in the MS. 
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tert-butyl{(tert-butoxycarbonylmethyl)[4-(hydroxymethyl)-7-coumarinyl]amino}acetate   
tert-Butyl [(tert-butoxycarbonylmethyl)(4-methyl-7-coumarinyl)amino]acetate 
purified earlier (0.342 mg, 0.850 mmol), SeO2 (0.215 g, 1.40 mmol) were mixed in 25 mL 
p-xylene and refluxed for 24 hours. It was filtered hot to get rid of SeO2 and dried using 
rotavap. 50 mL of anhydrous MeOH added and stirred for 30 min, and NaBH4 (0.1 g) was 
added, the reaction was run for 2 hours. It was filtered and dried on rotavap.  The crude 
mixture was then partitioned between DCM and water. DCM layer was washed thrice with 
water, then with brine and dried finally. Yield (215 mg, 60.1%); analytical method – 
reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run),  
solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 60 % B isocratic over 
15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 5.81 min; 
ESI-MS (m/z): [MH]+ calculated for C22H29NO7, 420.2; found, 420.2 (Figure 108). 
 
Figure 108: LCMS of tert-butyl{(tert-butoxycarbonylmethyl)[4-(hydroxymethyl)-7-
coumarinyl]amino}acetate. The peaks of 308.1 and 364.1 were due to the subsequent 
fragmentations of the ester bond and cleavage of the t-butyl group while flying in the MS. 
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{(Carboxymethyl)[4-(hydroxymethyl)-7-coumarinyl]amino}acetic acid 
The product purified above (42.8 mg, 0.10 mmol) was mixed in 4 mL cocktail 
containing 75% TFA: 1% water and 24% DCM. The reaction was run for 1 hour and dried 
using rotavap. Analytical method – reversed-phase HPLC (flow rate 1 mL min−1, runtime 
30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
gradient 0 % B to 100% B over 30 min, C18 Hypersil column (5 μm, 250 × 4.6 mm, 
Agilent), retention time: 8.8 min. (Figure 110). The 1H NMR for the hydrolyzed product is 
shown in Figure 109. 
 
Figure 109: NMR of {(carboxymethyl)[4-(hydroxymethyl)-7-coumarinyl]amino}acetic 
acid. 
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Figure 110: HPLC chromatogram of {(carboxymethyl)[4-(hydroxymethyl)-7-
coumarinyl]amino}acetic acid. 
 
 
1-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-2-{[2-(2-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}ethylamino)-2-oxoethyl][4-(hydroxymethyl)-7-
coumarinyl]amino}-1-ethanone 
 After Boc deprotection, the free carboxylic acid containing product (45.3 mg, 147 
µmol), 11-azido-3,6,9-trioxaundecan-1-amine (62 µL, 310 µmol), HOBt hydrate (90.3 mg, 
590 µmol) were dissolved in 0.6 mL of anhydrous DMF. Then EDC (79.2 mg, 501 µmol) 
was added to the mixture. However, it was not clean. Hence it was purified using flash 
chromatography using DCM as a solvent. Yield (8.6 mg, 8.2%); analytical method – 
reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run),  
solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 60 % B isocratic over 
15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 3.25 min; 
ESI-MS (m/z): [MH]+ calculated for C30H45N9O11, 708.3; found, 708.2 (Figure 111); 
reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-run), solvent 
A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0 % B to 100% B over 30 
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min, C18 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 16 min (Figure 
112). 
 
Figure 111: LCMS of the product. The product mass is seen at [MH]+=708.2 eluting at 
3.25-3.34 minutes.  
 
 
Figure 112: HPLC chromatogram of the product. 
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 Purified coumarin alcohol azide (CAA) (8.6 mg) was conjugated to insulin using 
CDI/DMAP as coupling reagents. Insulin could be caged successfully but at much lower 
yields. Large quantities of the caged material will be required for performing in-vivo 
studies, scale-up would be a problem if this route is followed. Also, the percent yield of 
the first step is close to 10% which is low. Moreover, given that 7-AMC is an expensive 
chemical, we started looking for more feasible and convenient synthetic routes. 
Route 2: Synthesis of 7-azido-4-methyl coumarin from 7-amino-4-methyl coumarin  
 Here, the original reaction conditions were taken from literature reported earlier.95–
98 The advantage here is that instead of alkylating 7-position amine with an ester, then 
hydrolyzing and subsequent coupling using an azide-containing linker (as shown in the 
route # 1), 7-position amino group could be converted to an azide moiety directly as shown 
in Figure 113. This reduces the number of steps from three to one and the reported yield in 
the literature is over 90%. Once the azide group is synthesized, 4’-methyl group could be 
oxidized by SeO2 to introduce aldehyde group. Thus, CAA could be synthesized in only 
two steps rather than four. 
 
Figure 113: Route # 2: Synthesis of CAA through 7-azido-4-methyl coumarin route. 
 
7-azido-4-methylcoumarin synthesis 
 7-AMC (3.000 g, 17.14 mmol, Chem-Impex®) was suspended in 66 mL DI water 
in a 3-necked flask in an ice bath. After 10 min, H2SO4 (18 mL) was added in a dropwise 
manner maintaining the temperature. Meanwhile, in separate flasks, sodium nitrite (1.500 
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g, 21.74 mmol) and sodium azide (1.98 g, 30.5 mmol) were dissolved in 20.4 mL and 12 
mL volume of water, respectively, and chilled in ice to 0 °C. Once H2SO4 addition was 
finished, sodium nitrite was added in a dropwise manner followed by sodium azide in the 
same fashion. A precipitate was observed immediately after sodium azide addition. It was 
stirred overnight, filtered and washed with 50 mL cold water. The precipitate was dissolved 
in DCM and washed DCM layer with saturated NaHCO3, followed by saturated NaCl, 
dried over MgSO4 and dried using rotavap. Yield (3.079 g, 89.3%); ESI-MS (m/z): [MH]+ 
calculated for C10H7N3O2, 202.1; found, 202.1 (Figure 115); analytical method – reversed-
phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% 
TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0 % B to 100% B over 30 min, C18 
Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 19.5 min (Figure 114); 
reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run), 
solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 60 % B isocratic over 
15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 5.36 min 
(Figure 115). 
 
 
Figure 114: HPLC chromatogram of 7-azido-4-methylcoumarin. 
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Figure 115: LCMS of 7-azido-4-methylcoumarin. The product mass is seen at 
[MH]+=202.2 eluting at 5.45 min. 
 
A test click reaction on 7-azido-4-methyl coumarin (7-AzMC) 
At this point, we wanted to run a test click reaction on 7-AzMC to see if azide is 
still reactive towards the strained alkyne and how much change in UV-vis spectrum occurs 
after the reaction, refer to the Figure 116. We suspected whether having an azide on the 
conjugated ring system would affect its reactivity or not. We wanted to test how this would 
affect the UV-vis spectrum of 7-AzMC. Hence, we set up a reaction between 7-AzMC and 
DBCO conjugated ChemMatrix resin (synthesis is described above in Chapter 3). If the 
click reaction is successful, 7-AzMC will get clicked onto the resin, which could be 
analyzed by performing TFA cleavage easily. 
7-Azido-4-methyl coumarin (0.6 mg, 3 µmol) was added to pre-swollen DBCO 
conjugated ChemMatrix resin in 20 µL DMSO. The mixture was shaken at 40 °C at 600 
rpm for 24 hours. After 24 hours, the resin was washed five times using 0.3 mL DMSO, 
then DCM and dried. TFA cleavage was performed to analyze the reaction. 
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Figure 116: Click reaction between DBCO conjugated resin and 7-azido-4-methyl 
coumarin. 
 
LCMS analytical method – reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 
min with 5 min post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), 
gradient 50 %B isocratic over 15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), 
retention time: 7.59 min; ESI-MS (m/z): [MH]+ calculated, 534.2; found, 534.4 (Figure 
117). 
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Figure 117: LCMS of the clicked product. It is seen at [MH]+=534.4 eluting at 7.59 min. 
 
 
Figure 118: UV-vis spectrum of the coumarin species synthesized in the above reaction. 
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The click reaction worked, and we could see the product as a single peak with the 
correct mass on LCMS. So, the reactivity of azide is retained despite it being conjugated 
on the ring. However, the spectra of both 7-AzMC and clicked product are very different 
from 7-AMC, refer to Figure 118. We want to photocleave coumarin at >400 nm 
wavelength i.e. visible light range. Both UV-vis spectra do not have any absorbance at that 
wavelength. Hence, we did not move forward with this approach. 
Route 3 – Synthesis using 7-hydroxy-4-methyl coumarin 
 
Figure 119: Synthesis using 7-hydroxy-4-methyl coumarin. 
 
The route # 1 was challenging mainly because of the first alkylation of 7-position 
amine. Just monoalkyating that amine was not working because in that case, SeO2 step 
generated many side products with a minimum yield of the desired product. Instead, the 
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SeO2 reaction proceeds well only with 3° amine and does not work with 2° amines. The 
dialkylation reaction was often incomplete, and the yield was close 10%. Hence to avoid 
these issues, we thought of utilizing 7-hydroxy-4-methyl coumarin (7-HMC) instead of 7-
amino-4-methyl coumarin. Here single alkylation could be performed easily in quantitative 
yield instead of worrying about mono versus dialkylation. The disadvantage, however, is 
that 7-AMC absorbs at longer wavelength compared to 7-HMC which is desirable. The 7-
AMC has λmax at 345 nm whereas 7-HMC has λmax at 325 nm. We could, however, modify 
the ring so that it would absorb higher wavelength light. For example, by replacing oxygen 
from second position carbonyl group with sulfur.90 The synthesis route is described in 
Figure 119. 
Methyl (4-methyl-7-coumarinyloxy)acetate 
7-HMC (11.44 g, 65.00 mmol) and K2CO3 (18 g, 65 mmol) were added in 80 mL 
DMF at 50 °C under reflux and stirred for 10 minutes. Then methyl bromoacetate (6.4 mL, 
67 mmol, Fisher Sci.) was added dropwise. It was run for 21 hours, and the solvent was 
evaporated using rotavap. The dried residue was partitioned in DCM and water. DCM layer 
was then washed with saturated NaCl, dried over MgSO4, filtered. Yield (13.28 g, 82.3%); 
LCMS method – reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 min with 
5 min post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 50 
% B isocratic over 15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention 
time: 5.35 min; ESI-MS (m/z): [MH]+ calculated for C13H12O5, 249.1; found, 249.2 (Figure 
120). 
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Figure 120: LCMS of methyl (4-methyl-7-coumarinyloxy)acetate. The product mass is 
seen at [MH]+=249.2 eluting at 5.35 minutes. 
 
Methyl [4-(hydroxymethyl)-7-coumarinyloxy]acetate 
Methyl (4-methyl-7-coumarinyloxy)acetate (1.02 g, 4.10 mmol) and finely crushed 
SeO2 (1.00 g, 9.02 mmol) was suspended in 46 mL p-xylene. The mixture was stirred under 
reflux for 20 hours. The mixture was filtered when hot, and the filtrate was dried on 
rotavap. To the dried residue, 80 mL methanol was added and stirred for 20 minutes. To 
this, NaBH4 (0.170 g, 4.51 mmol) was added. After 40 minutes, it was filtered and dried. 
The dried residue was partitioned between DCM, water. DCM layer was washed with 
saturated NaCl, dried over MgSO4, filtered, dried. Yield (0.37 g, 34 %); LCMS method – 
reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run),  
solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 50 % B isocratic over 
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15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 3.06 min; 
ESI-MS (m/z): [MH]+ calculated for C13H12O6, 265.1; found, 265.2 (Figure 121). 
 
Figure 121: LCMS of methyl [4-(hydroxymethyl)-7-coumarinyloxy]acetate. The mass is 
seen at [MH]+=265.2 eluting at 3.06 minute. 
 
Methyl [4-(acetoxymethyl)-7-coumarinyloxy]acetate 
 Methyl [4-(hydroxymethyl)-7-coumarinyloxy]acetate (0.20 g, 0.75 mmol), DMAP 
(0.230 g, 1.91 mmol), acetic acid (109 µL, 1.91 mmol) were added in mixture of 40 mL 
DCM+5 mL DMF cooled to 0 ºC. The mixture was stirred on ice for 10 min, and then EDC 
(295 mg, 1.90 mmol) was added. The ice bath was then removed and allowed to stir 
overnight. The product was purified by washing DCM first with water, 1 N HCl and 
saturated NaCl. DCM layer was dried over MgSO4, filtered and dried. Yield (0.183 g, 
79.4%); Reversed-phase HPLC-MS (flow rate 0.4 mL min−1, runtime 21 min with 5 min 
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post-run),  solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 50 % B 
isocratic over 21 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 
5.48 min; ESI-MS (m/z): [MH]+ calculated for C15H14O7, 307.1; found, 307.2 (Figure 122). 
 
Figure 122: LCMS of methyl [4-(acetoxymethyl)-7-coumarinyloxy]acetate. The product 
is seen at [MH]+=307.2 eluting at 5.49 minutes. 
 
Methyl [4-(acetoxymethyl)-2-thioxo-7-chromenyloxy]acetate 
Methyl [4-(acetoxymethyl)-7-coumarinyloxy]acetate (50.8 g, 0.166 mmol) and 
P2S5 (35.0 mg, 0.157 mmol) were refluxed in 5 mL toluene overnight. The reaction 
completion was monitored using HPLC. When a complete conversion was seen, toluene 
was removed using rotavap. The crude mixture was partitioned between DCM and water. 
DCM layer was washed with water, then with saturated NaCl. DCM layer dried over 
MgSO4, dried. The product could be easily identified because of a redshift in the UV-vis 
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spectrum. Yield (43 mg, 80%); analytical method – reversed-phase HPLC (flow rate 0.4 
mL min−1, runtime 15 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B 
(0.1% TFA in ACN), gradient 60 % B isocratic over 15 min, C18 Hypersil column (5 μm, 
150 × 3.2 mm, Agilent), retention time: 4.5-5.5 min (Figure 123). 
 
Figure 123: HPLC chromatogram of methyl [4-(acetoxymethyl)-2-thioxo-7-
chromenyloxy]acetate. 
 
 [4-(Hydroxymethyl)-2-thioxo-7-chromenyloxy]acetic acid  
Here for hydrolysis, first we tried NaOH but it was not used because it was too 
harsh and hydrolysis of lactone was always observed (Figure 124). Hence mild acidic 
conditions were used. Typically, water: ethanol mixture is used for hydrolysis in acidic 
conditions. However, this caused transesterification and hence couldn’t be used (Figure 
125). A mix of water: dioxane (1:1) was also used as a solvent for hydrolysis. The reaction 
was not clean, and several side products were observed (Figure 126). Upon MS analysis, 
it appeared that sulfur atom was being replaced by oxygen from thiolactone moiety during 
the hydrolysis reaction. Replacing the sulfur atom reversed the redshifted spectrum. We 
were not able to get the desired product cleanly despite several attempts. Hence, we 
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abandoned the thiol modification approach. Without thiol modification, this 7-HMC group 
has no absorption in the visible light range. Analytical method – reversed-phase HPLC 
(flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run), solvent A (0.1% TFA in 
H2O), solvent B (0.1% TFA in ACN), gradient 50 % B isocratic over 15 min, C18 Hypersil 
column (5 μm, 150 × 3.2 mm, Agilent). 
 
Figure 124: Hydrolysis of [4-(hydroxymethyl)-2-thioxo-7-chromenyloxy]acetic acid 
using NaOH. 
 
 
Figure 125: HPLC chromatogram of hydrolysis of [4-(hydroxymethyl)-2-thioxo-7-
chromenyloxy]acetic acid using water: ethanol under acidic conditions. 
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Figure 126: HPLC chromatogram of hydrolysis of [4-(hydroxymethyl)-2-thioxo-7-
chromenyloxy]acetic acid using water: dioxane under acidic conditions. 
 
Route 4: Synthesis using 7-amino-4-methyl coumarin (modification of route 1) 
 
Figure 127: Route 4 of coumarin synthesis. 
 
 In this synthetic route (Figure 127), which is similar to route # 1, the second 
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alkylation was performed using ethyl bromide to introduce an ethyl group. The described 
synthesis is analogous to the one reported earlier. The substitutions of electron donating 
groups on seventh position amino group enhance redshift in its absorption spectrum. The 
addition of the ethyl group promotes redshift absorption as seen from the data here. Also, 
we utilized methyl-4-bromobutyrate where the carbonyl group is at δ position. Carbonyl 
group is an electron withdrawing group which prevents redshift absorption, putting it away 
from amino nitrogen gets rid of this effect. The effect is shown in Figure 128. 
 
Figure 128: The effect of substitution on the UV-vis absorption spectrum of the coumarin 
ring. N-alkylation has an electron donating effect which redshifts the absorption but 
having an electron withdrawing carbonyl group at the β position nullifies that effect. 
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Methyl 4-[N-ethyl(4-methyl-7-coumarinyl)amino]butyrate 
 7-amino-4-methylcoumarin (8.89 g, 50.0 mmol), sodium iodide (7.5 g, 50 mmol), 
methyl-4-bromobutyrate (14.3 mL, 100 mmol) and DIPEA (35 mL, 200 mmol) were mixed 
in 170 mL acetonitrile and stirred for 48 hours under reflux. It was filtered and dried under 
vacuum. The dried residue was partitioned between DCM and 1N HCl, the DCM layer was 
subsequently washed 4-5 times with 1N HCl. Finally, it was partitioned between saturated 
NaHCO3 and DCM. DCM solvent then was evaporated under vacuum. The remaining 
residue was scraped off and added to a 20 mL pressure vessels (Ace Glass). To the pressure 
vessel, sodium iodide (2.1 g, 14 mmol), DIPEA (9.8 mL, 56 mmol) and ethyl bromide x 
(12.0 mL, 160 mmol) were added and sealed tightly. The reaction was performed at 150 
ºC and the reaction progress was followed on HPLC till the intermediate was consumed. 
After the complete conversion of the intermediate, it was dried and partitioned again 
between DCM, water. The water layer was discarded, the DCM layer was dried. It was 
purified using 5% ethyl acetate in DCM. The crude mixture was not purified all at once, 
rather it was divided into 3 parts and purified via flash chromatography. Yield (2.20 g, 
14.5%); LCMS analysis – reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 15 min 
with 5 min post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 
50 %B isocratic over 15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), 
retention time: 11 min; ESI-MS (m/z): [MH]+ calculated for molecular formula = 
C17H21NO4, 304.15; found, 304.30 (Figure 129); on HPLC the retention time: 10 min 
(Figure 130); 1H NMR (DMSO-d6 ,400MHz):  = 7.50 (d, J=9.0 Hz, 1 H), 6.73 (dd, J=9.0, 
2.3 Hz, 1 H), 6.58 (d, J=2.7 Hz, 1 H), 5.94 (d, J=1.2 Hz, 1 H), 3.62 (s, 3 H), 3.43 (q, J=7.0 
Hz, 2 H), 3.36 (t, 2 H), 2.41 (t, J=7.2 Hz, 2 H), 2.33 (d, J=1.2 Hz, 3 H), 1.80 (quin, 2 H), 
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1.11 ppm (t, J=6.8 Hz, 3 H) (Figure 131); 13C NMR (100 MHz, DMSO-d6): δ 173.17, 
160.73, 155.54, 153.49, 150.53, 126.16, 108.60, 108.37, 107.74, 96.84, 51.35, 48.73, 
44.40, 30.25, 22.05, 17.92, 12.06 (Figure 131). 
 
Figure 129: LCMS analysis of methyl 4-[N-ethyl(4-methyl-7-
coumarinyl)amino]butyrate. The product mass is seen at [MH]+=304.3 eluting at 11 min. 
 
 
Figure 130: HPLC of methyl 4-[N-ethyl(4-methyl-7-coumarinyl)amino]butyrate. 
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Figure 131: 1H Proton NMR (top) and 13C NMR of methyl 4-[N-ethyl(4-methyl-7-
coumarinyl)amino]butyrate. 
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Methyl 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyrate 
 Methyl 4-[N-ethyl(4-methyl-7-coumarinyl)amino]butyrate (1.43 g, 4.70 mmol) 
and SeO2 (1.04 g, 9.80 mmol) were suspended in 40 mL p-xylene. It was refluxed 
overnight, filtered hot and dried under vacuum. After drying, 400 mL methanol was added 
to it and stirred for 20 min. Then NaBH4 (0.20 g, 5.3 mmol) was added and allowed to go 
for 10 minutes. It was filtered and methanol was dried under vacuum. The crude was 
purified using 5% methanol in DCM using flash chromatography. Yield (0.5 g, 33.3%); 
LCMS analysis – reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 15 min with 5 
min post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), gradient 50 % 
B isocratic over 15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention 
time: 5.61 min; ESI-MS (m/z): [MH]+ calculated for molecular formula = C17H21NO5, 
320.14; found, 320.30 (Figure 132); on HPLC the retention time = 5 min (Figure 133); 1H 
NMR (DMSO-d6 ,400MHz):  = 7.44 (d, J=9.0 Hz, 1 H), 6.70 (dd, J=9.2, 2.5 Hz, 1 H), 
6.59 (d, J=2.7 Hz, 1 H), 6.08 (t, J=1.4 Hz, 1 H), 5.52 (t, J=5.7 Hz, 1 H), 4.67 (dd, J=5.5, 
1.2 Hz, 2 H), 3.61 (s, 3 H), 3.42 (q, J=6.9 Hz, 2 H), 3.36 (t, 2 H), 2.41 (t, J=7.0 Hz, 2 H), 
1.79 (quin, 2 H), 1.10 ppm (t, J=7.0 Hz, 3 H) (Figure 134); 13C NMR (100 MHz, DMSO-
d6):173.2, 161.1, 158.8, 155.5, 150.3, 125.0, 108.8, 105.8, 104.4, 97.10, 59.0, 51.3, 48.7, 
44.4, 30.2, 22.0, 12.1 (Figure 134). 
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Figure 132: LCMS of methyl 4-{N-ethyl[4-(hydroxymethyl)-7-
coumarinyl]amino}butyrate. 
 
 
Figure 133: HPLC of methyl 4-{N-ethyl[4-(hydroxymethyl)-7-
coumarinyl]amino}butyrate. 
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Figure 134: Proton NMR (top) and 13C NMR (bottom) of methyl 4-{N-ethyl[4-
(hydroxymethyl)-7-coumarinyl]amino}butyrate. 
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4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyric acid 
 Methyl 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyrate (0.39 g, 1.24 
mmol) was added to 40 mL mixture of water:THF in 1:1 ratio. HCl was added into it in 
50x molar excess to that of the substrate. The reaction was run for 2 hours and then 
neutralized with NaOH to bring pH to 7. Then the crude mixture was dried using a vacuum. 
The material was extracted from the dried residue by washing with a 10-15 mL mixture of 
acetone+ethanol three times. The yield was quantitative. LCMS analysis – reversed-phase 
HPLC (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-run), solvent A (0.1% FA 
in H2O), solvent B (0.1% FA in ACN), gradient 50 % B isocratic over 15 min, C18 Hypersil 
column (5 μm, 150 × 3.2 mm, Agilent), retention time: 3.17 min; ESI-MS (m/z): [MH]+ 
calculated for molecular formula = C16H19NO5, 306.12; found, 306.20 (Figure 135); 
retention time on HPLC: 3 min (Figure 136); 1H NMR (DMSO-d6 ,400MHz):  = 11.81 - 
12.71 (m, 1 H), 7.43 (d, J=9.0 Hz, 1 H), 6.71 (dd, J=9.2, 2.5 Hz, 1 H), 6.59 (d, J=2.3 Hz, 
1 H), 6.08 (s, 1 H), 4.67 (d, J=1.2 Hz, 2 H), 3.43 (q, J=6.8 Hz, 2 H), 3.35 (t, 2 H), 2.31 (t, 
J=7.0 Hz, 2 H), 1.75 (quin, J=7.4 Hz, 2 H), 1.23 (s, 1 H), 1.10 ppm (t, J=7.0 Hz, 3 H) 
(Figure 137); 13C NMR (100 MHz, DMSO-d6): 174.2, 161.2, 159.9, 155.6, 150.4, 125.0, 
108.6, 105.8, 104.0, 96.9, 59.0, 48.9, 47.1, 44.4, 30.6, 22.1, 12.1 (Figure 137, 13C not 
shown). 
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Figure 135: LCMS of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyric acid. 
 
 
Figure 136: HPLC of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyric acid. 
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Figure 137: NMR of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyric acid. 
 
4-{N-Ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}-1-(2-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone 
 The dried residue of 4-{N-Ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}butyric 
acid (1.24 mmol), EDC (0.4 g, 1.24 mmol), HOBt hydrate (0.380 g, 1.24 mmol) and 11-
azido-3,6,9-trioxaundecan-1-amine (0.270 mL, 1.364 mmol) were mixed with 25 mL 
DMF. It was stirred overnight. DMF was evaporated under vacuum. The dry crude reaction 
mixture was partitioned between EtOAc and water. EtOAc was then washed with saturated 
NaCl and dried over MgSO4. EtOAc was further filtered and dried under vacuum. Yield 
(0.574 g, 91.6%); LCMS analysis – reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 
15 min with 5 min post-run), solvent A (0.1% FA in H2O), solvent B (0.1% FA in ACN), 
gradient 50 % B isocratic over 15 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, 
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Agilent), retention time: 3.89 min; ESI-MS (m/z): [MH]+ calculated for molecular formula 
= C24H35N5O7, 506.25; found, 506.30 (Figure 138); 1H NMR (DMSO-d6 ,400MHz):  = 
7.93 (s, 1 H), 7.43 (d, J=9.0 Hz, 1 H), 6.70 (dd, J=9.2, 2.5 Hz, 1 H), 6.57 (d, J=2.3 Hz, 1 
H), 6.07 (s, 1 H), 5.49 - 5.54 (m, 1 H), 4.67 (dd, J=5.5, 1.2 Hz, 2 H), 3.50 - 3.62 (m, 13 H), 
3.40 (dt, J=15.0, 5.6 Hz, 7 H), 3.29 - 3.35 (m, 3 H), 3.22 (q, J=5.7 Hz, 2 H), 2.54 (s, 4 H), 
2.16 (t, J=7.0 Hz, 2 H), 1.69 - 1.81 (m, 2 H), 1.10 ppm (t, J=6.8 Hz, 3 H) (Figure 139); 13C 
NMR (100 MHz, DMSO-d6): 171.7, 161.1, 156.8, 155.6, 150.4, 125.0., 108.6, 105.7, 
103.9, 96.9, 72.3, 69.8, 69.7, 69.7, 69.5, 69.2, 60.2, 59.0, 50.0, 49.1, 44.4, 32.0, 22.7, 12.07 
(Figure 139); retention time on HPLC: 4 min (Figure 140). 
 
Figure 138: LCMS of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}-1-(2-{2-[2-
(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone. 
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Figure 139: NMR of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}-1-(2-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone. 
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Figure 140: HPLC of 4-{N-ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}-1-(2-{2-[2-
(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone 
 
Caging insulin using coumarin azide 
4-{N-Ethyl[4-(hydroxymethyl)-7-coumarinyl]amino}-1-(2-{2-[2-(2-
azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone (89.9 mg, 178 µmol), 
carbonyldiimidazole (CDI) (28.8 mg, 178 µmol) and 4-Dimethylaminopyridine (DMAP) 
(21.75 mg, 178 µmol) were mixed in 0.3 mL of anhydrous DMSO. Moisture from DMSO 
was removed by the following procedure – the molecular sieves were kept under vacuum 
in a 100 ºC heated chamber overnight. Then molecular sieves were suspended in DMSO 
to dry it. The activation reaction was kept at 40 ºC for 70 minutes. Then this mixture was 
added to insulin (1.2 g, 0.206 mmol) dissolved in 90 mL of anhydrous DMSO. The caging 
reaction was quenched by adding 5 mL of water after running it for 24 hours at 40 ºC. This 
reaction was performed multiple times on this scale to obtain caged insulin. ESI−MS (m/z): 
[M]+ calculated for, 6339.2; found, 6344.0 (Figure 141); analytical method – reversed-
phase HPLC-MS (flow rate 0.4 mL min−1, runtime 30 min with 5 min post-run),  solvent 
A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 0% B to 100 % B over 28 
min, gradient 100% B to 0 % B until 30 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, 
Agilent), retention time: 15.7-16.8 min (Figure 142). 
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Figure 141: MS of CIMA. The product mass is seen at [M]+=6344.0 (calc. for 6339.2). 
 
 
Figure 142: HPLC chromatogram of purified CIMA. The twin peaks are two isomers of 
CIMA. 
Determining the site of conjugation on insulin 
We were observing two prominent isomeric peaks for CIMA in HPLC, peak # 2 
being slightly in excess. The conjugation of coumarin to insulin occurs via carbamate 
linkage as evident from the mass spectrum as opposed to ester linkage because carbamate 
also introduced C=O which adds a mass of 28 amu. There are three primary amines on 
160 
insulin which could be involved. The carbonate formation could also happen on possible 
threonine and serine residues but less likely. Three possible amines are – terminal amine 
on chain A of Glycine, terminal amine of phenylalanine on chain B and the side chain of 
B29 lysine on chain B. We initially tried reducing insulin with DTT and analyzing the 
separated chains using the mass spec to identify whether conjugation solely occurring on 
chain B or chain A is involved as well. There was an issue with this procedure, it was seen 
that DTT treatment was hydrolyzing coumarin group from insulin. Initial DTT 
concentration was 0.72 M. Even reducing it to 50 mM did not help. Later, we used trypsin 
and GluC to digest insulin into smaller peptide fragments to map the sites of modification. 
To perform these studies, both the isomers of CIMA were purified individually using RP-
HPLC. Analytical method – reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 30 
min with 5 min post-run),  solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
gradient 0 % B to 100% B over 30 min, C18 Hypersil column (5 μm, 150 × 3.2 mm, 
Agilent), retention time: 17-18 min for both the isomers. Refer to Figure 143 for the 
chromatogram of the crude mixture and Figure 144 for chromatogram of purified isomers. 
 
Figure 143: HPLC chromatogram of the crude reaction mixture of insulin by coumarin 
azide. 
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Figure 144: HPLC chromatogram of CIMA isomer 1 and 2 overlaid (and normalized) on 
top of each other. 
 
Digestion using trypsin 
Trypsin (Fisher Scientific, catalog # 90057) and 4 mg insulin were mixed with 4 
mL 0.1 M Tris-HCl, pH=8.5; the concentration was 0.172 mM. 20 µg trypsin was dissolved 
in 20 µL 1 mM HCl solution. This 20 µL enzyme was mixed with 0.5 mL protein substrate. 
The reaction was incubated for 17 hours at 37 ºC and analyzed by HPLC and mass 
spectrometry. 
 The expected masses for the digested fragments are enlisted in Figure 145 and 
Table 7. HPLC chromatogram for the crude digestion mixture (Figure 146) shows two 
prominent peaks: a smaller peak 1 and a taller peak 2 at 14.5 and 16.2 min respectively. In 
the negative ion mode, peak 1 showed a mass of 857.7 amu which corresponds to fragment 
2. Fragment 2 GFFYTPK has a mass of 858.4 (Figure 147). While peak 2 shows a mass of 
4870 which corresponds to larger fragment 1. The expected mass is 4865.5 (Figure 148). 
After confirming that the digestion protocol was working on native insulin, we proceeded 
further to digest CIMA. 
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Figure 145: Trypsin digestion of insulin. 
 
 
Figure 146: HPLC chromatogram of trypsin digestion of native insulin. 
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Figure 147: MS infusion of peak 1 (Figure 146) of digestion of insulin by trypsin. 
 
 
Figure 148: MS infusion of peak 2 (Figure 146) of digestion of insulin by trypsin. 
 
CIMA isomer 1 digestion by trypsin 
 A stock solution of CIMA isomer 1 was prepared in DMSO (concentration = 8.47 
mM). 5.1 µL of CIMA isomer 1 from its stock solution was mixed with 0.25 mL 0.1 M 
Tris-HCl, pH=8.5, the concentration here was 0.172 mM. Trypsin 10 µg was dissolved in 
10 µL 1 mM HCl solution and was mixed with 0.25 mL protein substrate. The reaction was 
164 
incubated for 17 hours at 37 ºC and analyzed by HPLC and mass spectrometry. 
 Figure 149 shows the HPLC chromatogram of CIMA isomer 1 digestion by trypsin. 
It showed two main peaks of interest. Based on the knowledge of retention times, peak 1 
corresponds to unmodified fragment 2. Upon MS analysis, it showed the mass of ([M] - = 
857.5) of unmodified fragment 2 suggesting that the modification should be on fragment 1 
(Figure 150). Also, peak 2 showed a signal at 380 nm suggesting that it should have a 
coumarin chromophore attached to it. Upon MS analysis, the peaks corresponding to 
modified fragment 1 with coumarin (Figure 151) were observed. The predicted masses and 
m/z are calculated in Table 7. 
 
Table 7: Fragments of CIMA after trypsin cleavage. 
 
Fragments Sequence Mass Total 
mass 
after 
caging 
M/4 for 
4+ 
charges 
M/5 for 
5+ 
charges 
1 GIVEQCCTSICSLYQLENYCN + 
FVNQHLCGSHLVEALYLVCGER 
4865.5 5396.7 1349.2 1079.3 
2 GFFYTPK 858.4 1389.6  
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Figure 149: HPLC chromatogram of CIMA isomer 1 digestion by trypsin. 
 
 
Figure 150: MS infusion of peak 1 (Figure 149) of digestion of CIMA 1 by trypsin. 
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Figure 151: MS infusion of peak 2 (Figure 149) of digestion of CIMA 1 by trypsin. 
 
CIMA isomer 2 digestion by trypsin 
A stock solution of CIMA isomer 2 was prepared in DMSO (concentration = 7.79 
mM). 5.52 µL of CIMA isomer 2 from its stock solution was mixed with 0.25 mL 0.1 M 
Tris-HCl, pH=8.5, the concentration was 0.17 mM. 10 µg trypsin was dissolved in 10 µL 
1 mM HCl solution and it was mixed with 0.25 mL protein substrate. The reaction was 
incubated for 3 hours at 37 ºC and analyzed by HPLC and mass spectrometry. 
The digestion time for isomer 2 was shortened to 3 hours because the data was not 
informative when the digestion was performed for overnight. In Figure 152, the crude 
digestion mixture is run on HPLC; 3 major peaks were observed and collected for infusion 
in MS. Peak 1 shows a mass of 4870 corresponding the unmodified fragment 1 (Figure 
153). This suggests that the conjugation must be on fragment 2 for this CIMA isomer. Peak 
2 includes two distinct peaks when infused into MS showed the mass of undigested CIMA 
(Figure 154). Three hours digestion time is probably not enough for complete digestion of 
CIMA, hence we observed undigested CIMA as peak 2. Peak 3 showed a mass of 1490.3 
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which corresponds to the mass of peptide fragment GFFYTPKT + the mass of conjugated 
coumarin (Figure 155). Ideally, trypsin would cut after K and T should not be in the 
fragment. Since the conjugation is occurring on K, the bulky coumarin moiety is sterically 
hindering trypsin cleavage at T.  
 
Figure 152: HPLC chromatogram of CIMA isomer 2 digestion by trypsin. 
 
 
Figure 153: MS infusion of peak 1 (Figure 152) of digestion of CIMA isomer 2 by 
trypsin. 
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Figure 154: MS infusion of peak 2 (Figure 152) of digestion of CIMA isomer 2 by 
trypsin. 
 
 
Figure 155: MS infusion of peak 1 (Figure 152) of digestion of CIMA isomer 2 by 
trypsin. 
 
 
The results from trypsin digestion experiment were very useful and revealed the 
sites of conjugation. In the case of isomer 1, the conjugation is most likely on one of the 
amines of either chain A or chain B. The conclusion is summarized in Figure 156.  
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Figure 156: Possible sites of conjugation (red stars), based on the trypsin digestion 
results. 
 
Digestion of insulin by GluC 
 The trypsin digestion experiment helped to locate the site of conjugation for CIMA 
isomer 2, it is likely on K of fragment 2 of chain B. However, it couldn’t specify the site 
on isomer 1. Hence, we decided to use another protease GluC. GluC protease specifically 
cleaves on the C terminal side after a glutamic acid residue. Since GluC has a different 
pattern of proteolysis and it would help to locate whether the conjugation is on chain A or 
chain B of isomer 1 (Figure 157 and Table 8). 
Endoproteinase GluC (catalog # P8100s) was purchased from New England 
Biolabs. 50 µg of GluC was dissolved in 50 µL of milliQ water and 13 aliquots of 3.84 µL 
were prepared in 13 tubes. The aliquots were stored in -80 ºC until used. The following 
reagents were mixed to initiate the digestion of insulin; 0.1 mL water + 0.1 mL 2x buffer 
provided with the kit + 3.84 µL enzyme + 17.2 µL of 1 mM insulin solution prepared in 
DMSO. It was allowed to run overnight. Finally, the peaks were collected on HPLC and 
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analyzed by MS to determine the digestion fragments (Figure 158 - Figure 160).  
 
Figure 157: Insulin digestion by GluC. 
 
 
Figure 158: HPLC chromatogram of digestion mixture of insulin by GluC. 
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Table 8: GluC digestion fragments of insulin and their masses. 
 
Fragment Sequence Total mass Charged state 
[M/2] 
Total mass 
after 
conjugation 
1 GIVE 416.2 - 947.2 
2 QCCTSICSLYQLE 
+ 
FVNQHLCGSHLVE 
2972.2 1486.1 3503 
3 RGFFYTPKT 1115.5   
4 NYCN+ 
ALYLVCGE 
1378.5  689.2 - 
 
 
Figure 159: MS infusion of peak 1 (Figure 158) of digestion of insulin by GluC. 
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Figure 160: MS infusion of peak 2 (Figure 158) of digestion of insulin by GluC. 
 
CIMA 1 digestion by GluC 
A stock solution of CIMA isomer 1 was prepared in DMSO (concentration = 8.467 
mM). 1.84 µL of CIMA isomer 1 from its stock solution was mixed with 0.1 mL of 2x 
digestion buffer, 0.1 mL of milliQ water and 3.84 µg GluC. The reaction was incubated for 
3 hours at 37 ºC and analyzed by HPLC (Figure 161), peak 1 was collected and 
characterized by mass spectrometry. It showed the correct mass of fragment GIVE caged 
with photocleavable group (Figure 162). To further confirm the identity of peak 1, the 
fraction collected from HPLC was photolyzed using 405 nm. After the photolysis, the 
caged peptide was released, and we observe the mass of uncaged peptide GIVE in MS 
(Figure 163). Conclusions from the protease digestion and MS analysis are summarized in 
Figure 164. 
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Figure 161: HPLC chromatogram of CIMA isomer 1 by GluC protease. 
 
 
Figure 162: MS infusion of peak 1 (Figure 161) of digestion of CIMA isomer 1 by GluC. 
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Figure 163: MS infusion of peak 1 (Figure 161 and Figure 162) after exposing it to 405 
nm LED for 15 min. 
 
 
Figure 164: The sites of conjugation on insulin in both CIMA isomers. Coumarin is being 
conjugated to CIMA isomer 1 on terminal amine of chain A and on B29 lysine in the case 
of CIMA isomer 2. 
 
Measuring molar extinction coefficients of coumarin carbamate and insulin 
The experiment was set up to determine the molar extinction coefficient of 
coumarin carbamate. The molar extinction coefficient of 4-{N-ethyl[4-(hydroxymethyl)-
7-coumarinyl]amino}-1-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-1-butanone 
(coumarin azide) could not be used for this purpose because there is an increase in the 
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absolute molar extinction coefficient once the carbamate is formed. Hence it was decided 
to cage a test molecule to coumarin azide to measure its molar extinction coefficient. The 
caged molecule (shown in Figure 165) was synthesized using the same CDI conjugation 
chemistry used for caging insulin. The crude reaction mixture was run on prep HPLC and 
the desired product was purified. After drying the HPLC fractions, the dried product was 
dissolved in DCM and the organic layer was extracted with water to remove TFA salt. The 
HPLC chromatogram is shown in Figure 166.  
 
Figure 165: Test molecule used for determining the molar extinction coefficient of 
coumarin caged test molecule. 
  
 
 
Figure 166: HPLC chromatogram of purified coumarin caged test molecule on prep 
HPLC. 
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To measure the extinction coefficient, the dried residue of test molecule was 
dissolved in DMSO and aliquoted in three Eppendorf tubes. DMSO was evaporated in 
speedvac overnight to eliminate DMSO completely. The weight of the compound was 
recorded and dissolved in a known volume of DMSO and theoretical concentration was 
calculated. From the stock solutions, serial dilutions were performed to create solutions of 
different concentrations. The absorbance measurements were performed on each dilution 
and plotted against concentration. The results of three independent replicates are shown in 
Figure 167. The average slope of 3 plots was 19770 with a standard deviation of 34.2.  
Extinction coefficient of caged coumarin = 19800 M-1cm-1 
 
Figure 167: The standard curves of different dilutions from caged DEACM in triplicate. 
 
Measurement of photolysis rate constant of CIMA 
 This experiment was aimed at measuring photolytic rate kinetics of CIMA in 
solution. It would be interesting to compare the rate with DMNPE insulin photolysis rate 
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which was reported earlier.29 We decided to use PBS as a solvent for performing the 
photolysis as it closely mimics the physiological solvent. However, CIMA is fairly non-
polar and hence a small amount of DMSO was added to maintain its solubility. For 
photolysis, a stock solution of CIMA of 10.23 mM was used. Final concentration of CIMA 
was kept at 1 mM adding 8.8 µL stock solution + 1.2 µL DMSO + 80 µL PBS. The 
photolysis was performed in a microcentrifuge tube at a distance of 5 cm from the 405 nm 
LED. At every time point, 10 µL solution was removed, diluted to 80 µL using DMSO and 
injected (25 µL) in HPLC for analysis. A standard curve of insulin on HPLC was used to 
determine the amount of insulin being uncaged due to photolysis. All chromatograms from 
one of the replicates are overlaid and shown in Figure 168. The concentration of insulin at 
each time point was measured and averaged from triplicates. It was plotted against time in 
Kaleidagraph®.  
𝐴 = 𝐴0(1 − 𝑒−𝑘1.𝑡) 
The plot is shown in Figure 169. Calculated kinetic rate constant is k1 = 0.0184 sec-1 and 
fits the expected first order kinetics. 
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Figure 168: HPLC chromatograms of CIMA solution phase photolysis overlaid. 
 
 
Figure 169: Plot of insulin concentration versus time during CIMA solution phase 
photolysis by 405 nm light. 
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Synthesis and characterization of insulin trimer 
The trimer species were purified using a size exclusion column (Yarra 3 µm SEC-
2000 LC column 300 × 7.8 mm). ESI-MS (m/z): [M]+ calculated for, 20,008.89; found, 
20,023.00 (Figure 170); HPLC purification method – size exclusion HPLC (flow rate 0.5 
mL min−1, runtime 16 min with 3 min post-run), solvent A (H2O), solvent B (0.1% TFA in 
ACN), gradient 45 % B isocratic over 16 min, elution time – 10.7-11.4 min (Figure 171). 
 
Figure 170: The mass spec of insulin trimer. The trimer is seen at [M]+=20023 (calc. for 
20009). 
 
Figure 171: The analytical chromatogram of purified insulin trimer on the size exclusion 
column. 
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Preparation of insulin trimer particles 
 The insulin trimer was synthesized as described above. However, once all DMSO 
was evaporated from the tube containing trimer, the remaining material used to get stuck 
as a film. It was hard to remove and always a heterogeneous mixture of variable sizes and 
shapes. To make it uniform, we thought of grinding this material down to get small particles 
with a narrow size particle distribution. For this, a smaller motored pestle was used (Argos 
Technologies, catalog # A0001). Typically, to prepare particles, insulin trimer solution in 
DMSO was added to a microcentrifuge tube. DMSO was evaporated using speed-vac. 150 
µL PBS was added and ground using the pestle for about 4 min. The suspension was 
centrifuged heavily, and supernatant PBS was removed. Then fresh PBS was added as 
required. This procedure was performed just before using this material. The particles could 
be kept in -20 ºC after preparing in bulk. 
Optimization of particle size of trimer particles 
 To achieve the smallest particle size and narrower distribution, we tried grinding 
particles for different lengths of time using the procedure described above. Briefly, trimer 
containing 10 nmol of CIMA was dried in a microcentrifuge tube. These particles were 
suspended in 33 µL of PBS. The particles were ground using motor pestle for 30 seconds, 
1 min, 2 min, 4 min and 6 minutes in different tubes. This 33 µL was further diluted 
approximately 200x after grinding for particle size measurements using Zetasizer.  
As seen in Figure 172, there was no significant difference in grinding time either 
on particle size or PDI. The standard deviation, however, decreased as the grinding time 
increased. Based on this, we decided to keep the grinding time to 4 minutes to achieve the 
smallest particle size with a narrow size distribution. To test the ease of injection of these 
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particles into injection via needle-syringe, this suspension of particles in PBS was passed 
through a syringe having a 31G needle. The particles passed through it without any 
resistance. There were no particles seen stuck inside the syringe. Because of this, we 
decided to use these for animal studies. 
 
Figure 172: Particle sizes of coumarin insulin trimer particles as measured using 
Zetasizer. 
 
Final analysis of particle size of trimer used for in-vivo studies 
 For the final measurements of particle size, the trimer pellets were milled as 
described earlier. Briefly, the solution of insulin trimer in DMSO containing 140 nmol of 
insulin was aliquoted into 3 tubes and dried overnight in a speed vac. To dried pellet, 0.15 
mL of PBS was added, and particles were milled for 4 minutes. Additional 0.3 mL of PBS 
was used and added to current suspension after washing the plastic probe. Measured pH at 
this point was approximately 6.3, it was raised to 7.2 using 1 N NaOH. The tubes were 
centrifuged for one min at 7000 rpm, and the entire supernatant was taken out. 50 µL of 
fresh PBS was added and vortexed to suspend particles. The suspension was diluted 
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approximately 2000-fold in PBS and this solution was used to measure the particle size. 
Average size was calculated from triplicate measurements.  
 
Figure 173: Measurement of particle size of insulin trimer using DLS. 
 
Average diameter = 2461 nm with PDI of 0.7 (Figure 173). 
Solubility studies 
 This experiment was aimed at measuring the solubility of coumarin insulin trimer 
in PBS at pH 7.2 and comparing it with native insulin. The rationale was to measure how 
much insoluble insulin is in the form of trimer versus free insulin in aqueous solvents at 
pH 7.2. Less solubility is desirable as it would precipitate out and remain localized at the 
site of injection. 
To measure the solubility limit of the trimer, trimer pellet containing 140 nmol of 
insulin was dried in three tubes in speed-vac. 150 µL of PBS was added to it. Using the 
motorized pestle (Argos Technologies, catalog # A0001), it was ground into particles for 
4 min. 0.3 mL additional PBS was used to wash the plastic probe and added to the original 
solution. PH was adjusted to 7.2 using 1 N NaOH. It was centrifuged for 3 min at 13000 
rpm. The supernatant was carefully removed using gel loading pipette tip and remaining 
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particles were suspended in 70 µL PBS. It was kept for vortexing at speed 6 on Vortex 
Genie # 2 (Fisher Scientific) for two hours. The samples were centrifuged again at 14000 
rpm for 3 min. 1 µL of supernatant was diluted in DMSO and the absorbance measurements 
were performed using UV-VIS spectrophotometer at 380 nm using coumarin ɛ380 nm = 
59300 M-1cm-1.  
 The solubility limit of insulin was determined in a similar manner except 10 mg 
insulin was weighed and suspended in 0.2 mL PBS in three tubes. pH was adjusted to 7.2 
and vortexed in the same manner. The absorbance was recorded in PBS because the 
extinction coefficient of insulin was measured in PBS. ɛ280 nm = 5200 M-1cm-1. The 
maximum solubility of trimer measured = 1.01 µM and the maximum solubility of insulin 
measured = 2.14 mM. The solubility of insulin trimer was 2115-fold less compared to 
native insulin (Figure 174). 
 
Figure 174: The solubility difference between insulin versus insulin trimer in PBS at pH 
7.2. 
0
0.0005
0.001
0.0015
0.002
Insulin Trimer
C
o
n
ce
n
tr
at
io
n
 (
M
)
Solubility of insulin vs insulin trimer, PBS pH=7.2
184 
In-vitro photolysis of insulin trimer 
 At this point, we performed in-vitro photolysis of coumarin trimer material using 
405 nm LED. The aim was to mimic the photolysis under light/dark conditions as reported 
here.29 We noticed that the Tentagel® resin behaved very differently from the ChemMatrix 
® resin when subjected to in-vitro photolysis.73 Significant leaching was observed from 
Tentagel® resin which was not expected. This might be because insulin that is being 
released saturates PBS and we know that insulin has moderate solubility in PBS. As 
additional insulin is released, it cannot be solubilized due to saturation limit and as we 
replace fresh PBS, previously released but insoluble insulin gets solubilized and we see 
extended release profiles. Due to this, we decided to remove complete supernatant at each 
time point rather than removing 50% as performed earlier for the analysis of first-
generation material. The procedure is described in the next paragraph. 
 A solution of insulin trimer in DMSO containing 140 nmol of insulin was aliquoted 
into 3 tubes and dried overnight in a speed vac. To the dried pellet, 0.15 mL of PBS was 
added, and particles were milled for 4 minutes. Additional 0.3 mL of PBS was used and 
added to current suspension for washing the plastic probe. The measured pH at this point 
was approximately 6.3 and raised to 7.2 using 1 N NaOH. The entire suspension was 
transferred into glass tubes (Fisher Scientific, 1 mL). The tubes were centrifuged for one 
min at 7000 rpm, and the entire supernatant was taken out. 0.1 mL of buffer was added to 
the suspension, vortexed briefly and centrifuged in the same manner. The supernatant was 
collected and labeled as t=0’. At each time point, 0.1 mL buffer was added, vortexed, 
centrifuged and the supernatant was collected. At t=0 and t=60, a brief illumination was 
performed for two minutes each by keeping the vial at 6.4 cm from the 405 nm LED. The 
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samples were stored in -80 ºC. The samples were analyzed by loading 5 µL of the total 100 
µL of collected supernatant on a gel and running SDS-PAGE. Band intensities were 
measured using Photoshop®. For the control samples, an aluminum foil was kept between 
LED and samples to prevent exposure to light. To quantify the number of moles of insulin 
released, different amounts of insulin were loaded into wells to plot a standard curve. This 
plot was used to measure the amount of insulin in samples. Control samples resulted in no 
bands. The cumulative insulin release is plotted in Figure 175. 
 
Figure 175: Cumulative insulin release from in-vitro photolysis of coumarin insulin 
trimer suspension. Experimental samples are in blue while the controls are in orange. 
  
 This in-vitro photolysis is somewhat similar to what we observed with the Tentagel 
resin with first-generation material. Even after stopping the light exposure, insulin still 
comes off from the material and plateaus much later than desired. The low solubility of 
insulin in PBS is probably responsible for this. When we expose the material to light, a 
certain amount of insulin is released but not all of it can solubilize in the given volume of 
PBS. Because of this solubility issue, it precipitates out and when we centrifuge it at 7000 
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rpm for a minute, the solubilized portion comes off in the supernatant, which is then 
measured in the gel. The precipitated portion settled at the bottom after centrifugation and 
it gets solubilized later when fresh PBS is added for the next time point. That is why we 
see such a plot. Likely, a similar phenomenon could happen in an animal model as insulin 
may not be completely released in the bloodstream all at once. Although we might observe 
a quick burst into the blood, the release time may be prolonged. The lag could be accounted 
when creating a mathematical model of PAD insulin release kinetics in the future, thus the 
release could be predicted and fine-tuned. 
Optimization of 405 nm setup for avoiding high temperatures 
 As coumarin can be photocleaved using blue light, we planned on using 405 or 450 
nm LED for performing the photolysis. The inverse square plot of 405 nm LED was plot 
as described earlier. This was taken when the animal studies were being performed in 
March 2018 (Figure 176). 
 
Figure 176: Absolute irradiance of 405 nm LED (taken in March 2018). 
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405 nm LED temperature measurements 
The temperature measurements were performed using a flat temperature probe from 
Klein Tools. The in-vitro temperature measurements were performed by keeping the probe 
flat and holding a LED right on top of it on a wooden surface.  
The temperature went very high, much higher than expected. Within 10 seconds, it 
went higher than 200 ºF (Figure 177) from room temperature. We were planning to perform 
2-min irradiation for the animal studies, but that would have been too much. In pilot studies, 
it was found out that, even 7-8 seconds of irradiation was enough to cause a skin injury.  
 
Figure 177: Temperature of 405 nm LED as measured by a flat temperature probe. 
 
To get around this problem, we increased the distance between the LED and the 
base plate. To achieve this, Dr. Friedman designed smaller wooden spacers of 0.63 cm 
height with magnets so that it can be put between the LED and the base plate to increase 
the overall distance. The time course of temperature was measured again with this new 
setup and compared with the previous one without spacers (Figure 178).  
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Figure 178: The LED design was modified by inserting wooden spacers in between two 
black discs. 
  
The temperature did not increase much with the help of spacers and below 130 ºF even 
after irradiation of one minute (Figure 179). This change occurred because as we increased 
the distance approximately three times, the light intensity decreased 89% the original 
intensity. Also, the elevation allows space through which the heat escape, as opposed to a 
closed area with the compact LED on the surface. We estimated these temperatures would 
be tolerable to the skin. 
 
Figure 179: Temperature curve of 405 nm LED with and without spacers. 
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Thermal studies using LEDs on skin 
 The higher the energy being delivered to the depot in less amount of time, the more 
insulin will be released from the depot. Keeping the LED as close to the skin as possible 
and irradiating for a longer duration would ensure that the depot is being delivered the 
maximum amount of energy. We varied both the distance and time as these two parameters 
could be manipulated easily. Ideally, one could also alter the energy output of LEDs but 
here the aim is to vary the distance. In these studies, we are trying to measure what is the 
increase in temperature as we vary the distance between LED and skin as well as the 
duration of irradiation.  
 Dr. Friedman designed a scaffold which has 6 holes of 7 mm diameter each, through 
which the light passes for these experiments. A set of magnets were inserted surrounding 
the holes to add spacers of different heights to vary the distance (Figure 180). To measure 
the skin temperature, we utilized a FLIR ONE PRO infrared camera which could be 
operated by attaching to an iPhone. The images can be processed in software (provided by 
the company) to measure localized temperature. In all experiments, the holes were 
irradiated for specific periods of time at a certain distance. After irradiation, the LED was 
removed immediately, and a picture was taken. Thus, we measured heating occurring on 
the skin (Figure 181). 
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Figure 180: The scaffold used for the thermal studies (top). It was glued to the skin. The 
golden dots are magnets. LED was aligned over the open circle through a spacer 
(bottom). An opaque tape was placed over remaining open circles to prevent exposure to 
light when irradiating a spot. 
 
 
Figure 181: A screenshot of image processing in the FLIR Pro software. To measure the 
temperature of a spot, a circle was drawn around that and the measurements were 
recorded. 
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Attempt 1 for the thermal measurements 
 For the first attempt, we used both 405 nm and 450 nm LED. For spacers, we used 
the wooden spacers mentioned above. The total distance with two discs and wooden 
spacers was 0.95 cm. Time points selected were 0, 0.5, 1, 2, 4, 8 minutes.  
We monitored if there was any visible injury on the skin. As seen in Figure 182, 
there were no visible signs of phototoxicity on the skin with 405 nm LED. The heat 
measurements for LEDs are plotted in Figure 183 and Figure 182. The temperature increase 
was modest going from body temperature to low 40s in Celsius in the case of 405 nm LED. 
Then it stayed nearly constant for 8 minutes time. However, the light of higher wavelength 
(450 nm) generated more heat and higher temperatures within a minute. No injury was seen 
with 405 nm LED irradiation, this makes sense at temperatures generated using 405 nm 
are not high and seemed to be tolerable by the skin. Surprisingly, although the temperatures 
are higher only by a few degrees centigrade in the case of 450 nm, we observed a significant 
amount of skin damage for higher durations of irradiation. It is interesting to note that 8 
min of irradiation with 405 nm LED doesn’t cause skin damage and temperatures plateau 
around 43 ºC, while even two minutes irradiation with 450 nm LED cases visible skin 
damage and the temperature was approximately 48 ºC. The estimated relationship between 
distance and energy is calculated in Table 9 and Table 10. 
.  
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Table 9: Distances and corresponding absolute irradiance of 405 nm LED. 
 
Type of spacer Distance of 
spacer 
Total distance Inverse square 
of the distance 
Absolute 
irradiance 
(W/cm2) 
No spacer NA 2 × 1/16” = 
1/8” ≈ 3.2 mm 
(1/ (0.32)2) = 
9.76 
0.950556 
2 magnets 2 × 1/16” = 
1/8” 
1/8” + (2 × 
1/16”) = 1/4” = 
6.35 mm 
1/ (0.635)2 = 
2.48 
0.241439 
 
2 magnets 2 × 1/16” = 
1/8” 
1/8” + (2 × 
1/16”) = 1/4” = 
6.35 mm 
1/ (0.635)2 = 
2.48 
0.241439 
 
 
 
Table 10: Distances and corresponding absolute irradiance of 450 nm LED. 
 
Type of spacer Distance of 
spacer 
Total distance Inverse square 
of the distance 
Absolute 
irradiance 
(W/cm2) 
No spacer NA 2 × 1/16” = 
1/8” ≈ 3.2 mm 
(1/ (0.32)2) = 
9.76 1.848724 
2 magnets 2 × 1/16” = 
1/8” 
1/8” + (2 × 
1/16”) = 1/4” = 
6.35 mm 
1/ (0.635)2 = 
2.48 
0.469316 
Wood spacers 1/4” 1/4” + (2 × 
1/16”) =0.375” 
=9.5 mm 
1/ (0.95)2 = 
1.11 
0.209556 
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Figure 182: Pictures of irradiated skin spots which were irradiated using 405 nm (top) 
and 450 nm (bottom) for different periods of time. The pictures were taken after 24h, 48h 
and 96 hours. 
 
 
Figure 183: Average temperature on rat skin (inside 7 mm holes) after illumination with 
405 nm and 450 nm LEDs at 0.95 cm distance (wooden spacers). 
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Attempt 2 with 405 nm LED varying the distance 
 Because 450 nm LED showed a significant level of skin damage, we decided not 
to use 450 nm in future thermal studies. Also, for in-vivo studies, we will be using 405 nm 
LED so 450 nm was not a priority at the point. We varied the distance between LED and 
the skin – one of the spacers was a wooden spacer (total distance = 0.95 cm) and the other 
was 2 × 1/16” magnetic spacer (total distance = 0.63 cm). The time durations were kept the 
same as earlier. The plots are shown in Figure 184 and skin images are in Figure 186. As 
seen earlier, for the wooden spacers, the temperature was slightly lower than 45 ºC and it 
didn’t result in any scabs. However, with the lesser distance, temperatures went up as high 
at 51 ºC and even a two minutes irradiation was not tolerated. These studies provide a 
temperature range in which we should perform the animal studies when using these LEDs. 
Also, they help establish a correlation between temperature and skin damage. For example, 
a temperature of 43-44 ºC is harmless over 8 minutes but a temperature above 47-48 ºC 
burns the skin within two minutes. The skin samples irradiated using 405 nm LED didn’t 
show any signs of heat burns visually. We also performed histology using hematoxylin and 
eosin staining to see any difference between unirradiated and 8 min irradiated skin sample. 
The skin was excised 72 hours post-irradiation. As seen from Figure 185, the irradiated 
sample didn’t show any adverse reaction when compared with the control. 
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Figure 184: Average temperature on rat skin (inside 7 mm holes) after illumination with 
405 nm LEDs at 0.95 cm distance (wooden spacers) and 0.63 cm distance (2 × 1/16” 
magnetic spacers). 
 
 
Figure 185: Histology of excised skin samples which were irradiated using 405 nm LED 
at 0.95 cm distance. 
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Figure 186: Pictures of irradiated skin spots which were irradiated using 405 nm LED at 
0.96 cm distance (top) and at 0.63 cm distance (bottom) for different periods of time. The 
pictures were taken after 24h, 48h and 72 hours. 
 
In-vivo studies with coumarin trimer material 
 Once the heating issues related to LED were resolved, and we saw insulin being 
released in in-vitro setting, we tried to repeat the in-vivo studies using second-generation 
coumarin material, and longer wavelength 405 nm LED. There were the following 
differences compared to the earlier setting when first-generation material was tested in 
Chapter 3 – 
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i. Here due to the small size of the particles as opposed resin particles, smaller size 
needle could be used. Hence, we used the 31G needle as opposed to a 27G needle.  
ii. The wooden spacers were used to deal with the excess heat. 
iii. The longer wavelength is being used here as mentioned.  
iv. The rats were ordered from Harlan labs earlier, but the vendor was changed to 
Charles River. 
v. All glucometers were brand new (Freestyle). Earlier, glucometers from One Touch 
were old. 
Pilot studies 
In the following in-vivo pilot study, a material containing 133 nmol of insulin 
suspended in 65 µL sterile PBS (which was filtered through 0.22 µm syringe filters) was 
injected using a 31G needle. After injecting the depot, 20 min period was given to see any 
signs of immediate leaching. Then 1 min irradiation was performed after 20 min post-
injection and 24 hours as well. The aim was to see how active the depot is after 24 hours.  
One minute of irradiation using the wooden spacers was good enough to cause a robust 
therapeutic response in an animal but did not cause any scabs due to overheating. Hence, 
we decided to use a one min duration. In previous studies, we failed to see any response 
after irradiation post-24-hour injection. However, we observed a better response here 
(Figure 187). The Cmax after 24 hours was only 20% of the first irradiation when insulin 
concentrations were compared. The BG response was proportional to the insulin response 
in both cases. In this first irradiation, approximately 82% BG reduction was seen while in 
the second irradiation, 35% response was seen. The material was performing better 
compared to first-generation material.  
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Figure 187: Comparison of results of irradiation performed at t=0 and t=24 hours. The 
top plot compares insulin released due to irradiation, and the bottom plot compares the 
reduction in blood glucose. 
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In-vivo studies in replicates 
 The pilot studies were encouraging and based on the results, we decided to pursue 
animal studies in replicates. These were the parameters decided for performing the in-vivo 
studies. 
i. The particles were small enough to pass through a 31G needle as demonstrated 
earlier. However, a 31G needle is quite thin and rat skin is hard. Sometimes the 
injection would be incomplete and there is a need to pull out the needle from the 
skin and re-inject at a nearby site. At this point, the needle became blunt and it 
couldn’t be re-inserted into the skin. Due to this issue, we decided to use a 27G 
needle which is sturdier and could be reused.  
ii. The wooden spacers were used to deal with the excess heat. The total distance 
between LED and skin was ≈ 0.95 cm. 
iii. The rats were ordered from Harlan labs for the first-generation material, but the 
vendor was changed to Charles River. 
iv. Instead of performing single irradiation for 1 minute at t=0, we decided to perform 
two irradiation – at t=0 and at t=65 min each for the duration of 30 seconds. 
v. All glucometers were brand new (Freestyle®). For the first-generation material 
studies, glucometers from One Touch® were old. 
vi. The diameter of the hole of the base plate was increased from 0.35 cm to 0.775 cm. 
The diameter of the injected depot was larger than 0.35 cm hole used for its 
irradiation. Hence, the depot was being irradiated incompletely. To correct this, the 
diameter was increased to ensure all depot material is being irradiated. 
The results for the replicates are reported below in Figure 188. In one of the experimental 
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replicates, the final time point of t=125 was not measured. Although, that time point is 
statistically significant with a p-value of 0.003 with unequal sample size using the t-test, in 
the plot below, the rest of the values were plotted with an equal sample size of four. Hence 
the star symbol used for showing statistically significant points is removed from the plot. I 
have also plotted it after dropping a poor data set (Figure 189). 
 
 
Figure 188: Average concentrations of insulin and glucose from in-vivo studies of 
coumarin insulin trimer (N=4). The irradiation was performed for 30 seconds each at t=0’ 
and t=65’. The statistically significant points p<0.05 are shown by an asterisk. 
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Figure 189: Average concentrations of insulin and glucose from in-vivo studies of 
coumarin insulin trimer (N=3, after dropping a poor data set). The irradiation was 
performed for 30 seconds each at t=0’ and t=65’. The statistically significant points 
p<0.05 are shown by an asterisk. 
 
 The second-generation material was performing significantly better compared to 
first-generation material. The improvements are summarized below. 
i. % w/w density of first-generation PAD material was 9% w/w. In the case of the 
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density. In the given loading of the depot, we can load 10 times more insulin at a 
given time. 
ii. Calculation of energy being delivered for irradiation –  
Table 11: Calculation for LED energy output in both studies 
 
For first-generation materials 
Irradiation intensity at the skin 0.71 W/cm2 
Area irradiated circle pi*(.35cm)2 0.385 cm2 
Duration of irradiation 240 seconds 
Total energy 0.71 × 0.385 × 240 65.6 J 
For second-generation materials 
Irradiation intensity at the skin 0.11 W/cm2 
Area irradiated circle pi*(.775cm)2 1.88 cm2 
Duration of irradiation 60 seconds 
Total energy 0.11 × 0.385 × 60 12.4 J 
     
For the second-generation materials, the total energy that is being delivered at the 
depot size is 5.3-fold less compared to first-generation material.  
iii. Calculations for the area under the curve –  
We performed the calculations for measuring the area under the curve for insulin 
concentrations for first versus second-generation materials. The AUC is 6 times higher for 
second-generation material as opposed to first-generation.  
Considering a six-fold increase in AUC and 5.3-fold decrease in total energy, we made an 
estimated improvement of 32-fold improvement in terms of energy and the amount of 
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insulin being released.  
iv. The improvements mentioned above could be measured quantitively. However, 
there were other qualitative improvements as well. For example, the first gen 
material was challenging to inject using a 27G needle. However, the trimer particles 
which are of ≈ 3 µm size could be injected using 27G needle without any resistance 
or blockage. They also could be injected using a 31G needle which is used by 
diabetics for insulin administration without any issue.  
v. Furthermore, 405 nm light is likely to have reduced phototoxicity compared to 365 
nm light in the long-term. It is known that high energy UV radiation can cause DNA 
damage. It would be interesting to design experiments in the future to determine 
the extent of phototoxicity and DNA damage caused by the light of this wavelength 
in the cells.  
Histology pictures 
 We performed histology of the injected depot site. The objective was to visualize 
the location of the depot. This would give us an idea about the diameter and the depth of 
injected material. It was challenging to visualize it using hematoxylin and eosin staining, 
hence Dr. Kover utilized anti-insulin antibodies to stain skin sections. As shown in Figure 
190, the depot can be visualized using this staining technique. For this experiment, an 
injection holding ≈ 44 nmol of insulin in the form of coumarin insulin trimer was made. It 
resides just below the skin as expected. In the future, such studies could be carried out to 
follow the fate of injected materials for days, and whether the depot material is migrating 
away from the injected site.  
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Figure 190: Histology of injected depot site. 
 
In summary, we synthesized advanced material in this project which not only 
solved existing issues such as low density and injectability but also brought 
improvements such as faster, more insulin release and low phototoxicity. Furthermore, 
we demonstrated the efficacy in diabetic animal models. The efforts to improve the 
coumarin scaffolds have already been undertaken to make redshift the absorption 
spectrum and increase its quantum yield as demonstrated in this chapter (synthesis 
route # 3). It would be interesting to see how these newer scaffolds influence the insulin 
release kinetics in-vivo. 
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Chapter 5 
LIGHT ACTIVATED SiRNA NANOPARTICLES 
The RNA interference (RNAi) has revolutionized the understanding of the roles of 
smaller RNA molecules involved in controlling the expression of genes. The mechanism 
is prevalent in many animals and plants.99 First reported by Fire et al. in Caenorhabditis 
elegans using microRNA (miRNA),100 the tool is being widely used for controlling biology 
processes, phenotypes, identification of biological functions of genes and for the treatment 
of diseases using gene therapy.  
There are mainly two types of RNA molecules involved in RNAi – short interfering 
RNA (siRNA) and microRNA (miRNA). It is said that 1-5% of the human genome code 
for miRNA and they all further regulate at least 30% of protein-coding genes.101 miRNA 
are known to be associated with critical cellar processes and many diseases including 
cancer.102 They provide additional control over the regulation of important pathways and 
offer fine-tuning through the RNAi machinery. Unlike miRNA, which is coded by the 
genome, siRNA are exogenous and can be introduced into the cell to trigger RNAi. 
Significant efforts are underway to develop siRNA-based therapeutics to silence harmful 
genes for the treatment of diseases like cancer and others.103 The delivery and possibility 
of off-target effects remain the major obstacles for the development of such therapeutics in 
the clinical settings.104 
Pathways for RNAi using both siRNA and miRNA have been discovered and well 
understood.99 Although the biogenesis of miRNA is different from that of siRNA, many of 
the components overlap. As mentioned already, miRNA is encoded by the genome, then 
transcribed and released in the nucleus as pri-miRNA. These transcripts are up to 1000 nt 
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long and can be either single-stranded or double-stranded. The microprocessor complex 
trims pri-miRNA to yield precursor miRNA (pre-miRNA) in the nucleus which are 65-70 
nt in length. Later, it is exported into the cytoplasm to bind to their complementary mRNA 
(Figure 191).  
RNA interference 
 
Figure 191: RNAi pathway. Reprinted by permission from Springer Nature.105  
  
When miRNA is exported from the nucleus into cytoplasm or siRNA is transfected 
into the cellular cytoplasm, they both are cleaved by an enzyme named Dicer to excise into 
short miRNA or siRNA. siRNA is 21-25 nt in length with phosphates on all four termini. 
This siRNA binds to Argonaute protein which is complexed with other proteins. This 
assembly of proteins is called the RNA-induced silencing complex (RISC). One of the 
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strands from siRNA is selected as a guide strand which remains bound to Argonaute while 
other is discarded. RISC along with guide RNA scans the cytoplasm to bind to mRNA 
through complementary base pairing. The complementarity does not need to be 100%; the 
binding still occurs even if there are multiple mismatches. The position, number, and nature 
of mismatches dictate the silencing efficiency and off-target effects.106 Upon binding to 
mRNA, Argonaute cleaves the target strand, silencing the expression of that gene. In some 
cases, RISC represses the translation to silence the gene expression. There are several 
attempts to control RNAi for a variety of applications. In our lab, it has been attempted 
using light. 
Light Activated RNA Interference (LARI) 
 The Friedman lab has pioneered a technique of “light activated RNA interference” 
(LARI) to control RNAi using light. The concept involves caging siRNA using a 
photolabile group which renders it inactive and blocks RNAi temporarily by preventing it 
from binding to RISC. Upon light exposure, photolabile groups come off from siRNA. 
Now the uncaged siRNA is free to undergo RNAi and cause gene silencing. Using LARI, 
the spacing, timing, and degree of gene expression can be controlled. LARI has been 
demonstrated in our lab.32–34 The schematic is shown in Figure 192. 
First, siRNA must be caged with a photolabile group. In the initial experiments, 
DMNPE was used for caging siRNA. The diazo functionality on DMNPE diazo reacts with 
the terminal phosphates on siRNA to yield tetra-modified siRNA. Due to the presence of 
photolabile groups, siRNA fails to form a complex with RISC. Thus, RNAi gets 
suppressed. Upon exposure to light of a certain wavelength (365 nm in this case), the 
phosphoester bonds are broken, releasing free siRNA.  Released siRNA then binds to RISC 
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and undergoes RNAi to alter gene expression. 
 
Figure 192: The concept of light activated RNA interference (LARI). 
 
The nature of photolabile groups can be further modified to improve the efficiency 
of LARI and to increase its dynamic range in response to light. Light-cleavable nucleic 
acids which could be uncaged using light have been used in dissecting the roles of genes 
and proteins in understanding biology and to develop therapeutic interventions. In the past 
10-15 years, there is substantial interest in developing and utilizing such tools. It has found 
applications in studying developmental biology,107,108 micro-patterning of cells in cell 
culture,35 therapeutic strategies,109,110 and to deepen the understanding of cellular 
biology.111  
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Challenges in siRNA Delivery 
 Though RNAi is convenient, effective and easy to demonstrate in in-vitro cell 
culture-based studies using siRNA, it is challenging to show similar efficacy in animal 
models. For the cell culture studies, the major barriers are stability in the serum and 
permeability through the cell membrane. siRNA can be degraded rapidly by RNase present 
in the serum and due to its polar charged nature, it cannot cross the lipid bilayer on its 
own.112 Using commercially available transfection reagents like Lipofectamine®, both 
issues can be solved; the formulation protects siRNA from degradation as well as helps it 
in crossing the lipid bilayer for cytosolic delivery. However, siRNA face host of other 
challenges in-vivo; i) instability against nucleases, ii) attack from the immune system, iii) 
renal clearance, iv) non-specific protein-binding, and v) inefficient cellular penetration.113 
There is no single solution to solve many of the problems described here hence the in-vivo 
delivery remains challenging. Many of the methods used for in-vitro studies are not feasible 
for in-vivo studies. This might be the reasons why there are difficulties in getting approval 
for siRNA based therapeutics by the FDA.114,115 Keeping such challenges in mind, we 
started investigating other possible ways for delivery in the LARI approach. 
Nanospheres for enhancing siRNA delivery for LARI applications 
 Nanospheres are extremely small spherical particles in size ranging from 40-1000 
nm in diameter. Typically, their preparation procedures have been optimized to produce 
such spheres of uniform size across the batch. Both inorganic and organic materials based 
nanospheres are available commercially. Materials such as glass, polystyrene, polylactide, 
ceramic, alumina, dextran, poly(methyl methacrylate) (PMMA) are for preparation and 
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available in many different diameters. Biodegradable materials are also available. 
Depending on the material, nanosphere surface can be functionalized with either -NH2 or 
-COOH groups to covalently conjugate other moieties on top of it. Because of these 
features, there is an interest in using nanospheres for the purposes of drug delivery. 
 One of the benefits of using nanospheres is their extremely small size. It is reported 
that these spheres have good penetrating properties in the cells. Some of the studies 
showing such evidence are listed in Table 12 below. The ability of cell internalization is 
seen for nanospheres ranging widely in their size, material, nature of the charge of its 
surface (cationic or anionic), and tested in different cell lines, etc.  
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Table 12: Studies demonstrating evidence for internalization of nanospheres into different 
cell lines. 
 
Author Size and material Cell lines Conclusions 
Rejman J. et 
al.116 
Fluorescent latex 
beads (50, 100, 200, 
500, 1000 nm) 
B16 cells Beads ˂ 200 nm – Clathrin-
mediated endocytosis. 
Beads ˃ 200 nm – Caveolae-
mediated endocytosis. 
Santos et 
al.117 
Fluorescent – 
COOH polystyrene 
(40 – 2000 nm) 
HeLa, 
A549, 
1321N1, 
HCMEC 
D3, RAW 
264.7 
Uptake observed of all particles 
in all cell lines to varying 
degrees. 
Smith et al.118 Fluorescent 20 nm – 
-COOH polystyrene 
HeLa, 
MDCK 
Clathrin but not caveolar-
mediated endocytosis observed + 
passive diffusion to some extent. 
Presence of serum retards uptake. 
Ekkapngpisit 
et al.119,120 
30 nm –COOH 
polystyrene 
50 nm – NH2 
polystyrene 
Ovarian 
NIH-
OVCAR3, 
SKOV-3 
cancer cells 
30 nm beads – Not toxicity, no 
lysosomal localization observed. 
50 nm – Toxicity and lysosomal 
localization observed. Uptake via 
a caveolae-independent pathway. 
 
Table continued 
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Author Size and material Cell lines Conclusions 
Lai et al.121 24, 43 nm –COOH 
PS 
HeLa, 
HUVEC 
43 nm beads – Clathrin-mediated 
uptake observed. 24 nm beads 
uptake through non-clathrin, non-
caveolae, cholesterol 
independent pathway. The novel 
mechanism which doesn’t 
involve endo/lysosomal route and 
delivery to the perinuclear region. 
Lorenz M. R. 
et al.122 
168, 206, 337, 489, 
1290 nm –NH2 
polystyrene 
HeLa, MSC 
(stem cells), 
Jurkat, 
KG1a 
Uptake is seen without the use of 
transfection reagent into HeLa, 
MSC cells. Particles were 
accumulated in compartments 
resembling endosomes, 
cytoplasmic localization wasn’t 
clear. 
Musyanovych 
et al.123 
80-150 nm PCL, 
PLLA, PLGA beads 
HeLa, 
Jurkat 
The presence of surfactant on 
particle like SDS has a greater 
influence than size. PLLA and 
PCL particles were endocytosed 
much faster than polystyrene 
particles. 
 Table continued 
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Author Size and material Cell lines Conclusions 
Liu et al.124 50, 100, 500 nm 
polystyrene both –
COOH and -NH2 
beads 
HeLa, 
NIH 3T3 
Uptake was observed with both –
COOH and -NH2 beads. No 
cytotoxicity observed for –
COOH beads. 
-NH2 beads showed toxicity by 
delaying G1 phase and 
decreasing cyclin expression. 
S. Prabha et 
al.125 
70 nm, 202 nm 
PLGA particles 
encapsulate with a 
plasmid for 
transfection 
COS-7 cells, 
HEL293 
cells 
70 nm sized particles showed a 
higher level of transfection than 
202 nm particles. 
Y. Patil et 
al.126 
PLGA-PEI 
encapsulated siRNA 
- 230±8 nm 
MDA-kb2 Addition of cationic PEI in 
PLGA particles increased the 
capacity of siRNA encapsulation 
and its release profile  
Delivered siRNA in the 
cytoplasm  
Particles are serum-stable and no 
toxicity was observed   
 
 
Table continued 
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Author Size and material Cell lines Conclusions 
K. Tahara et 
al.127 
Chitosan surface 
modified PLGA NS 
encapsulated siRNA 
– 300 nm 
A549 cells Chitosan modification improved 
delivery profile over plain PLGA 
nanoparticles and naked siRNA 
 
 The features describe above allow flexibility in selecting the system; the size of 
nanospheres, the material (biodegradable vs non-biodegradable), surface functionality (-
COOH vs -NH2), etc., hence we selected nanospheres for LARI.  
The approach here involved conjugating caged siRNA to the surface of nanospheres. This 
delivery system would have the following advantages –  
i. Since the nanospheres have excellent cell penetration properties, it would carry 
siRNA along with it. This would be important for in-vivo studies where traditional 
transfection reagents have limited efficacy in siRNA delivery. 
ii. The entire construct would be very dense and compact. This might render siRNA 
more resistant towards nucleases due to the steric hindrance.  
iii. The LARI as a tool can be applied for an in-vivo system using this system. 
 We describe the route for conjugating caged siRNA to a nanosphere. The reagents 
used here are the same that were used in the insulin project to immobilize insulin on the 
solid phase resin. Click chemistry reagents like DBCO can be coupled to the surface with 
EDC, HOBt chemistry on nanospheres. siRNA can be caged with DDA to synthesize 
dimod caged siRNA where two azide functionalities will be on each side of siRNA. Upon 
reacting azide caged siRNA with DBCO conjugated nanospheres, both strands will be 
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conjugated covalently through the triazole ring. Due to the property of the nanospheres, 
siRNA will be carried into the cell. In the cells, upon photolysis, siRNA will be uncaged 
and photoreleased as native siRNA to cause RNAi. The synthesis of individual components 
is discussed shown in Figure 193 and discussed below. In the future for the purpose of in-
vivo studies, biodegradable nanospheres should be used which would be degraded and 
eliminated from the body. Polylactic-co-glycolic acid (PLGA) seems reasonable for such 
applications and PLGA nanospheres are commercially available.128 
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Figure 193: Stapling of caged siRNA on the nanosphere surface. 
  
217 
Cellular uptake of 43 nm nanospheres 
Nanospheres were ordered from Polyscience (catalog # 19773-10). The pilot 
experiment was performed to see if the nanospheres have cell-penetrating ability or not. 
The nanospheres contained a fluorophore for visualization. In this experiment, the particles 
were incubated when HeLa cells were at 70% confluency. The concentration of particles 
was 0 and 200 µg/mL in a 96-well plate. The cells were washed twice using PBS prior to 
taking images. The images were taken after 27-28 hours after incubation with nanospheres 
in Dr. Kun Cheng’s lab. Both bright-field and fluorescence images were captured (Figure 
194). 
 
Figure 194: The cellular internalization study of 43 nm nanospheres. The fluorescent can 
be visualized in cells when incubated at 200 µg/mL concentration. 
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The experiment was repeated, and very similar results were observed. The exact 
location of the nanospheres in the cell could be determined using the confocal microscopy 
i.e. how and where the nanospheres are getting distributed in the cells? Though the images 
suggest the presence of nanospheres in cells, it left important questions unanswered. 1) 
Whether the particles are stuck on the outer membrane or inside the cells? 2) Are the 
nanospheres specifically localized to one more cell organelle or uniformly distributed 
inside the cells? 3) How much % of the total particles can make it inside? 4) Is there any 
toxicity due to these particles? Does it affect cell viability? etc. Next, we worked on 
immobilizing siRNA onto the nanospheres. 
Synthesis of dimod caged siRNA 
 The protocol for caging siRNA was followed as reported.129 GFP silencing siRNA 
was used, the sequence is reported in the literature published from the lab previously. 17.83 
nmol of each strand of GFP siRNA were mixed to anneal them in Tris-EDTA buffer. (5.57 
µmol) N-(2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-
methoxy-5-nitro-phenoxy]-acetamide was added in 48 µL DMSO + 13.45 mg MnO2 and 
vortexed for 45 min in the dark. Then it was filtered through celite to remove MnO2 
particles and washed with additional DMSO to wash off unfiltered diazo. Annealed siRNA 
and diazo were mixed at 25.2 µM and 6.3 mM concentration respectively. The ratio of 
water: DMSO was 2:1 in the final reaction mixture. The reaction was kept at room 
temperature for 80 min and divided into 2 equal parts. In each tube, 85 µL 10 M ammonium 
acetate, 5 µL glycogen (20 mg/ mL) and 0.65 mL ethanol was added. It was incubated in -
20 °C freezer overnight. The siRNA pellet was isolated using centrifugation and caged 
siRNA was purified by HPLC as described in the protocol. The mass spectrum of purified 
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dimod siRNA is shown in Figure 195 presentation two peaks of caged sense and antisense 
strand. 
 
Figure 195: MS of purified dimod siRNA showing each sense and antisense strands 
modified. 
 
Clicking caged siRNA on nanospheres surfaces 
 The first step involved conjugating DBCO amine to the nanosphere surface. 
Because the nanospheres were made from uncrosslinked polystyrene, organic solvents like 
DMF or NMP could not be used as such solvents would dissolve the nanospheres. Hence 
the coupling was performed in water under four different conditions using water-soluble 
coupling agents like EDC, NHS, and sulfo-NHS. The following protocol was followed – 
i. Add 0.15 mL 43 nm particle solution in 1.6 mL of 50 mM MES buffer, pH=5.5 
ii. Add DBCO amine (1.6 mg, 5.8 µmol) and Triton X-100 at 0.05% concentration.  
iii. From this mixture, 436 µL was removed for control. 
iv. To the remaining mixture, EDC (4.5 mg, 23 µmol) was added. This was then 
divided into three tubes of 436 µL. 
v. To one tube, only EDC was used for coupling. In the third tube, NHS (3.0 mg, 26 
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µmol) was added. In the fourth tube, sulfo-NHS (5.0 mg, 23 µmol) was added.  
vi. pH was adjusted to 6.5 in all four tubes.  
vii. After the overnight reaction, the samples were dialyzed against DI water 
extensively. 
5 µL were taken from all 4 reaction mixtures and mixed with 1 µL of 30 µM caged siRNA 
solution. The reaction was performed overnight at room temperature and analyzed by 
PAGE. The nanospheres don’t run on PAGE gel as it all gets stuck at the loading site. 
siRNA however ran, and the bands were visualized using EtBr staining. If siRNA is clicked 
on the beads, it shouldn’t be free and hence shouldn’t appear on the gel. 
 
Figure 196: The PAGE analysis of reaction between DBCO conjugated nanospheres and 
azido caged siRNA. 
 
 
The gel results were mixed and did not confirm whether the reaction is occurring 
or measure the reaction yield (Figure 196). The siRNA bands look slightly fainter and 
diffused than control siRNA band, however, the results were ambiguous and not 
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encouraging. Because of this lack of confirmation of conjugation and the nanospheres were 
so tedious to work with, this approach was suspended here. 
Preparation of siRNA nanoparticles 
 Because the reactions with nanospheres were challenging and there was no way to 
characterize the extent of reactions due to lack of Rink amide linker, another approach was 
investigated. The concept is to cross-link caged siRNA to make compact siRNA 
nanoparticles (Figure 197). This siRNA will be caged using photolabile group. When light 
is irradiated, the nanoparticles will fall apart releasing uncaged siRNA.  
The procedure for caging siRNA was very much like what we reported earlier.129 
GFP silencing siRNA was used. 10 nmol of each strand of GFP siRNA were mixed to 
anneal those together in Tris-EDA buffer. (4.0 mg, 8.3 µmol) N-(2-{2-[2-(2-azido-ethoxy)-
ethoxy]-ethoxy}-ethyl)-2-[4-(1-hydrazono-ethyl)-2-methoxy-5-nitro-phenoxy]-acetamide 
was added in 50 µL DMSO + 20 mg MnO2 and vortexed for 45 min in the dark. Then it 
was filtered through celite to remove MnO2 particles and washed with an additional 0.15 
mL DMSO to wash off unfiltered diazo. The concentration of diazo in the filtrate was 38.6 
mM as determined using UV-vis spectroscopy. Annealed siRNA and diazo were mixed at 
25.8 µM and 6.45 mM concentration respectively. The ratio of water: DMSO was 2:1 in 
the final reaction mixture. The reaction was kept at room temperature for 80 min and 
divided into 2 equal parts. In each tube, 82.5 µL 10 M ammonium acetate, 5 µL glycogen 
and 0.63 mL ethanol was added. It was incubated in -20 °C freezer overnight. siRNA pellet 
was isolated using centrifugation and caged siRNA was purified by HPLC as described in 
the protocol (Figure 198).  
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Figure 197: The reaction between dimod caged siRNA and TDL2. Upon multiple 
intermolecular click reactions, cross-linked siRNA nanoparticles could be formed. 
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Figure 198: Analytical HPLC of purified dimod caged siRNA. 
 
The synthesis of TD linker # 2 was reported in earlier chapters and published as well.130 
The reaction between caged siRNA and TDL2 was set up by keeping their concentration 
at 0.16 mM and 0.106 mM respectively in 2:1 mixture of DMSO: water. We monitored the 
reaction progress every few days. In Figure 199 (below), a gel of reaction mixture after 22 
days of incubation is shown.  
 
Figure 199: Analysis of higher MW siRNA nanoparticles using gel. Lane 1 shows the 
MW markers, lane 2 shows the crude mixture of azide caged siRNA + TD linker after 22 
days of reaction. Band 1 is unreacted caged siRNA and 2, 3 and 4 are cross-linked siRNA 
nanoparticles. 
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  The gel results were encouraging on the third day after the reaction; many new 
higher MW bands were observed which most likely resulted from the cross-linking. The 
number of moles was too low to perform mass spectrometry analysis. The reaction was 
continued until 7 days and analyzed later in the same manner. The number of total bands 
reduced on day 7, the reason is not yet clear. Perhaps the nanoparticles assumed the shape 
of a tetrahedron or a cube where the edges will be made up of TD linker # 2 and sides will 
be siRNA. We also photolyzed these formed particles and they underwent uncaging to 
release native siRNA (data not shown).  
 
Figure 200: Testing the efficiency of light-activated siRNA nanoparticles in HeLa cells 
without any transfection reagent. 
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 The materials were tested by Ashish who was collaborating on this project for LARI 
in the cell culture model using HeLa cells. We were also hoping that the nanoparticles 
would have cell penetration properties but no response to the GFP signal was observed 
after incubation and light exposure. No further experiments were performed to troubleshoot 
this. 
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Chapter 6 
 
INTRACELLULAR PROTEIN DELIVERY USING PROTEIN PRODRUGS 
Introduction and rationale 
 Development of recombinant DNA technology played a pivotal role in the way 
protein or peptide-based therapeutics were designed and mass produced. Since the approval 
of recombinant insulin for the treatment of diabetes in the 1980s, ninety-one protein-based 
therapeutics have been approved by the FDA.131 Protein-based therapeutics have 
advantages over small molecular drugs due to their complex structure and very specific 
functions. Proteins can be utilized for performing sophisticated roles that small molecules 
cannot perform. For example, gene editing by CRISPR-cas9. Also, the time required for 
approval by the FDA is relatively short for proteins as compared to small molecule drugs. 
On average, protein-based therapeutics take approximately one year less in an approval 
process.132 These therapeutics can further be classified broadly as enzymes or hormones 
e.g., insulin for the treatment of diabetes; antibodies for targeting for such as Trastuzumab 
for breast cancer therapy, vaccines (cancer vaccines are under developments), etc.  
 Most of these developed protein therapeutics have extracellular targets. 
Intracellular delivery remains a big challenge. Small molecules can cross the cell 
membrane either by active or passive diffusion. Due to the larger size of proteins, it is much 
more challenging for it to cross the lipid bilayer and make it into the cellular environment. 
Several strategies have been investigated to deliver macromolecules intracellularly. Some 
of the strategies can only be utilized for in-vitro studies and are impractical for in-vivo use. 
For example, microneedle or electroporation. These are very useful to demonstrate proof 
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of concept or to study the mechanism of action of a therapeutic. However, their translation 
from in-vitro studies to in-vivo studies in rat/mouse has been challenging. Hence there is 
an urgent need for the development of delivery methods for clinical settings. Intracellular 
protein delivery could be useful to restore the functions of defective proteins and could be 
utilized in regenerative medicine, cancer therapy, and intracellular organelle-specific 
imaging, etc. Below are the few most commonly used methods for the intracellular delivery 
of proteins.  
1. Cell-penetrating peptides (CPP) 
One of the earliest discovered CPP was Tat peptide derived from HIV-1 Tat protein.133 
The peptide was found to have excellent cell penetration properties. CPPs are also known 
as protein transduction domains (PTD). CPPs are rich in positively charged amino acid 
residues such as arginine, lysine. Positive charges are essential for its cell-penetrating 
ability. The cell membrane is negatively charged due to the presence of phosphates, 
sulfates, and carboxylates, etc. Arginine-rich peptide exploits electrostatic interactions to 
bind tightly to the cell surface due to its cationic nature.134 The hydrophobicity and 
secondary structure of the peptide also influence the uptake.135 By covalently conjugating 
CPPs with any protein, proteins as large as 120 kDa have been delivered inside the cell.136 
Along with proteins, CPPs are also shown to carry siRNA, antisense oligonucleotides, 
plasmids, various nanoparticles and fluorescent probes such as quantum dots inside the 
cells which would otherwise have poor cell-penetrating property on their own. Various 
mechanisms have been proposed. However, it is not yet obvious what exactly drives it. 
Table 13 below lists some of widely used CPPs. 
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Table 13: List of some commonly used CPPs with their sequences. 
 
Peptide name Peptide sequence Peptide 
length 
Oligoarginine RRRRRRRRR 8-15  
Penetratin RQIKIWFQNRRMKWKK 16 
Transportan 
10 
AGYLLGKINLKALAALAKKIL-amide 21 
HIV-Tat YGRKKRRQRRR 11 
Transport GWTLNSAGYLLGKINLKALAALAKKIL 27 
VP-22 DAATATRGRSAASRPTERPRARARSASRPRRPVD 34 
 
Although the exact mechanism of CPP is yet unclear, the following mechanisms have been 
proposed with some evidence. 
i. Direct penetration 
Direct penetration is an energy-independent process and doesn’t need any specific 
transporters or receptors for internalization. Models such as the inverted micelle model, 
toroidal pore model, and carpet model (refer to Figure 201), etc. have been 
investigated.137,138 Due to the cationic nature of CPPs, they interact and bind with 
negatively charged moieties like sulfates, phosphates present on the lipid bilayer. After 
these initial interactions, the peptides are probably internalized through the lipid membrane 
destabilizing followed by penetration through it. This mechanism dominates when the 
peptide is present in high concentrations.   
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ii. Endocytosis 
Other than direct translocation, endocytosis is deemed as another pathway for CPP 
internalization. Cell internalization includes two mechanisms; phagocytosis which 
involves engulfing particles and pinocytosis which involves uptake of liquids. Pinocytosis 
could be achieved via these three mechanisms; Clathrin or caveolin-dependent, Clathrin or 
caveolin-independent, and macropinocytosis, etc.138 Some of the studies have observed 
that CPP internalization takes place even at 4 ºC, the temperature at which the receptor-
mediated endocytosis would slow down.139 Because of this, there was a debate which 
pathway is being utilized by CPPs for penetration. However, with the use of modern 
techniques, it is being understood that endocytosis is the major pathway. Peptide 
sequences, concentration and the composition of lipids play important roles as well.   
 
Figure 201: Various proposed mechanisms of internalization of CPPs. Reprinted with 
permission from Elsevier.140 
 
Another unclear aspect of this proposed route is the escape of cargo from the endosome. 
Once the load is internalized in the endosome, it must be released from the endosome into 
the cytosol. Otherwise, endosomes mature into lysosomes and degradation might occur in 
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an acidic environment of the lysozyme or endosomes get recycled with membrane 
components and cleared from the cellular environment. CPP, when conjugated with 
fluorophores, delivered intracellularly show localization in the endosomes, not all of it 
reaches the cytosol. However, with the help of endosome disrupting strategy, cytosolic 
delivery is often improved. Thus, endosomal escape remains a barrier for the delivery.141 
Hence endosomatic strategies are often incorporated with CPPs to enhance the cytosolic 
delivery. 
2. Nanoparticles  
Protein delivery using nanoparticles is a broad field, and it includes cationic lipid-
based systems, inorganic nanoparticles, modified proteins nanocarriers, etc. There is 
significant interest in the development of nanoparticulate formulations because –  
i. The nanoparticles can be multifunctional. Due to this, moieties which reduce its 
immunogenicity, increase its circulation time, facilitate endosomal escape, enhance 
target-specificity could be included. Furthermore, imaging functionalities can also 
be included. Thus, the nanoparticles offer much flexibility in the design aspect. 
While preparing the nanoparticle, factors such as size, shape, zeta potential can be 
fine-tuned to achieve greater delivery efficiency. 
ii. Due to the larger overall size compared to the protein, it can bypass renal clearance 
and have larger circulation time in the body. 
iii. Proteins can be shielded by the nanoparticles by localizing in the inner core of 
particles to prevent it from degradation. 
The existing systems could be further classified into four categories as follows.142 
1. Cationic lipid-based systems 
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i. Dioctadecylglycylspermine 
ii. BioPORTER which is commercially available 
2. Inorganic systems 
i. Quantum dots 
ii. Gold nanoparticles 
iii. Mesoporous silica nanoparticles 
iv. Magnetic nanoparticles 
v. Single-walled carbon nanotubes 
3. Polymer-based systems 
i. pH-sensitive systems 
ii. PEI based systems 
iii. Self-assembling cationic nano gels 
4. Protein-based systems 
i. Supercharged proteins 
ii. Protein nanocapsules 
Our approach to solving the problem of protein delivery would fall under the category of 
the protein-based system as per the above classification. 
Preparation of protein prodrugs 
Prodrugs are chemically modified versions of the active pharmaceutical ingredient. 
Prodrugs undergo a reversible transformation in the body to yield the native drug (Figure 
202). The modifications are performed for a variety of reasons but primarily to overcome 
the poor aqueous solubility of a drug, to increase its absorption, to improve 
pharmacokinetics, to alter its metabolism and to reduce local irritation. The transformation 
232 
often occurs enzymatically where an enzyme cleaves the labile linker to release the original 
drug. There are many chemical linkages through which drugs are conjugated with pro-
moieties. The choice of linkage depends on the functionalities presented by the drug. 
Depending on the functional groups, linkages such as esters, carbonates, carbamates, 
phosphoesters, oximes, imines, amides ethers, etc. have been used.143  
 
Figure 202: An example of how prodrugs work. In this case, the drug is not able to cross 
a barrier on its own. However, a prodrug can pass through it and then broken down to 
yield native drug. 
 
The proposed system here is based on the concept of prodrugs. There are several 
small molecule-based prodrugs that have been on the markets for decades. However, this 
concept has not been investigated for proteins in such depth.  
The hypothesis of protein-based prodrugs 
The main objective behind the preparation of prodrugs is often to improve the 
pharmacokinetic properties, to alter aqueous solubility, or to reduce local irritation, etc. In 
our approach, the prodrug concept will be used to enhance the intracellular penetration of 
proteins (Figure 203). Thus, it would help to achieve the challenging goal of intracellular 
protein delivery. The prodrug protein itself may or may not have any therapeutic activity. 
However, once inside the cellular environment, it will be converted to native protein either 
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chemically or due to enzymatic action. 
 
Figure 203: The idea of protein prodrugs. Proteins cannot cross the lipid bilayer on its 
own. However, it can be delivered inside the cell by chemically modifying it. Once 
delivered inside, the modifications will be reversed by the action of enzymes or 
chemically. 
 
The approach is outlined in Figure 204. The key components we require here to test 
this hypothesis are; 1) A linker which is chemically or enzymatically cleavable; and 2) A 
modification of the protein which would make it cell permeable. We decided that the 
linkage here would be an ester-based linkage. The rationale for selecting this was two-fold: 
i) an ester can be synthesized easily from carboxylic acid functionality by simple coupling 
reactions, and ii) esterases are present ubiquitously in the body to reverse the 
modifications.144  
Proteins have several carboxylic acid functionalities present on their surfaces. The 
C-terminal, as well as the side chains of aspartic and glutamic acids, provide -COOH 
groups. Through the linker, a cationic moiety can be introduced on the protein surface. The 
cationic charge would enhance the cell membrane permeation.145 It should be noted that, 
upon esterification of a carboxylic acid group, one negative charge will be quenched. This 
removal of one charge is equivalent to the addition of a positive charge on the protein. If a 
protein has 6 -COOH groups and if all 6 get modified, 6 negative charges will be quenched, 
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or 6 positive charges will be created. 
 
Figure 204: The concept of protein prodrug via an ester linker. The prodrug can be taken 
up inside the cell by virtue of positive charges. Once internalized, esterases present can 
hydrolyze the ester bond to yield native protein. 
 
Below are several methods which we pursued to create protein prodrugs for cellular 
internalization. 
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Route # 1 – Fischer esterification - Esterification using azido alcohol 
  
Figure 205: Esterification of insulin with azido alcohol. 
 
We started investigating esterification using the Fischer esterification method under 
acidic conditions (Figure 205). Low molecular weight alcohols like methanol or ethanol 
can be coupled to carboxylic acid functionalities on the protein using this approach.146,147 
Insulin was selected as a test protein molecule. Insulin does not represent most proteins 
because it is a peptide and is extremely small compared to most proteins. Because insulin 
can be easily analyzed by mass spectrometry (MS) in the HSB building, we decided to use 
insulin. Once we are reasonably sure that the conjugation and internalization method works 
with insulin, we can start investigating other proteins. 3-azido propanol was selected as the 
alcohol. Azide functionality was kept intentionally for introducing a variety of useful 
functional groups through click chemistry in a facile manner. 
 The reaction was set up in the following manner. Insulin (4.6 mg, 0.79 µmol) was 
mixed with 3-Azidopropanol (100 µL, 0.522 mmol) without adding any solvent. Insulin 
remained insoluble at this point even after vigorous shaking. 2 µL of 37% HCl was added 
to it and kept on vortex for 10 min. After 10 minutes, insulin was completely solubilized, 
and the reaction mixture was clear. It was run overnight and analyzed next day by HPLC 
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and MS. Reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 15 min with 5 min post-
run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), gradient 40% B 
isocratic for 15 min, retention time: 3 min (Figure 206); C18 Hypersil column (5 μm, 150 
× 3.2 mm, Agilent); ESI-MS (m/z); Monoesterified insulin, calculated, 6009.0; found, 
6011.0 (Figure 207). 
 
Figure 206: HPLC chromatogram of Insulin + 3-azidopropanol reaction mixture. 
 
 
Figure 207: MS of HPLC fraction collected from the chromatogram above. 5810.0 
corresponds to native insulin, and 6011.0 corresponds to mono-esterified insulin. 
 
The issue with the above reaction was that the yields were extremely low. Even after using 
660 equivalents of alcohol to one equivalent of insulin, only one carboxylic acid group was 
esterified. The reaction was run for several weeks after this at the room temperature. We 
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observed di-esterified insulin after 3 weeks (not shown here) when analyzed by MS. This 
suggested that the reaction progressed but very slowly. We had very limited success in the 
esterification of all 6 carboxylic acid groups on insulin. 
Fischer esterification using methanol 
We also tried following the conditions from the insulin esterification article to 
reproduce the conditions mentioned there.147 This reaction would result in the synthesis of 
methyl ester. The final goal is not to synthesize methyl esters of insulin; this reaction was 
performed just to check what are the yields of the esterification reaction. Insulin (25 mg, 
4.3 µL) was dissolved in 2 mL anhydrous methanol, and HCl in methanol was added to a 
final concentration of 0.115 N. Most insulin was dissolved in methanol but not all, the 
solution was little turbid. The reaction was analyzed by HPLC followed by MS. Reversed-
phase HPLC (flow rate 1 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% 
TFA in H2O), solvent B (0.1% TFA in ACN), 0 to 100% gradient B isocratic for 30 min; 
C18 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 18-20 min (Figure 
209). As seen in the MS analysis (Figure 208), the esterification reaction using methanol 
was successful. Probably all the -COOH groups on insulin were esterified. This is likely 
because the reaction was strictly performed under anhydrous conditions and the solvent 
itself was the reactant. Hence there was a huge excess of methanol and it was present in 
very high concentration. In MS, after 48 hours, further modifications were seen. We 
observed 7, 8 and 9 modifications, although there are only 6 -COOH groups on insulin. It 
is possible that acidic conditions hydrolyzed asparagine and glutamine side chains and free 
-COOH groups were generated which then underwent esterification reaction. The 
concentration of HCl, temperature and reaction time could be optimized further to reduce 
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these side reactions. This was performed to test whether esterification takes place or not 
under acidic conditions. Though Fischer esterification worked well with methanol, the 
results were not encouraging when 3-azido propanol was used under identical conditions.  
 
 
Figure 208: MS analysis of HPLC purified mixture of methyl esters of insulin. The top 
spectrum is taken after 24 hours of reaction and bottom spectrum after 48 hours. The 
number annotated refers to the number of carboxylic acids that are esterified by 
methanol. 
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Figure 209: HPLC chromatogram of standard insulin (top) and the crude reaction mixture 
of methyl esters of insulin (bottom). 
  
Fischer esterification using choline chloride 
The next attempt was performed using choline chloride (Figure 210). These were the 
following reasons for choosing choline chloride for this project – 
i. The linker must have two functionalities: alcohol to form an ester bond with the 
protein and an amino group to introduce positive charges on the protein surface. 
Choline chloride is very small in MW and has both the functionalities on it.  
ii. Furthermore, there is a quaternary amine which will be positively charged under all 
pH ranges. 
iii. Choline chloride forms deep eutectic mixture when mixed with urea, ethylene 
glycol. Both choline chloride and urea are solid at the room temperature. But when 
mixed in a 1:2 ratio, it becomes a viscous liquid.148 Thus, this ionic liquid could act 
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as a solvent and reactant at the same time in the esterification reaction, like 
methanol in the esterification reaction reported earlier.  
  
Figure 210: Esterification of insulin using choline chloride. 
 
The ionic liquid can be prepared easily. Insulin was insoluble in the ionic liquid 
mixture. It cannot be dissolved even after raising the temperature of 50 ºC or after addition 
of HCl to protonate amines. Because of the solubility issues, we could not continue 
working on this approach. 
Route # 2 –Esterification using diazo 
Since the first attempt using Fischer esterification did not exactly work, the diazo 
route was attempted. The lab has expertise in utilizing diazo for ester formation as 
performed in the case of siRNA and insulin. Since I have already synthesized DDA earlier, 
we used the same one here to estimate what is the extent of caging with the diazo (Figure 
211). 
The reaction of diazo with insulin was performed under two slightly different 
conditions. Rather than using only DMSO for this reaction, acid was added to lower the 
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pH. The esterification using diazo and the carboxylic acid is more efficient at lower pH 
than neutral when all carboxylic acid functionalities are protonated.149 
  
Figure 211: Esterification of insulin using DDA. In the figure, only one of the carboxylic 
functionalities is undergoing reaction, but all can be modified in this way. 
 
 
Here, we decided to supply acid/protons in two different ways. Method 1 – in this 
approach, insulin was treated with pH 2 water for a brief period. This acidic pH probably 
protonated all the carboxylic acid and amino groups on insulin. Then it was freeze-dried. 
It is expected that in the dry form, insulin would be protonated completely and would 
probably stay in a salt form. Method 2 – it involved reducing the pH of the reaction mixture 
by HCl. HCl in dioxane was used to avoid the presence of water in the reaction. For each 
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reaction, 2.6 mg (0.447 µmol) insulin was used. Azido hydrazine, used earlier for caging 
insulin, was used here as shown in the reaction above. Azido hydrazone (43 µmol) in 0.25 
mL DMSO was mixed with 105 mg MnO2. It was vortexed for 45 minutes in the dark and 
filtered through the celite column to remove particulate MnO2. Total diazo volume after 
DMSO washing of the celite column was 1.19 mL. It was split equally into two reaction 
mixtures for two different conditions mentioned earlier. The pH for condition # 2 was kept 
at 4.3.  
After 24 hours of reaction, insulin + caged insulin products were precipitated by 
adding cold acetone to the reaction mixture. DMSO and unreacted DDA went into the 
acetone layer while the insulin + caged insulin precipitated out. It was analyzed using 
HPLC (Figure 212, Figure 213). Reversed-phase HPLC (flow rate 1 mL min−1, runtime 30 
min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 
0 to 100% gradient B isocratic for 30 min; C18 Hypersil column (5 μm, 250 × 4.6 mm, 
Agilent). 
 
Figure 212: HPLC chromatogram of the reaction mixture after acetone extraction 
performed using method 1. No reaction is seen. 
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Figure 213: HPLC chromatogram of reaction after acetone precipitation performed using 
method 2, many modifications were observed.   
  
 
Figure 214: MS analysis of modified insulin collected from the HPLC run. 
 
 The reaction performed using method 1 showed no progress. No new peaks 
corresponding to the products were seen. We don’t know the reason yet. However, there 
were a lot of new peaks in the second reaction. The peaks from 19-25’ were collected and 
infused into MS for analysis. After using a 50× excess of diazo under acidic conditions, 
the extent of modifications was only 4 per insulin molecule. No traces of pentamodified or 
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hexamodified insulin were detected in MS (Figure 214). Among the products, trimodified 
was seen in the highest concentration not tetramodified. This study suggested that it was 
challenging to get completely hexamodified insulin. For this reaction, 100% DMSO was 
used. Other proteins will not be compatible with 100% DMSO, and the reaction must be 
performed in an aqueous solvent. However, the diazo gets easily hydrolyzed in water, so 
the reaction yields will be significantly lower than what we observed here. Hence, because 
of these limitations, we started investigating alternative routes other than diazo. 
Route # 3 – Esterification using EDC/ DCC 
The third approach included using EDC as the coupling reagent. EDC works like 
DCC except it is water soluble and used in coupling reactions which are performed in 
aqueous solvents.150 Insulin (5.0 mg, 0.86 µmol, 3.2 mM), 3-azido propanol (0.99 mmol, 
3.6 M, EDC (3.00 mg, 15.5 µmol) and DMAP (0.95 mg, 7.7 µmol) were mixed in DMSO. 
The reaction was run at room temperature for 48 hours. Reversed-phase HPLC (flow rate 
1 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent 
B (0.1% TFA in ACN), 0 to 100% gradient B isocratic for 30 min; C18 Hypersil column 
(5 μm, 250 × 4.6 mm, Agilent). The analysis is in Figure 215 and Figure 216. 
 
Figure 215: HPLC chromatogram of the crude reaction mixture. 
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Figure 216: MS analysis of the fraction collected from the chromatogram earlier. No 
sharp peak corresponding to the product is observed. 
 
Introduction of R9 peptide in the approach – Diazo route 
 
Figure 217: Esterification using diazo. The R9 peptide is conjugated to diazo to facilitate 
intracellular delivery.  
  
246 
We introduced the R9 peptide in the delivery approach. The cell-penetrating 
properties of R9-peptide are well documented for carrying cargo inside the cells.151–153 
Hence, we hypothesized that conjugating R9-peptide to the protein through labile ester 
linkages might succeed. The first attempt was to use diazo for esterification as described 
here (Figure 217). 
The reaction I – Conjugation of NKA of R9-peptide 
R9-peptide on the resin was ordered from Peptide 2.0. The first step involved 
deprotecting FMOC from the peptide using piperidine. The resin (75 mg) was weighed and 
washed with 0.5 mL DMF thrice; then treated with 0.5 mL of 20% piperidine in DMF 
thrice for 5 minutes each; then washed again with 0.5 mL DMF five times for 5 minutes 
each to wash off piperidine. Meanwhile, NKA (40.3 mg, 0.15 mmol), HATU (57 mg, 0.15 
mmol) and DIEA (52.2 µL, 0.3 mmol) were mixed in 0.235 mL anhydrous DMF. It was 
pre-activated for 15 min and added to the resin. The reaction was stopped after an overnight 
reaction, and the resin was washed with DMF and followed by DCM, dried. A small 
amount of resin was cleaved using TFA and then analyzed by HPLC and MS. ESI-MS 
(m/z): [M]+, calc. 1675.0; found, 1675.0 (Figure 218); analytical method – reversed-phase 
HPLC (flow rate 0.4 mL min−1, runtime 30 min with 5 min post-run), solvent A (0.1% TFA 
in H2O), solvent B (0.1% TFA in ACN), 0 to 100% gradient B isocratic for 30 min; C18 
Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 12.2 min (Figure 219). 
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Figure 218: MS of R9-NKA cleaved from the resin using TFA. 
 
 
Figure 219: HPLC chromatogram of R9-NKA. Retention time = 12.2 min. 
 
Reaction II – Conversion of R9-NKA to R9-hydrazone 
R9-NKA (10 mg resin, 1.43 µmol) was added in Hydrazine monohydrate (2.77 µL, 
57.2 µmol) and acetic acid (0.12 µL, 2.14 µmol) in 20µL of EtOH and NMP each. The 
reaction was run at 50 °C at 1000 rpm shaking in the thermomixer for 24 hours. Then it 
was washed with DMF followed by DCM 5 times. A small portion was cleaved by TFA 
for analysis. The reaction was incomplete, but the hydrazone conversion was confirmed. 
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Higher temperature or excess of acetic acid and hydrazine monohydrate could drive it 
towards completion. The hydrazone peak was purified using HPLC in multiple runs. 
Reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 30 min with 5 min post-run), 
solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 0 to 100% gradient B 
isocratic for 30 min; C18 Hypersil column (5 μm, 150 × 3.2 mm, Agilent), retention time: 
12 min (Figure 220); ESI-MS (m/z): [M]+ calc., 1688.0; found, 1688.0 (Figure 221). 
 
Figure 220: Chromatogram of the crude reaction mixture of hydrazone conversion. The 
taller peak at 13-14 min is unreacted R9-NKA, and 12 min twin-peaks are R9-hydrazone. 
 
Figure 221: MS of R9-hydrazone. The peaks at 12 min in the chromatogram above were 
collected and infused in MS. 
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Reaction III - Conversion of R9-hydrazone to R9-diazo  
The conversion of R9-hydrazone to diazo didn’t work out well. It was thought that 
MnO2 probably also reacts with guanidino groups of arginine to give side products. Due to 
this, the yield of the diazo reaction is substantially lower with lots of side products. Similar 
reactions were performed by other lab members and were unable to get the products in a 
clean manner with higher yields. Due to the challenges, this approach was stopped here. 
Introduction of R9 peptide in the approach – Carbamate route 
The carbamate route seemed easier than the hydrazone-diazo route. It has been 
demonstrated in the lab by senior students that small molecules can be caged via carbamate 
onto the solid phase support. This approach was mentioned in Chapter 1. Insulin, however, 
failed to undergo coupling reaction in this manner. Hence, we decided to perform TFA 
cleavage of R9-NAA (alcohol) first and then do the carbamate coupling with insulin in the 
solution phase. The first reaction of NKA coupling to the resin was described earlier. Here 
the procedure for the next reactions is described (Figure 222). 
 
Figure 222: Carbamate route of making carbamate ester of proteins + R9 attachment. 
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Reaction II – Conversion of the ketone to alcohol 
0.1 g R9-NKA resin (13.4 µmol) + NaBH4 (29 µmol, 1.1 mg) were added in 1 mL mixture 
of ethanol+DMF (1:1) in a small glass reaction vial. The vial kept open to let the in-situ 
generated CO2 escape. It was stopped after 4 hours. The resin was washed 5 times with 
DMF followed by DCM. Then a small portion was cleaved using TFA for analysis.  
 
Figure 223: HPLC chromatogram of R9-NAA after reduction with NaBH4. The peak 
between 11-13 min was collected and analyzed by MS. 
 
 
Figure 224: MS of R9-NAA after reduction with NaBH4. This is MS infusion of HPLC 
peak purified in the figure above. 
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Reversed-phase HPLC (flow rate 0.4 mL min−1), solvent A (0.1% TFA in H2O), solvent B 
(0.1% TFA in ACN), 0 to 100% gradient B isocratic for 30 min; C18 Hypersil column (5 
μm, 150 × 3.2 mm, Agilent), retention time: 12 min (Figure 223); ESI-MS (m/z): [M]+ 
calc., 1677.0, found, 1677.0 (Figure 224). 
Reaction III – Caging of insulin by R9-NAA 
R9-NAA (0.5 µmol) was added to CDI (0.08 mg, 0.5 µmol), DMAP (0.06 mg, 0.5 
µmol) in anhydrous DMSO 14 µL. It was kept for activation at 37 °C for 2 hours. In another 
tube, insulin (3.0 mg, 0.51 µmol) was dissolved in 0.2 mL DMSO. The activated solution 
was then added to insulin in DMSO. A similar reaction was also performed in PBS instead 
of DMSO, but upon addition of all reagents to PBS, a precipitate was observed. Hence the 
PBS reaction was not analyzed. However, no traces of products were seen in the reaction 
performed in 100% DMSO (Figure 225). It is plausible that CDI might have some 
reactivity with guanidino groups preventing it from reacting with the alcohol.  
 
Figure 225: HPLC chromatogram of reaction between R9-NAA and insulin. 
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The reaction was attempted with different conditions varying the percentage of water in 
the reaction mixture, pH, etc. However, there was no product detected on HPLC. 
Protein nanocapsules 
What is a protein nanocapsule? 
 The idea of “protein nanocapsules” was first published by Yan et al. where they 
trapped a single protein in a capsule covalently for intracellular protein delivery.154 First, 
small linkers were reacted onto the protein surface using amide conjugation chemistry to 
introduce monomeric acryl cross-linker. Then cross-linking reagents were added to the 
protein to cross-link all the monomers. The polymerization reaction took place on the 
protein surface, and it formed a thin polymeric capsule surrounding the protein. Hence it 
is called “protein nanocapsule.” There is flexibility in choosing the desired cross-linkers. 
The crosslinkers could be designed or selected to have desirable properties. The capsule 
could be either biodegradable or non-biodegradable or containing positive charges or 
disulfide bridges or combinations of these things etc. Thus, depending on the protein, its 
role, route of delivery and the target tissue, the capsule can be modified. Based on this 
work, stimuli-sensitive nanocapsules have been developed which respond to external 
environmental stimuli and open to release proteins accordingly. For example – enzyme 
sensitive,155 temperature sensitive,156 light sensitive,157 etc. protein nanocapsules have been 
developed. Further work has been performed in this area to create more efficient 
nanocapsules and is reviewed here.158 The nanocapsules approach is appealing for several 
reasons –  
1. The polymeric encapsulation of proteins on their surface might render it resistant 
towards proteases or an immune system of the body and increase its half-life in the 
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body. The capsule may sterically hinder the access of the proteases to the site of 
proteolysis. Material such as PEG could be included in the cross-linker which is 
known to increase circulation time of protein therapeutics in the plasma.159 
2. The cross-linker could carry positive charges as shown earlier. Decorating protein 
surfaces with positive charges is strongly proved to enhance protein uptake. Many 
groups have worked on this idea using a multitude of strategies. Liu group has 
synthesized “supercharged proteins” by replacing certain amino acid residues with 
cationic amino acid on the protein surface. These highly cationic proteins are shown 
to have excellent cell-penetrating properties and also act as carriers to carry cargoes 
inside the cells with some modifications.145 Thus, there is no need to biologically 
engineer proteins to get these charges; the cross-linker would easily impart positive 
charges on its surface. Also, the charges will be only as a temporary modification, 
once the protein is internalized, the polymeric capsule would break down, and 
charges will be separated from the protein. This reversible modification alters the 
protein structure temporarily until it is internalized or exposed to certain stimuli. 
3. The cross-linker could have disulfide linkages which are vulnerable to the reducing 
environment of the cell. A recent study has used this concept for the intracellular 
delivery of proteins.160 Intracellular environment is reducing in nature and 
disulfides get reduced rapidly. If the nanocapsules are made up of cross-linkers 
having disulfide bridges, the entire nanocapsules polymers get degraded quickly 
inside the cells. However, the nanocapsules stay intact outside and protect proteins 
from undergoing degradation before cellular penetration. The concept has been 
studied and is being used widely for delivery purposes.161  
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Self-immolative linkers 
The strategy of self-immolative linkers (SIL) provides a convenient way and 
additional control over the release of the drug candidate. Typically, in the case of prodrugs, 
the drug is modified by a promoiety to alter its pharmacokinetic, physical properties. 
However, sometimes an additional linker which is called a ‘self-immolative linker’ is 
inserted between these two. The conjugated moiety (or promoiety) is connected via a stable 
but stimuli-sensitive bond i.e. it is stable under normal conditions but cleaved upon 
exposure to specific stimuli.162,163 The concept is outlined in Figure 226. The stimuli could 
be temperature, pH, enzymes (esterases or proteases), light, etc. Once the construct is 
exposed to certain stimuli, the bond is cleaved exposing the SIL. Until this point, the SIL 
is inactive but once the conjugated moiety is cleaved off, it undergoes self-cleavage 
yielding the native drug. 
 
Figure 226: The concept of self-immolative linkers. A moiety is attached to the native 
drug through the self-immolative linker. Upon exposure to stimuli, the conjugated moiety 
is cleaved off. At this point, the linker undergoes self-cleavage to release the native drug.  
 
The SEL strategy has been used by different groups for modifying the properties of 
drug molecules. For example, Pires et al. used this to design a sensor for intracellular thiols 
(Figure 227).164 They modified the amines on the fluorophore ring to temporarily quench 
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its fluorescence. Once it is taken up inside the cells, glutathione reduces the disulfide 
linkage. The thiol attacks the carbamate, yielding free amino. The free amino group is 
responsible for the fluorescence and hence upon cellular delivery, fluorescence is restored. 
The fluorescence signal is proportional to the concentration of glutathione in the cell. 
  
Figure 227: An example of the self-immolative linker. A dye is conjugated through an 
SEL. The modification makes the fluorescence inactive. The disulfide linkage is reduced 
once it goes inside the cells. After disulfide reduction, the SIL undergoes self-cleavage to 
release original dye molecule which is fluorescent. The fluorescence can be detected 
inside the cells.164 
  
The Wender group has attached oligo-arginine peptides to cancer drugs like Taxol, 
coelenterazine through SIL.165 By doing so, Taxol can be delivered in cancer-resistant cells 
by effectively avoiding Pgp efflux pumps. Taxol by itself fails to penetrate in these resistant 
cell lines due to efflux pumps.165 Many groups have utilized this system which has been 
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reviewed already.166 
 We thought of applying the concept of SIL into the protein nanocapsules design. In 
all the protein nanocapsule designs, the monomer is introduced on the protein surface by 
modifying the amino groups via an amide bond. These modifications are irreversible as 
amide bond is very stable compared to an ester. In our approach, we plan to introduce 
monomers via a carbamate bond which would be reversible. The monomers will be cross-
linked to each other via disulfide-containing linkers. The cross-linkers can contain cationic 
charges to enhance protein uptake inside the cells. When the nanocapsules are taken up 
inside the cells, reducing environment would trigger disulfide cleavage. The cleavage 
would expose a free thiol which would undergo self-immolation to cleave the carbamate 
yielding native protein as opposed to protein modified with all monomers due to amide 
linkage. The synthetic scheme is outlined below (Figure 228). 
 The amino groups on any protein can be modified via carbamate linkage with 2-(2-
pyridyldithio)ethanol using coupling agents like CDI. The similar reaction was used for 
caging insulin in the earlier chapter. 2-(2-pyridyldithio)ethanol is an activated disulfide. 
Any free thiol could displace 2-Pyridinethiol ring and form a new disulfide link. The 
strategy has been used successfully before.151 We envision that once multiple amino groups 
on the protein are modified, a dithiol cross-linker would undergo reactions to cross-link 
protein on its surface. The cross-linker could be designed as required. The PEG backbone 
could be included; cationic charges could be added, but it would have to have thiols at each 
end. Inside the cellular environment, the cross-linking would fall apart exposing free thiols. 
These thiols would attack carbamate to give free amino groups, yielding native protein 
inside the cells. 
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Figure 228: Protein nanocapsules + SIL approach. 
 
Because UMKC does not have any functional MALDI-TOF to analyze protein 
modifications at this point, we relied on using insulin as a model protein to conduct initial 
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pilot experiments. The Department of Pharmaceutical Sciences has a functional QTrap 
3200 MS on which insulin modifications could be characterized. Below are the 
experiments with insulin using this strategy. 
Synthesis of 2-(2-Pyridyldithio)ethanol  
2-Aldrithiol (Sigma-Aldrich, catalog # 143049, 0.47 g, 2.14 mmol) was added to 
2.2 mL methanol and purged using N2 by dipping the needle into it for 1 hour. To this, 
mercaptoethanol (55 µL, 0.78 mmol) was added using a needle through a rubber septum. 
The mixture became yellow immediately. It was stirred for next 2 hours. The solvent was 
evaporated, and it was purified by flash chromatography using 20% ethyl acetate in DCM. 
Yield = 0.11 g (83%); analytical method – reversed-phase HPLC (flow rate 0.4 mL min−1, 
runtime 30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA 
in ACN), 0 to 100% gradient B for 30 min; C18 Hypersil column (5 μm, 150 × 3.2 mm, 
Agilent), retention time: 13 min (Figure 229); ESI-MS (m/z): [MH]+ calc. for C7H9NOS2, 
188.0; found, 188.1 (Figure 230). 
 
Figure 229: HPLC chromatogram of purified 2-PDE. 
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Figure 230: MS-infusion data of 2-PDE. The peak corresponding to 210.1 is a sodium 
adduct. 
 
Synthesis and purification of insulin PDE dimod 
 A 2-PDE stock solution of 3.77 M was prepared in anhydrous DMSO. 88 µL of 
stock solution (330.6 µmol) was mixed with additional 50 µL DMSO to achieve a final 
concentration of 2.4 M. To this, 53.6 mg (330.8 µmol) of CDI was added and incubated at 
37 ºC for 70-75 minutes. After incubation, it was diluted with 0.1 mL additional DMSO to 
make a final volume of 0.27 mL. This was divided into 4 equal parts. 60 mg insulin (10.33 
µmol) was added into 4 glass vials each and dissolved in 4 mL 0.1 M carbonate buffer (pH 
= 8.95) + 0.1 mL DMSO. Each part of activated CDI was added to insulin solution and 
incubated at 40 ºC for 24 hours until turbidity was observed. Then it was stored in -20 ºC 
until purified using prep HPLC. Prep-HPLC method – reversed-phase HPLC (flow rate 2 
mL min−1, runtime 40 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B 
(0.1% TFA in ACN), 0 to 60% gradient B over 40 min; C18 Phenomenex column (5 μm, 
250 × 10 mm, Agilent), retention time: 34.4 – 34.9 min; Yield ≈ 4 µmol (9.68%); UV/vis 
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(DMSO): 280 nm (13800 M−1 cm−1); reversed-phase HPLC (flow rate 0.4 mL min−1, 
runtime 30 min with 5 min post-run), solvent A (0.1% TFA in H2O), solvent B (0.1% TFA 
in ACN), 0 to 100% gradient B over 30 min; C18 Hypersil column (5 μm, 150 × 3.2 mm, 
Agilent), retention time: 19-20 min (Figure 231); ESI-MS (m/z): [M]+ calc. for, 6234.0; 
found, 6235.0 (Figure 232). 
 
Figure 231:  Analytical chromatogram of purified insulin PDE dimod. 
 
 
Figure 232: MS of purified insulin PDE dimod. 
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Cross-linking with dithiols  
 After synthesizing insulin PDE dimod which has two thiol-sensitive thio-pyridyl 
groups, the next step was to select dithiols for performing the cross-linking. For 
intracellular delivery, we would prefer cationic linkers flanking thiols at each end such as 
CKKKC sequences. This would encapsulate proteins in cationic charges helping cellular 
penetration. However, first, we thought of testing stability against proteases. The purpose 
of performing the cross-linking here is to prevent the unwinding of helices by proteases 
and/or just prevent binding of proteases to proteins. The shorter the cross-linker, the tighter 
would be the linkage and the greater the degree of resistance against proteases. Hence, we 
focused on selecting dithiols with the least possible atoms in between. In aliphatic dithiols, 
we selected ethanedithiol, 1,3-propanedithiol, 1,4-butanedithiol, 2-mercaptoethyl ether. 
For aromatic dithiols, we used 1,4-benzenedithiol. For dithiols with peptide backbones, we 
planned to synthesize cysteine dipeptide, both in L and D configuration. All planned 
dithiols to be used are shown in Figure 233. Except for the cysteine-containing peptides, 
all reagents were ordered from Sigma-Aldrich and Fisher Scientific.   
 
Figure 233: Dithiols that will be used for cross-linking in this approach. 
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Synthesis of cysteine-containing peptides 
 Friedman lab has been following a fixed protocol for peptide synthesis for years. 
However, cysteine has a tendency to undergo racemization during the coupling step.167 
Hence the procedure was modified as reported by Han et al.168 Significant racemization is 
observed if cysteine is coupled as the very first amino acid residue on the resin on C-
terminus. Hence, we decided to couple a glycine first followed by two cysteines. The 
reaction conditions are described in Table 14. 
 
Table 14: Conditions used for the synthesis of cysteine-containing peptides. 
 
Step in synthesis Conditions used 
Coupling Fmoc-Cys (1): HATU (4): HOBt (4): collidine (4) in DCM: 
DMF (1:1), no pre-activation, 1-hour reaction. Concentration 
used = 0.2-0.3 M 
Fmoc-deprotection 20 % piperidine (2 min and 8 min) 
Capping 10 % acetic anhydride + 5% DIPEA in DMF 
TFA cleavage  95% TFA + 2.5 % TIPS + 2.5% water, 1 hour 
 
Reversed-phase HPLC (flow rate 0.4 mL min−1, runtime 30 min with 5 min post-run),  
solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in ACN), 0 to 100% gradient B over 
30 min; C8 Hypersil column (5 μm, 250 × 4.6 mm, Agilent), retention time: 8.3 min (Figure 
234); ESI-MS (m/z): [MH]+ calc. for molecular formula = C8H16N4O3S2, 280.1; found, 
281.2 (Figure 234). 
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Figure 234: Characterization of L-GCC peptide – HPLC (top) and MS (bottom). 
 
DTNB assay for determination of thiol concentration 
 We optimized the 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB) assay for thiol 
quantitation using Ellman’s reagent.169 To prepare a solution of DTNB reagent, 50 mg of 
DTNB reagent was added to 1 mL water, vortexed for a few minutes and centrifuged to 
settle the undissolved amount. The supernatant was taken out and used directly in the assay. 
For the assay, 12 µL of Ellman’s reagent supernatant + 25 µL of 1M Tris-HCl + 0.15 mL 
of cysteine standard (0-100 µM) were mixed in a 96 well plate. The absorbance was 
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measured at 405 nm. In the proposed dithiols, we needed this assay to measure the 
concentration of synthesized peptides i.e. (L-GCC and D-GCC) and DBT as it had poor 
solubility in DMSO. Along with cysteine standard samples, diluted solutions of dithiols of 
unknown concentrations were subjected to the assay and their concentrations were 
determined using the standard curve (Figure 235).  
 
Figure 235: The standard curve of cysteine using Ellman’s reagent. The absorbance was 
measured at 405 nm and plotted against known concentrations of cysteine in water. 
 
Cross-linking on insulin surface 
 After synthesizing insulin PDE dimod and having dithiols in the lab, we proceeded 
to confirm whether we could perform cross-link on insulin surface using the selected dithiol 
candidates. The following reactions were set up with these conditions at a very small scale 
of approximately 24-40 nmol to just confirm the formation of the product. Insulin PDE 
dimod was used in the same quantity and the ratio of dithiol: ins PDE dimod was 1:1. 
Hence, their concentrations were also the same (Table 15). All MS of crude reaction 
mixtures are shown in Figure 236. All spectra show a single mass consistent with the 
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desired product. 1,3–propanedithiol reaction didn’t show expected mass, only the mass of 
unreacted starting material was seen. All chromatograms show a cluster of peaks between 
18-21’ which show the correct mass (Figure 237). Because all chromatograms look similar, 
I am providing a single representative chromatogram.  
 
Table 15: Concentrations of dithiols and insulin PDE dimod. 
 
Dithiol Insulin PDE dimod concentration 
Ethanedithiol 2.9 mM 
1,3-propanedithiol 2.9 mM 
1,4-butanedithiol 2.9 mM 
2-mercaptoethyl ether 2.9 mM 
L-GCC peptide 2.4 mM 
1,4-benzenedithiol 1.4 mM 
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Figure 236: MS of crude mixtures dithiols crosslinking on insulin surface. In all reactions 
except 1,3-propanedithiol, a single peak consistent with the desired product mass is seen. 
 
 
Figure 237: A representative HPLC chromatogram of the crude reaction mixture of 
ethanedithiol. The desired product is found in the cluster of peaks eluting between 18-
20.5’. All chromatograms look very similar and hence only one is shown. 
 
 Once after synthesizing and purifying cross-linked species, they will be evaluated 
for their proteolytic stability by testing against serum or proteases such as pepsin, trypsin, 
chymotrypsin, carboxypeptidase A comparing with native insulin. The characterization 
could be performed via gel, HPLC and MS. 
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Summary and future direction of the project 
 In Chapter 6, several chemical approaches to improve intracellular delivery of 
proteins are reported. For protein modifications, enzyme cleavable linkers were used – 
esters linkages are cleavable by esterases and disulfide linkages are cleavable by 
glutathione reductase (these are present intracellularly). In addition, the selected linkers are 
cationic in nature, making the target protein positively charged. Cationic charges help in 
cytosolic delivery of cargo. For the studies, insulin was used as a model protein because of 
ease of MS and HPLC characterization and significant experience with the chemistry of 
insulin. The most recent work involves multiple modifications of insulin using 2-(2-
pyridyldithio)ethanol through carbamate linkage and cross-linking the reacted groups 
through dithiol cross-linkers. I purified doubly modified insulin and performed the cross-
linking using several dithiol cross-linkers (Figure 233). The MS characterization is shown 
in Figure 236. These linkers are neutral in charge and may stabilize the protein from 
proteases; the next step is to test the stability of these cross-linked species against proteases 
such as trypsin, chymotrypsin, carboxypeptidase A, pepsin, etc. Finally, we would 
synthesize cationic dithiol peptides where lysine sequences would offer positive charges 
flanked by two cysteines required for cross-linking. We would purify cationic cross-linked 
species and test them for their ability to cross the lipid bilayer and reach the cytosol.  
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